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Parvoviruses are small, non-enveloped, single stranded DNA viruses. The 
specific attributes of the capsid and genome dictate how the virus interacts with the 
environment and the host cell in terms of transmission, tissue tropism, anti-viral 
immunity, and disease states. 
A major focus of these studies is viral entry into host cells. During infection, the 
parvovirus capsid hijacks cellular pathways to reach the nucleus for genome replication. 
Receptor binding is critical for determining host range and tissue tropism, and various 
receptors are utilized by different parvoviruses. However, the intracellular trafficking 
pathways followed by viruses after endocytosis are poorly understood. Chapter 2 
examines the dynamic nature of parvoviral uptake and entry by wild type viruses, while 
chapter 3 examines the ability of these viruses to use variant receptors for uptake and 
infection.  
In addition to successfully navigating entry into host cells, parvoviruses must 
survive in the environment and evade host defenses. Humoral immunity plays a 
particularly important role in the control of these viruses. This is a benefit as vaccination 
is generally successful in controlling parvoviral disease, but is a challenge that must be 
overcome in the development of adeno-associated viruses as gene therapy vectors.  
 
The studies that follow expand our knowledge about the interaction of antibodies with a 
newly described variant of CPV in raccoons, RPV-2 (Chapter 4) and the adeno-
associated virus capsid (Chapter 5).  
 One final aspect of parvoviral biology addressed in this work is how changes in 
host range, antigenicity, and receptor interactions have evolved with small numbers of 
capsid changes in these closely related viruses. The trafficking studies in chapters 2 
and 3 were performed within this contextual framework to examine the differences in the 
interactions of FPV and CPV with host cells. Chapter 4 describes the phylogenetic 
origin, host range, and receptor binding properties of several recently characterized 
parvovirus strains isolated from raccoons, and places this animal as an important 
intermediate host in the evolution of CPV. Finally, two of the more dissimilar serotypes 
of AAV were examined in Chapter 5 to look at the interaction of antibodies with capsids 
displaying somewhat different surface features. 
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CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sections 1.8 to 1.8e modified from Harbison C.E., Chiorini J.A., Parrish C.R. 2008. 
The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol. 
16(5): 208-14, with permission.
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1.1 Taxonomy 
The family Parvoviridae is divided into two subfamilies. The Parvovirinae infect 
vertebrate hosts and the Densovirinae infect invertebrates; only the former will be 
considered here. Within the Parvovirinae are several genera including Parvovirus and 
Dependovirus. Many parvoviruses of veterinary importance are contained within the 
genus Parvovirus, including feline panleukopenia virus (FPV), canine parvovirus (CPV), 
porcine parvovirus (PPV), and minute virus of mice (MVM). The adeno-associated 
viruses (AAVs) are within the genus Dependovirus, so named for their dependence on 
helper viruses for replication.  The other genera within the family include Erythrovirus, of 
which the human B19 virus is a member, Amdovirus, containing the Aleutian mink 
disease virus (AMDV), and Betaparvovirus.  
1.2 Parvovirus capsid structure 
All of the Parvoviridae have small (~25 nm diameter), non-enveloped capsids 
with T=1 icosahedral symmetry. The CPV capsid is comprised of 60 copies total of the 
major capsid proteins, VP1 and VP2. In general, 90% of the capsid protein is comprised 
of the 65 kDa VP2, with several copies of the 83 kDa VP1 per capsid. In full capsids, 19 
amino acids may be cleaved off the amino (N) terminus of some VP2 copies to form the 
63 kDa VP3 (96). The carboxyl (C) terminus of each of these proteins is identical, and 
the unique 143 base pair N terminus of VP1 contains sequences with phospholipase A2 
and nuclear targeting activity (82, 100). These sequences are not exposed in the intact 
capsid, but are released during viral entry and play an essential role in infectivity. VP2 
alone can assemble into capsids, but these virions are non-infectious (85, 152, 159).  
The core of the CPV capsid is formed by an 8-stranded anti-parallel β-barrel 
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structure commonly found in icosahedral viruses, which internally contacts the single 
stranded DNA viral genome through hydrogen bonding interactions (20, 58). The 
intervening loops between the β strands contain the most variable sequences between 
different viruses and are responsible for the major surface features of the capsid, 
including the three-fold spike, the five-fold cylinder surrounding a pore, a deep canyon 
surrounding the five-fold cylinder, and a depression (dimple) at the two-fold axis of 
symmetry (Figure 1.1a) (151, 173). The pore at the five-fold axis is ~8 Å wide, large 
enough to accommodate one peptide or DNA molecule at a time, and is the site for VP1 
N terminus and genome extrusion during entry and DNA packaging (12, 43). In 
structures solved by cryo-electron microscopy or X-ray crystallography, the N termini of 
both VP1 and VP2 are disordered, indicative of their flexibility (43, 96). These features 
are shared between many members of the Parvoviridae with the exception of the 
human virus B19, which appears to lack the prominent three-fold spike and the pore at 
the five-fold axis (69). 
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FIGURE 1.1. Parvovirus capsid structure. Cryo-electron microscopy reconstruction of 
A) CPV and B) AAV-2 capsids at 21Å resolution. The major surface features are 
indicated; note the overall similar topology between the capsids.  Modified from Walters, 
R. W. et al. 2004. J. Virol. 78(7): 3361-3371, with permission. 
 
The adeno-associated viruses also show variations on this structural theme. The 
AAV capsid is made up of 3 capsid proteins, VP1, VP2, and VP3, in an approximately 
1:1:10 ratio, and like the autonomous parvoviruses these proteins contain shared C 
terminal regions. 12 AAV serotypes have been described that possess varying host 
ranges, tissue tropisms, and receptor binding properties (30). The differences between 
the serotypes stem primarily from mutations within the surface-oriented loops located 
between the β strands, whose sequences are less conserved than the β-barrel capsid 
core. Serotypes 1, 2, 3, and 6 share ~85% of their capsid sequence with each other, 
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while AAV5 is the most divergent and shares only ~55% capsid sequence identity (33, 
162). Furthermore, the capsid genes share only about 10-20% identity with the CPV 
VP2 protein (21). Nonetheless, the internal structure and same basic surface topology is 
present, as described above, except that that three-fold spike of CPV is instead a trimer 
of spikes with an intervening depression at the three-fold axis (Figure 1.1b) (75, 97, 
172).  
1.3 Genome organization and gene components  
 The ~5.1 kb, usually negative sense, single-stranded DNA genome of CPV 
contains two open reading frames that encode the non-structural (NS1, NS2) and 
structural (VP1, VP2) proteins. Alternate RNA splicing gives rise to the two different 
gene products from each open reading frame. Two promoters drive gene transcription 
and are named for their genomic position (p4 and p38, respectively). There is a single 
polyadenylation site on the right hand end of the genome, and the terminal sequences 
are comprised of palindromic sequences that organize into variable hairpin secondary 
structures (Figure 1.2a) (121).  
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FIGURE 1.2. Parvovirus genome organization. Schematic representation of the A) 
CPV and B) AAV viral genomes, including the major transcripts encoding the non-
structural (NS, Rep) and structural (VP) proteins. Other features shown are the 
locations of the various promoters, the single polyadenylation sequence within each 
genome, and the secondary structure formed by the inverted terminal repeats or 
hairpins (not to scale).  
 
The non-structural proteins perform supportive roles in parvoviral replication. 
Neither protein has DNA polymerase activity, and the viruses depend on cellular 
proteins or helper viruses for this functionality. The 83 kDa NS1 protein is known to 
initiate replication by binding to and nicking the right-hand hairpin to start the process of 
secondary strand synthesis (167). It also has helicase and ATPase functions, is a 
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regulator of both viral promoters, and mediates RNA splicing and cytotoxic effects (1). 
Phosphorylation by the cellular factor phosphokinase C is required for one or more of 
these functions (76). The smaller NS2 protein is not required for infection in all cases, 
and its function(s) have not been completely elucidated. For example, the Parvovirus 
H1 NS2 is required for infection in rats, but not for infection of hamster or human cells 
(79). In MVM, NS2 has been show to support capsid assembly and translation of the 
capsid protein mRNA, and infection is inhibited in mutants lacking a functional version of 
the protein (40). NS2 also binds to regulatory proteins in the cytoplasm (14-3-3 proteins) 
and nucleus (Crm1) and may play a role in cell cycle control or other intracellular cell 
signaling pathways (16). In CPV, however, no specific role for the the19 kDa protein has 
been identified, and it appears to be dispensable for infection (165, 175).  
The 4.7kb AAV genome is organized similarly to that of the autonomous 
parvoviruses. There are four non-structural rep genes (large reps: Rep 68/78 and small 
reps: Rep 52/40) that are analogous to the NS1 and NS2 genes, respectively (11). RNA 
splicing and alternate translational start sites allow for the generation of these multiple 
gene products as in the autonomous parvoviruses. These transcripts, as well as the 
structural cap genes, are driven by separate promoters within the viral genome (p5, p19 
and p40) (Figure 1.2b). Like the NS genes, they are involved in several aspects of the 
AAV life cycle including replication, transcription, packaging, and integration. Though 
both large and small Rep proteins contain helicase domains, the helicase function 
provided by the small Rep protein is essential for complete genome packaging. The 
large Rep proteins also have DNA binding, helicase, and ATPase activity like the 
autonomous parvovirus NS1 protein described above. These proteins also interact with 
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the helper virus to modify its replication in some cases (146).  
1.4 Parvovirus evolution 
The structural and functional differences between FPV and CPV strains arise 
primarily from a small number of VP2 capsid protein mutations that affect receptor 
binding, host range, antigenicity, and capsid flexibility. CPV-2 emerged in the mid-
1970s, and was first recognized in 1978 as a novel disease of dogs that rapidly spread 
worldwide to cause a global pandemic (107, 114). It arose during a host-switching event 
as a monophyletic clade from FPV, or an FPV like virus, and this process may have 
involved other carnivore intermediate hosts (61, 139). Within two years of CPV-2’s 
emergence, new antigenic strains emerged that quickly replaced the original circulating 
strains in the wild, though the reasons these strains possess evidently enhanced fitness 
have not been determined. Of the newer antigenic variants, CPV-2a emerged in 1981, 
CPV-2b in the late 1980s, and CPV-2c in the early 2000s (18, 110, 113). These more 
recent strains are co-circulating to this day in different proportions varying by 
geographic area, and new mutations continue to arise. For a DNA virus, CPV has a 
relatively high rate of mutation that is comparable to the levels found in RNA viruses 
(~1.7 × 104 substitutions per site per year). The majority of the positively selected 
mutation sites are located within the VP2 gene (129).  
The different parvovirus strains have distinct host ranges in vitro and in vivo, 
largely based on their ability to bind to the transferrin receptor of the host species (108). 
In vitro, FPV can only bind to and infect feline cells, while CPV variants can bind to and 
infect both canine and feline cells, although to different levels (101).  In vivo, FPV infects 
a wide variety of carnivores but does not cause disease in dogs. Interestingly, however, 
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FPV can infect canine thymocytes, but this phenomenon has not been investigated in 
detail (111, 150). CPV-2 gained the ability to infect dogs by capsid changes at residues 
93 and 323 that allowed it to bind the canine cellular receptor, but in that process lost 
the ability to infect cats due to concurrent changes at residues 80, 564, and 568 (Figure 
1.3) (109, 148). The more recent CPV antigenic variants maintained the canine host 
range but regained the ability to infect cats through the acquisition of novel mutations at 
residues 87, 300, and 305 and not through back mutation to the feline residues at the 
sites listed above (149). CPV-2b and -2c are defined by a single point mutation at 
residue 426, which has undergone repeated changes (it is an Asn in FPV, CPV-2, and -
2a, Asp in CPV-2b, and Glu in CPV-2c). Other changes of unknown significance are 
present in various recent isolates, such as Ser297Ala, which emerged in CPV strains in 
the mid 1990s, and Ile101Thr. Furthermore, the importance of CPV infections in cats is 
not well understood, but has been recognized in the literature as an occasional cause of 
generally mild disease (32, 67, 94, 149).  
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FIGURE 1.3. Classical view of CPV Evolution. Changes in the VP2 capsid protein 
during the evolution of CPV resulted in alterations in host range and antigenicity. 
Mutations in blue are responsible for the gain of canine host range. Mutations in red are 
important for loss of the feline host range during the evolution of CPV-2, while those in 
green are the compensating mutations in CPV-2a that allowed it to regain the ability to 
infect cats. Point mutations at residue 426 define the difference between CPV-2a and 
more recent variants, all of which can infect both cats and dogs. 
 
Structurally, some of these mutations affect flexibility in the capsid by altering 
hydrogen-bonding patterns between surface residues. Within the threefold spike of 
CPV, mutations in surface loops 1 and 2 remove a hydrogen bond that is present in 
FPV between residues 93 with 225 and 227. This residue is a Lys in FPV and an Asn in 
CPV. An additional hydrogen bond is present between Asp323 and Arg377 in FPV that 
is abolished with the Asp323Asn mutation in CPV (63). FPV and CPV capsids also have 
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different numbers of associated divalent cations that affect stability. The surface 
oriented loop 3 (residues 359-75) organizes two calcium ions in CPV, but three in FPV 
due to the presence of an Asp at positions 373 and 375 (CPV is Asn375).  This loop 
affects the sialic acid binding properties and controls the pH and temperature 
dependence of hemagglutination. FPV requires acidic pH to hemagglutinate red blood 
cells, while CPV can bind sialic acids at acidic and neutral pH (81, 132).  
Because naturally circulating strains are often found to contain multiple 
concurrent residue changes, experimental site-directed mutagenesis has been useful in 
investigating the functional significance of individual residue changes. Following in vitro 
selection in feline cells, for example, a CPV-2 Ala300Asp mutation was selected. This 
strain has altered structure compared to CPV-2 due to the creation of a salt bridge 
between the Asp300 and Arg81, which changes the antigenicity and in vitro host range 
as infection of canine cells is significantly inhibited (112). This mutation was also seen in 
the wild in CPV-2a-derived isolates from wild leopard cats in Vietnam, and was also 
present in CPV-like isolates from raccoons described in chapter 4 (66, 68). Confusingly, 
this mutation was also designated CPV-2c by some authors, though is unrelated to the 
Glu426 strains described above. Other experimental mutations have mapped important 
host range-determining residues to VP2 299, 301, and 387, and have identified 
additional residues important for hemagglutination at VP2 377, 396, and 397 (81, 105).  
1.5 Transferrin receptor-Cellular receptor for CPV, FPV  
 CPV and FPV use the transferrin receptor type-1 (TfR) for entry into host cells, 
and TfR expression is sufficient to allow infection in otherwise non-permissive Chinese 
hamster ovary (CHO) cells (104). The TfR is a 90 kDa, 760-residue type II membrane 
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protein, meaning that its N terminus is on the cytoplasmic side of the membrane (2). 
The cellular function of TfR is to allow the regulated uptake of iron via iron-loaded 
transferrin (Tf) (119). Iron is an essential cofactor in a wide variety of cellular proteins 
including hemoglobin and lipoxygenase, an enzyme involved in arachadonic acid 
metabolism. The TfR is an essential protein, and the TfR knockout mutation in mice is 
embryonic lethal due to anemia based on a lack of functional, oxygen carrying red blood 
cells (95). While nearly ubiquitously expressed on most cell types, the expression levels 
of TfR are highest on rapidly dividing cells, which is a useful feature for this group of 
viruses that requires cellular S phase to complete their replication. 
 At the cell surface (pH 7.4), TfR binds one or two molecules of the bilobed 
transferrin protein (Tf) that, in turn, carries one or two ferric iron (Fe3+) atoms per 
holoTf. The iron-free form, apoTf, binds poorly to TfR at this pH. Once bound, the 
targeting sequence Tyr-Thr-Arg-Phe on the cytoplasmic portion of TfR interacts with the 
clathrin endocytic machinery through adaptor protein 2 (AP-2) for rapid endocytosis 
(48). Deletion of this tail decreases the Tf internalization rate by ~90%, with the residual 
endocytosis occurring by non-specific membrane turnover (27). The receptor and its 
cargo are delivered sequentially to the early and recycling endosomal compartments, 
where the iron is released in response to a low pH signal that results in a conformational 
change of Tf. The iron-depleted apoTf remains bound at acidic pH and is recycled with 
the receptor back to the cell surface, where it is released to make the TfR available for 
another round of uptake. Clustering the TfR with oligomeric transferrin diverts the 
receptor into a longer-lived perinuclear recycling compartment and acts as a luminal 
retention signal to delay recycling. This phenomenon is not dependent on the 
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cytoplasmic tail, and likely has relevance for the trafficking of multivalent ligands such 
as viral capsids (87). Under normal conditions, a single transferrin receptor can undergo 
approximately 100 rounds of endocytosis during its normal lifespan before being 
targeted for degradation by ubiquitination and proteosomal digestion (42, 46).  
1.6 Transferrin receptor structure 
 The crystal structure of the soluble human TfR ectodomain has been determined 
at pH 6.7, and is likely similar to that of the canine and feline TfRs which share ~80% 
sequence identity (63, 78). The tertiary structure of the transferrin receptor can be 
divided into several functional domains: the apical domain (residues 189-383, human 
TfR numbering), the protease-like domain (residues 127-188 and 384-606), the helical 
domain (607-760), a 30Å perimembrane stalk (90-126), the transmembrane domain 
(62-89), and an amino-terminal 61 amino acid cytoplasmic tail. The protease-like 
domain is located adjacent to the membrane and has an overall structure similar to 
carboxy- and amino-peptidases, although functionally the TfR has no protease activity. 
The apical domain is distal to the membrane and is made up of a β-sandwich flanked by 
two α-helices. No known cellular function for this domain has been identified. The 
helical domain, as the name suggests, consists of a four-helix bundle and two α-
hairpins. The intervening loops between the helices are important for dimerization and 
accurate protein folding. The specific residues involved in Tf binding are located within 
the helical and protease-like domains, and vary slightly depending on the iron-loaded 
status of Tf (23, 46). In its native form, the protein exists as a homodimer on the surface 
of the cell and has a butterfly-like shape with the apical and protease-like domains 
forming the bipartite wing and the helical domain comprising the body (Figure 1.4) (2). 
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FIGURE 1.4. Human transferrin receptor structure. The different domains of the 
dimeric transferrin receptor are indicated on one monomer. The crystal structures of the 
stalk, transmembrane, and cytoplasmic domains have not been determined and are 
indicated schematically. Apical domain residues important for parvovirus binding are 
highlighted; a Leu221Ser feline TfR mutant is unable to bind CPV or FPV capsids, and 
residue 383 contains a glycosylation site contributing to viral host range that is present 
in the canine but not the feline TfR (79). 
 
 CPV and FPV bind to the apical domain for cellular entry, and do not sterically 
inhibit Tf binding (102). One major difference between the canine and feline TfRs 
controls parvovirus host range; the presence of a glycosylation site in the canine TfR at 
residue 383 prevents FPV binding and thus, infection of canine cells. Mutational 
analysis of the TfR only identified one mutation that completely knocked out parvovirus 
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binding, TfR Leu221Ser, though Thr300Asp and Asp369Lys mutations partially reduced 
binding and infection (Figure 1.4)(49, 101). Several residues in the virus capsid control 
viral host range by affecting binding to the TfR, and these are located over a relatively 
large area around the shoulder of the three-fold spike. Cryo-electron microscopy studies 
have identified this footprint, and have shown asymmetric binding whereby each capsid 
associates with only one or a small number of receptors (54).  
 CPV and FPV can also bind sialic acids on the surface of cells. These viruses 
bind specifically to the sialic acid moiety N-glycolylneuraminic acid (NeuGC), present on 
feline but not canine red blood cells. However, the significance of these interactions, 
and their role in the viral life cycle, is unclear; treating cells with neuraminidases does 
not inhibit CPV/FPV binding or infection and a non-hemagglutinating virus mutant is still 
infectious (8, 63, 102, 147). 
1.7 Parvoviral disease, pathogenesis, and control 
The small, non-enveloped parvoviral capsid provides protection from a wide 
variety of environmental conditions outside the host, including variations in pH, 
temperature, and humidity, and the presence of detergents (15). Harsh cleaners such 
as bleach or Virkon-S (potassium peroxymonosulfate) are required to kill the virus, as 
hot water, alcohol, grapefruit extract, and quaternary ammonium compounds are 
ineffective (41).   
Because maternal antibodies and appropriate vaccination are protective against 
disease, unvaccinated or incompletely vaccinated animals and newborns from 
unvaccinated bitches/queens are most commonly affected by parvoviruses. CPV also 
appears to have some breed predispositions among dogs, with disease 
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overrepresented in “black and tan” breeds such as Rottweilers and Doberman 
Pinschers (31). The age window between 6 and 16 weeks is the highest risk period for 
puppies and kittens, even for those receiving the vaccination series. This is the period 
where maternal antibody levels are waning and may no longer be protective against 
disease but may still be high enough to interfere with vaccination efficacy. Multiple 
vaccinations (every 3-4 weeks between 6-8 and 14-16 weeks) are recommended to 
give the highest chance of protection (19).  
For CPV and FPV, direct fecal-oral transmission is the primary route of disease 
spread between animals, but given the stability of the capsid fomites commonly play a 
role. In addition, vertical transmission to the developing fetus has been demonstrated 
for CPV (72). In the acute phase the virus is shed in large quantities in feces and may 
be present in other bodily fluids. Shedding may last up to several weeks or months in 
some cases, but for CPV and FPV, there appears to be no long-term carrier phase (77). 
Other parvoviruses are spread by alternate routes, such as respiratory transmission for 
human B19 virus and venereal transmission for porcine parvovirus (17, 130). AMDV is 
shed in the urine, and is an example of a parvovirus that can set up a persistent 
infection in the kidneys and other tissues (116).  
Following oral inoculation, CPV and FPV first infect the dividing lymphocytes in 
the tonsils and oral lymphoid tissue. The virus then spreads systemically through free 
viremia and/or in association with the infected lymphocytes to secondary sites such as 
the intestine and bone marrow (92). The TfR is highly expressed on rapidly dividing 
cells including lymphocyte precursors and gastrointestinal epithelium, and the viral 
replication requirement for cellular passage through S phase helps to account for the 
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major symptoms of disease.  
 Some parvoviruses, most notably AAV, are non-pathogenic. Others can cause 
severe and often fatal disease. The clinical manifestations of CPV and FPV reflect the 
tissue tropisms of the virus. The most common manifestation of CPV is segmental 
enteritis with copious, foul smelling diarrhea, often containing frank blood. Small 
intestinal histopathology shows necrosis of the enteric crypt cells (crypts of Lieberkühn), 
villous effacement, and intranuclear inclusion bodies (118). Other common clinical signs 
include fever, inappetence, vomiting, and severe dehydration. Lymphopenia and 
generalized leukopenia are common laboratory findings, and along with the breakdown 
in the intestinal barrier this often results in secondary systemic bacterial infections and 
sepsis. No specific anti-viral treatment exists, but aggressive supportive care is usually 
required to combat the ongoing fluid losses and to prevent or control secondary 
infections. Without treatment, many cases are often acutely fatal, and severely affected 
cases may die even when treatment is administered. Those animals that recover from 
disease retain long lasting, likely life-long, immunity (164).  
In the developing fetus, abortion occurs when the animal is infected with CPV or 
FPV during the first half of gestation. This is a common syndrome associated with 
infection by other parvoviruses including bovine and porcine parvovirus, as well as the 
human B19 virus. CPV and FPV infections occurring later in gestation or just after birth 
may lead to localized disease including cerebellar hypoplasia in kittens and myocarditis 
in puppies (9, 71).  
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1.8 The parvovirus life cycle 
Successful entry into animal cells by viruses requires a series of interactions that 
culminates in the release of viral genetic material into a compartment permissive for 
replication. Many viruses utilize cellular receptor-mediated endocytic and vesicular 
trafficking pathways for uptake and directed, cytoskeleton-dependent transport (88, 131, 
133). The choice of receptor can determine host specificity and tissue tropism and 
influences the subsequent endosomal trafficking within the cell. For the parvoviruses, 
infection and intracellular trafficking can be divided into five main stages: receptor 
binding and uptake, vesicular trafficking, endosomal escape, cytoplasmic trafficking, 
and nuclear entry. Where it has been examined the particle-to-infection ratio of most 
parvoviruses is typically high (>1000:1), and thus the majority of entering particles 
appear to be trafficked through a non-productive entry pathway. 
1.8a Receptor-dependent virus internalization 
The pathways of endosomal uptake and trafficking are summarized in Figure 1.5. 
All parvoviruses utilize receptor-mediated endocytosis for cellular uptake, and a wide 
variety of glycoproteins, glycans, and glycolipids function as receptors for various 
viruses (Table 1.1).  
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FIGURE 1.5. Parvovirus endocytosis. The processes of cellular uptake and 
endosomal trafficking by the different parvoviruses are shown, outlining the conserved 
pathways and the various steps that appear to differ between viruses. Capsids are 
shown in association with viral receptors including the TfR (CPV), αVβ5 integrin (AAV2), 
or heparin sulfate proteoglycan (HSPG) (AAV2). Uptake from the cell surface mostly 
appears to be clathrin-mediated, but other uptake pathways may be possible. Red 
arrows indicate intracellular pathways that have been identified for various viruses, but 
may differ depending on the cell type and specific experimental conditions used to 
examine virus trafficking. 
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Table 1.1. Parvoviral Receptors. Receptors defined as binding to parvoviruses, which 
in most cases also mediate the process of cell infection. 
Virus Cell-surface receptors and binding 
molecules 
Hosts 
Minute Virus 
of Mice 
Sialic acids Rodents 
Human B19 
virus 
Globotriaosylceramide or globoside 
erythrocyte P antigen 
Humans 
(primates) 
FPV and 
CPV 
Transferrin receptor-1, Sialic acid in some 
breeds 
Cats, dogs, 
other carnivores 
AAV2 Heparin sulfate proteoglycan, αVβ5 integrin, 
fibroblast growth factor receptor 1 
Humans 
AAV4 O-linked α2–3 sialic acid Humans 
AAV5 N-linked α2–3 sialic acid, platelet-derived 
growth factor receptor 
Humans 
AAV6 N-linked α2–3 and α2–6 sialic acid Humans 
AAV8 37/67-kDa laminin receptor Humans 
Bovine AAV Gangliosides Bovines 
 
Some viruses use multiple receptors, and there is sometimes uncertainty exactly 
how those interact to allow optimal infection under different circumstances. CPV and 
FPV bind the TfR for infection, and are primarily endocytosed by clathrin-mediated 
endocytosis (103). However, altering the TfR Tyr-Thr-Arg-Phe (YTRF) internalization 
signal or expressing a dominant negative dynamin-2 construct that interferes with 
clathrin-mediated endocytosis reduces and delays, but does not abolish, uptake and 
infection by CPV indicating that other uptake mechanisms can also be used (37, 62, 
104). MVM and AAV2 capsids are also taken up by clathrin-mediated endocytosis, 
despite using primary receptors that are not specifically associated with this pathway 
(sialic acids and heparin sulfate proteoglycan (HSPG), respectively) (10, 80). Other 
potential routes of uptake into the cell include macropinocytosis, caveolin-mediated 
endocytosis, and other less well-defined, clathrin- and caveolin-independent 
mechanisms (88, 90, 133). For example, porcine parvovirus binds sialic acids on the 
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cell surface and appears to use macropinocytosis and other uncharacterized pathways 
in addition to clathrin-mediated endocytosis for uptake, with viral aggregates 
preferentially using non-clathrin mediated uptake mechanisms (13). The specific 
pathways of uptake may also vary by cell type. AAV5 appears to use clathrin- and 
caveolin- mediated endocytosis in D7 cells, whereas in HeLa cells clathrin-mediated 
endocytosis is exclusively used. In HeLa cells in particular, capsids were seen 
concentrating on filopodia and at cell-cell junctions, a phenomenon observed in CPV 
binding to canine cells in chapter 2. The significance of this phenomenon is still being 
investigated (5). 
An unresolved question for most parvoviruses is the specific role that receptor 
binding and/or clustering plays in initiating cellular signaling pathways to enhance viral 
uptake or alter cellular gene expression. AAV2, for example, binds and clusters αVβ5 
integrins, which signal through Notch1 and Rac to enhance the rate of internalization by 
clathrin-mediated endocytosis (127). Receptor clustering and cross linking may also 
affect the intracellular trafficking of the receptor-virus complex (87). Interestingly, in 
some cases viruses bind and are internalized into cells but infection is nonetheless 
blocked, possibly due to some alteration in trafficking that prevents viral release. For 
example, transduction of recombinant AAV2 capsids is more efficient from the 
basolateral surface of polarized human airway epithelia compared with the apical, 
despite similar numbers of particles entering from each surface (38). Similarly, chimeric 
TfRs with the cytoplasmic and transmembrane sequences replaced with those of the 
influenza neuraminidase or the extracellular domain replaced with an anti-viral antibody 
fragment both bind and take up CPV but do not allow infection (62). However, the 
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specific intracellular blocks to infection in these cases have not been determined.  
1.8b Trafficking within the endosomal system  
The rapid dynamics and complexity of viral movement within and between 
endosomal compartments is becoming increasingly appreciated. Somewhat different 
pictures of viral entry are seen when intracellular capsid distribution is examined by live-
cell microscopy versus analysis of capsids in formaldehyde fixed cells. For CPV, viral 
uptake into cells that are subsequently fixed and stained with antibodies show capsid 
accumulation in perinuclear vesicles within 30 minutes (103), and this pattern can be 
disrupted by depolymerization of the microtubule network with nocodazole, low 
temperature, or by expression of a dynamin-2 Lys44Ala dominant negative mutant. 
These treatments also reduce infection, however it is difficult to distinguish direct effects 
on viral infectivity from indirect effects on cell viability and progression through the cell 
cycle (142, 158). After uptake, capsids are found in several intracellular locations, but 
dissecting the infectious pathway and determining from which endosomal 
compartment(s) the viruses escape into the cytoplasm has proven a difficult task (141). 
Furthermore, the number of entering virions actually completing the replication cycle is 
very low for this family of viruses, and particle to infectivity ratios have been calculated 
as low as 250:1 but may be much higher in some cases (177). The infectious proportion 
of the entering virions appear to stay associated with the TfR in the endosomal system 
for four hours or more, as infection can be blocked up to that time by intracellular 
microinjection of an antibody against the TfR cytoplasmic tail. After fixing the cells at 
different times after uptake, CPV and AAV capsids can be stained and co-localized with 
markers of the early endosome, late endosome, recycling endosome, and lysosome 
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within the first hours of infection (10, 35, 36, 103). Live cell analysis with fluorescently 
labeled particles, which more accurately represents the dynamic nature of the 
processes compared to fixed cell work, indicates there are several overlapping types 
and rates of particle movement within the vesicular system (128).  
The intracellular trafficking patterns of AAVs differ by viral serotype. For example, 
capsids of AAV5 but not other examined serotypes accumulate in the Golgi complex (6). 
Cell type and capsid concentration also affect both the distribution of AAV2 particles in 
endosomes as well as the efficiency of transduction (36, 56). When cells are fixed after 
viral uptake using low multiplicities of infection, AAV2 capsids localize primarily in Rab7-
labeled vesicles (late endosomes), while at high multiplicities they are found 
preferentially in Rab11-positive vesicles (recycling endosomes). Studies where Rab7 or 
Rab11 are overexpressed or are inhibited by RNAi treatments, suggest that the Rab11 
pathway allows more efficient transduction of AAV2 compared with the Rab7 pathway 
(36). However, other studies suggest that AAV2 escapes from an early endosomal 
compartment and thus trafficking to later compartments is dispensable for entry (10, 
85). The reasons for these differences are unclear, but are likely due to the use of 
different experimental approaches or analytical methods and to the complex nature of 
the trafficking that may be difficult to define when only fixed cells are examined.  
Endosomal acidification is essential for infection by all parvoviruses examined to 
date, although the specific function(s) in triggering the initiation of viral infection are not 
yet resolved. Bafilomycin A1 inhibits the ATPase responsible for endosomal 
acidification, while NH4Cl directly neutralizes the endosomal pH, and both significantly 
reduce infection if added within 30 minutes of AAV inoculation or within 90 minutes for 
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CPV. Prior low pH incubation of capsids does not substitute for the cellular block in vivo 
(10, 103, 142). The results of these experiments suggest that low pH may trigger a 
required conformational change in the capsid that must occur in the context of the 
intracellular environment. Some reversible changes occur in the capsid structures when 
incubated at low pH in vitro, and internal components of the capsids such as the VP1 
unique region may be more easily released in these conditions (43, 85, 159). 
Alternatively, the viruses may require the activity of an acid-dependent host factor 
present in specific endosomal compartments (such as acid-dependent proteases), or 
the endosomal trafficking and vesicular fusion pathways themselves may be directly 
affected by endosomal neutralization (3, 135, 156, 158). Both the choice of which 
trafficking pathway is followed and the stage at which the particles leave the endosome 
are emerging as critical to the transduction activity of AAV gene therapy vectors (3). 
1.8c Capsid structural changes and endosomal escape 
The parvovirus capsid is a very stable structure, and neither major 
conformational changes nor complete capsid disassembly have been detected during 
the viral entry process. The details of the responses to low pH and proteases vary 
between different parvoviruses, suggesting that there are virus-specific processing 
requirements. Parvovirus B19 is sensitive to inactivation at low pH and exposes both 
the VP1 unique N terminus and the genome under these conditions, while CPV and 
MVM capsids remain intact and infectious (14, 125, 132). CPV replicates in and is shed 
from the intestine, and is therefore likely required to be more stable than B19, which 
appears to use mainly respiratory routes of infection and spread. The full capsids of 
autonomous parvoviruses such as MVM and CPV expose a proportion of the VP2 
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protein N-termini, and 19 to 22 residues of that sequence may be cleaved off to form 
VP3 (153, 166). In the case of MVM, this sequence is cleaved during viral entry, 
enhancing the release of the VP1 N terminal sequences and capsid recycling to the cell 
surface (124). Whether this happens with CPV has not been determined, nor have 
inhibitor studies identified the protease responsible for the cleavage of MVM VP2 to 
VP3 (166).  
The N termini of VP1 proteins contain both phospholipase A2 (PLA-2) sequences 
and basic nuclear localization signals (NLSs), and both activities are required for 
infection (157, 177). This sequence becomes exposed during uptake, but may not 
require acidification for release. CPV capsids show VP1 exposure even in the presence 
of endosomal neutralizing drugs, and MVM and AAV2 will expose their VP1 N termini in 
vitro in response to urea or heat treatment (74, 85, 141). PLA-2 activity appears to be 
either directly or indirectly responsible for endosomal escape by MVM and AAV2, as 
non-infectious point mutants lacking PLA-2 activity may infect when complemented in 
trans by treatments that lyse endosomes, such as polyethylene imine or adenovirus 
capsids. This effect can be separated from the helper virus functions of adenovirus (Ad) 
as the rescue of these PLA-2 mutants does not occur with Ad variants that are deficient 
for endosomal escape (43, 138).  
Exposure of AAV to acidic conditions also results in conformational changes that 
activate or expose the PLA-2 domain of AAV2 capsids. PLA-2 active site mutations had 
no influence on capsid assembly, packaging of viral genomes into particles, or binding 
and entry into HeLa cells. Early viral gene expression, however, was delayed in cells 
incubated with these mutants, suggesting this region is important during viral entry (47). 
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Furthermore, as with other parvoviruses, capsid mutations that block exposure of the 
PLA-2 domain dramatically decrease infectivity (12, 51). 
PLA-2s modify membranes and induce curvature by modifying the lipid head 
groups and changing their packing in the membrane, but the connection to viral 
membrane penetration has not yet been specifically determined. Furthermore, the 
contribution of other viral or cellular factors and the details of the mechanism of escape 
are both unknown. Pore formation is more likely than wholesale endosomal lysis for 
CPV escape, as neither α-sarcin nor large dextrans enter the cytoplasm with incoming 
viral capsids (103, 141). 
1.8d Viral trafficking in the cytoplasm and access to the nucleus 
The capsid processes that operate in the cytoplasm and are associated with 
nuclear entry are summarized in Figure 1.6. Although some conformational changes 
begin in the endosome, there is evidence for further capsid processing in the cytoplasm. 
Treating cells with protease inhibitors reduces MVM and PPV infectivity if added 3-12 
hours after infection, late enough to affect a cytoplasmic proteosomal processing event 
(13). The proteasome may cleave the capsid VP2 at specific sites to initiating 
disassembly, but does not seem to be involved in the specific cleavage of VP2 to VP3 
or in the externalization of the VP1 N terminus. Viruses infecting cells in the presence of 
protease inhibitors accumulate at the cytoplasmic side of the nuclear membrane but 
were not see to enter the nucleus (124, 136). However, this treatment can affect a 
variety of cellular enzymes including those within endosomes, and they are also 
generally toxic to the cells, which may non-specifically reduce viral replication. 
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FIGURE 1.6. The cytoplasmic and nuclear trafficking of viral capsids. Viral release 
occurs from the endosome after PLA-2 modification, although the process is not 
completely understood. In the cytoplasm capsids may be susceptible to digestion by the 
proteosome, with enhancing or inhibitory effects depending on the virus. The 
involvement of microtubules and microtubule-associated motors (particularly dynein) 
may vary. The process of nuclear entry may involve direct transport through the nuclear 
pore by the more-or-less intact capsid or may directly or indirectly affect the nuclear 
membrane structure. 
 
 In contrast, various proteases appear to play both positive and negative roles in 
AAV infection. The proteosome plays an inhibitory role in AAV entry. Treatment with 
proteasome inhibitors enhances AAV transduction, perhaps by altering endosomal 
trafficking or processing of capsids or by decreasing ubiquitination-dependent 
degradation of viral capsids. Intact particles appear not to be ubiquitinated, and 
endosomal processing and partial disassembly may be required to prime AAV capsids 
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for ubiquitination (174).  
Cathepsins B and L, on the other hand, interact with AAV2 or AAV8 proteins as 
shown by yeast two hybrid screening, and inhibiting these proteases decreases in vivo 
transduction (3). Trypsin cleavage sites have also been identified on the AAV2 capsid 
surface, and may be involved in structural rearrangements that increase capsid 
flexibility in preparation for uncoating. While the particles remain intact during protease 
treatment in vitro, differences in negative staining suggest structural rearrangement or 
flexibility due to the cleavage event. Prolonged incubation with these proteases reduces 
the infectivity of the particle as a result of loss of heparin binding activity, but may assist 
in uncoating and release of the viral genome once inside the cell (154). Microinjection of 
particles treated with various proteases into cells would show whether these post-entry 
modifications are sufficient to activate the particles. Indeed, some capsid processing 
steps are essential, as microinjecting AAV2 virions into the cytoplasm did not result to 
productive infection even in the presence of Ad5 (136). Cleavage of capsid proteins 
may directly lead to DNA uncoating or may be required to prime the capsids for 
ubiquitination (179). 
From the site of endosomal release, the capsids must be further transported to 
the nucleus to allow genome replication. If transported to an immediately perinuclear 
position within endosomes, an active mechanism for transporting free capsids in the 
cytoplasm may not be required. Regardless, microtubules may be used by incoming 
CPV capsids for targeting to this location, as treating cells with nocodazole leads to a 
redistribution of microinjected capsids so that they become scattered throughout the 
cytoplasm (160). However, more recent data in another study conflicts with this finding, 
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as microinjected CPV capsids were observed to remain stationary within the cytoplasm 
at the site of injection for long periods of time, indicating a lack of interaction with 
cytoskeletal components (S. Lyi, unpublished data).  
For AAV, the details of cytoplasmic trafficking and interactions with the 
cytoskeleton are also not well resolved. AAV2, 5 and rh10 strains have been observed 
to interact with microtubule-associated proteins (70), but different studies show various 
effects of nocodazole or other microtubule-directed drug treatment on virus infection or 
transduction. In some cases, these treatments prevented directed motion of viral 
particles in the cytoplasm and nucleus, while in others they had little effect on 
transduction (127, 128). Paclitaxol (taxol) treatment, which stabilizes microtubules, gave 
a mild enhancement of transduction by AAV2 in one study (60). 
1.8e Nuclear entry and uncoating  
For most of these viruses, the proportion of capsids that enter the nucleus is 
quite small, and the majority appears to persist in a perinuclear location (most likely in a 
non-degradative endosomal compartment) for several hours. Theoretically, the 26 nm 
diameter capsids should be able to pass through the nuclear pore complex (NPC) 
intact, as this is seen for newly synthesized capsids during viral egress (93). The role of 
potential NLS sequences in AAV capsid nuclear trafficking has been examined. 
Expression of the VP1 basic region sequence (PARKRLNF) on the exterior of the 
capsid was found to allow infection of otherwise non-infectious particles made up of only 
VP3, indicating that the NLS plays an important role in targeting the incoming capsids to 
the nucleus (51). However, some evidence suggests that MVM may not enter the 
nucleus through the NPC and may instead use a pore-independent entry mechanism, 
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despite the presence of NLSs in the unique N terminus of VP1 that become exposed 
during entry. In one study, disruption of the outer nuclear envelope was seen when 
MVM capsids were microinjected into the cytoplasm of Xenopus oocytes, and blocking 
the nuclear pore by adding wheat germ agglutinin (WGA) did not inhibit nuclear entry by 
the injected capsids (26). This phenomenon was also seen during entry into mouse 
fibroblast cells (25). For the parvovirus H1, in mammalian cells permeabilized with 
digitonin nuclear envelope breakdown following virus addition resulted in chromatin 
extrusion, possibly via activation of caspases (M. Kann, unpublished data). Finally, 
AAVs were found to enter isolated nuclei in the absence of cytoplasmic factors required 
for transport through the pore, and this was also unaffected by WGA addition (57). A 
role for the NLS in these viruses may therefore be to target the capsid to the nuclear 
membrane and/or dock it at the NPC, instead of directing transport through the pore. 
However, further studies are required to define the mechanisms involved in productive 
infection. 
The capsid form that enters the nucleus is also still unresolved, and may vary 
between viruses. Although MVM capsid proteins have not been detected in the nucleus, 
this may simply indicate a low efficiency of transfer or may suggest that the capsids 
dock at the NPC (85). Conversely, in some studies microinjected CPV capsids appear 
to enter the nucleus intact, though after a delay of three to six hours (159, 166). For 
AAV, there is conflicting evidence whether uncoating occurs before or after nuclear 
entry. Fluorescently labeled AAV2 capsids were detected by microscopy within the 
nucleus within 2 hours (10), and some particles were seen within membrane 
invaginations of the nuclear envelope after only 15 minutes in studies utilizing single 
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particle tracking technology (128). Co-infection with adenovirus was found to enhance 
nuclear entry of AAV capsids, though the process was still inefficient and the majority 
(>90%) of particles remained outside the nucleus (83, 170). The results of two additional 
studies suggest that the AAV genome is associated with the capsid when it contacts the 
nucleus (136, 145). Microinjection of anti-capsid antibodies into the nucleus was found 
to block infection in one study, and exposure of capsids to nuclear extracts in another 
had the ability to induce genome release in vitro. Taken together, these results may 
suggest that uncoating occurs dynamically during or shortly after the process of nuclear 
entry, and this step may represent a bottleneck in the efficiency of infection by 
parvoviruses.  
The uncoating mechanism of parvoviruses is also not well understood, but in 
general the particle is quite robust and complete disassembly may not be required for 
genome release (96). Instead, the viral DNA may be extruded or extracted from 
relatively intact capsids (28). In support of this hypothesis, a fluorescently labeled probe 
for the 5’ end of the MVM genome detected the partial exposure of DNA from VP2 5-
fold cylinder mutants in the cytoplasm while the 3’ end (which would prime new DNA 
synthesis) remained inside the capsid (85, 125). In a more recent study with wild-type 
virions, however, genome extrusion occurred from the 3’ to 5’ direction (designated a 
“pass-though” or “second portal” model) in capsids depleted of divalent cations. These 
results further support a role for capsid conformational changes during the entry 
process that allow the DNA to be released in a form immediately permissive for second 
strand synthesis, though the in vivo trigger remains to be defined (28). As with nuclear 
entry, genome release from the capsid occurs slowly and inefficiently for autonomous 
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parvoviruses, as microinjecting antibodies to the capsid into cells could block CPV 
infection even when administered several hours after inoculation (160).  
1.8f Parvoviral replication 
Parvoviral replication is dependant on exogenous DNA polymerases, as the 
viruses do not encode their own. The autonomous parvoviruses are dependent on 
cellular S phase for replication, in accordance with their tropism for rapidly dividing cells, 
while AAVs generally also require co-infection with helper viruses such as adenoviruses 
or herpesviruses. In the absence of helper virus infection, AAV can establish latency 
either by integration into the host chromosome or by maintenance as an episomal 
concatemer. Treatment of cells with UV light, heat, or cyclohexamine can also induce 
AAV replication, likely by stimulating DNA damage-repair mechanisms within the cell 
(11).  
Once inside the nucleus, CPV has been shown to cause rearrangements of the 
nuclear architecture, though parvoviruses are unable to directly stimulate cellular 
division. Late in the process of replication, DNA “replication bodies” may fill the majority 
of the nucleus, with the cellular chromatin marginated at the nuclear periphery (64).  
The parvoviruses replicate by a rolling-hairpin mechanism that proceeds through 
a variety of duplex intermediates culminating in the release of genomes with a NS1 
protein covalently linked to the 5’ end. After the MVM genome is released from the 
capsid the first step in replication is the synthesis of the second (complimentary) DNA 
strand, which is primed using the 3’ terminal hairpins and elongated by cellular 
polymerases. The right-handed terminal hairpin is joined to the end of the elongating 
strand, and then is nicked by the viral NS1 protein to allow the second strand to be fully 
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extended (167). The secondary structure at the ends is then restored, and the new 3’ 
hairpin can be used to prime further rounds of DNA elongation. Single stranded 
genomes are released by additional DNA binding, nicking, and helicase activities of 
NS1 (65).  
The replication of AAV is similar, except that helper viruses facilitate DNA 
synthesis instead of cellular polymerases, and the large Rep proteins take the role of 
NS1. AAV replication may also be completed in a helper virus-free manner by co-
transfection of the individual helper genes, specifically adenovirus E1A/B E2A, E4orf6, 
and VA RNA (126). These genes act to facilitate RNA processing, regulate viral 
promoters, and inhibit cellular antiviral responses (89). 
1.8g Capsid assembly and viral egress 
The details of capsid assembly remain elusive, but the most likely pathway 
involves the capsid proteins (VP1 and VP2) assembling into dimer, trimer, and/or 
pentamer intermediates, before or after transport into the nucleus (175). VP1 contains 
four basic regions that have been shown to function as NLSs, and the MVM VP2 also 
contains a putative NLS and a nuclear localization motif that is functional after VP2 
trimerization (29, 82, 159). Once inside the nucleus, several highly conserved 
hydrophobic amino acids along the interface between the trimers likely facilitate this 
spontaneous organization (122). Not all trimers include a VP1 molecule, and complete 
capsids can assemble from only VP2, though they are non-infectious (123, 152). The 
subsequent steps from trimerization to complete capsid formation have not been 
determined, but appear to occur before DNA incorporation into the capsid.  
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While empty capsid assembly can occur within minutes, mature, genome-
containing capsids can take up to an hour or more to be produced. The genome is 
packaged 3’ end first into the intact, empty capsid through the five-fold pore. The 
process appears to proceed quickly for the first 2kb of packaging, but then stalls and 
requires the helicase action of NS1 (or the small rep proteins for AAV) for completion. 
This reaction may be facilitated by structural interactions between the DNA backbone 
and the capsid that help to reduce the energy required for packaging. Even in the 
complete, mature capsid, about 21 bp of the 5’ end of the genome remains exposed on 
the capsid surface with a covalently linked NS1 protein attached (175).  During 
packaging, in some cases the VP2 N termini are extruded from the five-fold pores to 
expose sequences necessary for nuclear export of the mature virion (a process which 
does not readily occur in empty capsids) (86). The autonomous parvoviruses package 
99% negative strand genomes, while AAV packages approximately 40% positive strand 
DNA. Secondary structure formation within the genome may interfere with efficient 
packaging, and may explain why positive strand DNA is poorly encapsidated in some 
but not all viruses. Furthermore, structural limitations on genome packaging may also 
be an overlooked complication in cases of limited yields during gene therapy vector 
production (29).  
Mature viral capsids are released from dying cells in a process that involves 
NS1-mediated cytotoxicity but is not well understood. A recent study identified markers 
of early apoptosis in CPV-infected NLFK cells, but the process of apoptotic was 
incomplete (98). Thus virus release may simply be a passive process of membrane 
permeabilization accompanying cell death, but the viruses may also be playing more of 
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an active role in tailoring how the cell dies and may be changing the organization of the 
cytoskeleton at this stage (7, 22). 
1.9 Introduction to antibody neutralization  
In an effort to prevent or contain viral spread, the infected host produces 
antibodies to bind and inactivate the viral capsids. The mechanism of antibody 
neutralization is direct or indirect interference with the functions of the viral capsid 
proteins. Antibodies can aggregate viral particles in solution and reduce the number of 
virions available to infect cells; however, this mechanism is often reversible and/or 
incomplete. Antibodies can also inhibit the interaction of viral surface proteins with the 
cellular receptor. They can either compete directly for the receptor binding site, or in 
some cases may coat the virus in an apparently non-specific way to sterically prevent 
interaction with the cell. However, given that the receptor-binding site is likely to have 
sequence constraints necessary to maintain the requisite structural interactions with the 
cellular receptor, these areas make good antigenic targets, particularly when they are 
located on a highly accessible portion of the capsid.  
Various models of neutralization exist, including the single and multiple hit 
models (106). The single hit model emphasizes the importance of antibody binding to a 
key site on the viral capsid. Inactivation is achieved, for example, by the induction of 
structural rearrangements that renders the capsid non-infectious (34). This model does 
not, however, explain neutralization in all virus systems and if it occurs is likely 
uncommon (73). The multiple hit model explains neutralization as the result of 
antibodies coating the surface of the capsid by occupying a certain threshold 
percentage of available epitopes. Determinants of the stoichiometry of neutralization, or 
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the number of antibodies per viral capsid needed to prevent cellular infection in vivo, 
include capsid size, epitope accessibility, and the organization of the viral surface 
proteins. For icosahedral viruses, capsid size is generally proportional to the number of 
antibodies needed to neutralize and is related to the surface area that must be directly 
or sterically inhibited from interacting with host cells. Other details such as the location 
of the antigenic epitopes on raised or depressed areas of the capsid, as well as the 
spacing and density of the epitopes, may affect neutralization properties. For 
Picornaviruses, different antibodies have been shown behave according to the tenets of 
each of these models. A single hit antibody, for example, can mimic receptor binding 
and lead to premature uncoating in solution, while multiple hit antibodies must reach a 
certain occupancy before successfully being able to block cellular receptor binding. Not 
all of the accessible epitopes need to be coated in order to neutralize, and the required 
stoichiometry varies by antibody (117). Bivalent binding and steric hindrance by 
antibodies may decrease the threshold for neutralization.  
Neutralization may also occur after virus attachment, for example if antibody 
binding inhibits interaction with intracellular cofactors required for infection. Antibodies 
can also facilitate or block conformational changes in the capsid and may interfere with 
intracellular events such as endosomal trafficking, release of the viral capsid into the 
cytoplasm, and genome uncoating. Antibodies directed against a flexible region on the 
West Nile virus capsid, for example, act at a post-attachment step by inhibiting 
intracellular fusion of the viral envelope with cellular membranes to prevent genome 
release (161). 
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In vivo, activation of complement, antibody dependent cellular toxicity, and other 
Fc related functionality further contribute to protection against infection. Specifically, 
interaction with TRIM-21 was recently identified as a method for degrading antibody 
coated viral capsids, regardless of the specific antibody-virus interaction (84). Given the 
wide range of neutralization mechanisms, in vitro neutralization does not always 
correlate to the efficacy of protection in vivo (99). For example, anti-West Nile virus Fab 
antibody fragments selected for neutralization ability in vitro provided poor neutralizing 
ability in vivo, though the mechanism behind this phenomenon was not further 
investigated (39).  
1.10  Antigenicity of the CPV capsid 
Antibodies are an essential part of the immune response against CPV. The major 
antigenic sites on the capsid are located within the surface oriented loops between the β 
strands, with loops 1 and 3 containing the most antigenically important residues. 
Furthermore, while many parvoviruses that infect carnivores are antigenically 
indistinguishable from FPV (such as viruses from raccoons, mink enteritis virus, and 
blue fox parvovirus), these sites are useful for distinguishing between FPV and the 
various CPV antigenic types based on monoclonal antibody binding patterns. These 
sites contain conformational epitopes, and have been grouped into 2 partially 
overlapping areas, named the “A site” and the “B site” (Figure 1.7) (53, 140).  
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FIGURE 1.7. CPV antigenicity. The two major antigenic sites on the CPV capsid are 
projected onto a roadmap of the capsid asymmetric unit. The “A site” is outlined in red, 
and the “B site” is outlined in blue. The area outlined in green includes residues 
important for receptor binding. Modified from (53), with permission.  
 
The “A site” contains VP2 residues near the tip of the three fold spike, including 
93, 222, 224, and 426, important in the antigenic differentiation of CPV-like strains 
isolated from raccoons (chapter 3) and CPV-2c from other CPV strains. The “B site” 
contains residues located on the shoulder of the 3-fold spike, including the CPV-2 to 
CPV-2a mutations of Ala300Gly and Asp305Tyr as well as residues 299 and 302. This 
epitope partially overlaps with the receptor-binding site, and suggests that inhibition of 
receptor binding is one mechanism of neutralization used against these viruses. Other 
residues important for antigenicity lie under the capsid surface but have indirect effects 
on its structure, namely 80, 101, 103, 375, 564, 588 (140). Note that several of these 
antigenically important residues also affect receptor binding properties and host range, 
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(93, 300, etc.) and that both pressures likely influence selection of specific amino acids 
at these sites (61).  
1.11 Adeno-associated viruses (AAVs) as gene therapy vectors 
AAV is currently under investigation as a vector for therapeutic gene delivery. A 
variety of features make AAV an attractive vector, including the stability of the capsid, 
the inability of the virus to replicate without helper genes, the lack of disease associated 
with infection, the ability to induce long term expression of packaged genes, and the 
ability to transduce a variety of cells, both dividing and non-dividing (134, 137, 155).  
This group of viruses was first discovered in the 1960s as a contaminant in 
adenovirus preparations (4). 12 different serotypes have been discovered in different 
host species to date, and of those AAV2 was the first serotype studied and is the best 
characterized. The cellular receptor for AAV2 is heparin sulfate proteoglycan (HSPG), 
though the virus can use  αVβ5 integrins as co-receptors and has also been shown to 
interact with the basic fibroblast growth factor receptor 1 (FGFR1) (120, 143). Other 
serotypes examined for use in different target tissues include AAV1 based on its 
superior ability to transduce muscle and hematopoitic stem cells compared to other AAV 
serotypes (178) and AAV5 for efficient transduction of muscle, airway epithelia, and 
brain tissues compared to AAV2 (176). Both of these serotypes utilize sialic acids as a 
cellular receptor (163), and AAV5 additionally binds to the platelet derived growth factor 
receptor (PDGF) as a co-receptor (115).  
The AAV genome lends itself naturally to replacement with small gene products. 
Transgenes may be efficiently packaged into the AAV capsid by flanking any gene with 
the AAV inverted terminal repeats (ITRs), without including any viral proteins otherwise 
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encoded by the genome. Furthermore, despite small intrinsic genome size, strategies 
have been developed for the delivery of genes larger than the normal AAV packaging 
capacity (~5 kb) (45). Though naturally found in association with adenoviruses in nature, 
various helper virus-free production systems have emerged. Often, this involves 
transducing mammalian cells with the capsid gene of interest, two AAV Rep genes 
(p78/68), the adenovirus helper genes (E2A, E4, VA), and the genome to be packaged 
(52, 171).  
1.12 Immunity to adeno-associated viruses  
Despite a relatively low immunogenicity compared to other viral vector systems, 
humoral immunity leading to virus neutralization is a major challenge for gene therapy. 
Natural antibodies exist in up to 30%-80% of subjects in different studies, and these 
antibodies may be capable of preventing gene transduction by neutralizing the virus 
even at the first administration. Reactivity against serotypes 1, 2, 3, and 5 appears to be 
the most common, with variation according to geographic location and age of the 
subject. Furthermore, elicitation of memory B cell responses can preclude the 
implementation of repeat dosing schedules where necessary for sustained treatment. 
These responses are affected by the route, dose, and serotype of the administered 
virus, as well as the identity, expression level, and promoter of the transgene product 
(59, 144).  
Pseudotyping the transgene using different serotypes of AAV has been 
attempted to circumvent the problems encountered with multiple administrations, as the 
capsids can very in up to 20% of amino acid residues such that antibodies tend not to 
cross-react significantly between serotypes (55, 169). Re-dosing with serotypes AAV5, 
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7, and 8 are of current interest because they are the most divergent from AAV2 and 
have lower levels of pre-existing immunity in some studies (24, 44). Concurrently dosing 
immunosuppressants to reduce reactivity to the AAV vector has also been attempted 
with some success in clinical trials. This strategy is of particular benefit when the 
immune response is directed against the transgene itself. 
In addition to humoral immunity, innate and cell-mediated immune mechanisms 
may also play roles in interfering with the delivery of gene therapy vectors. On their 
own, most AAV capsids poorly transduce antigen presenting cells and are below the 
threshold of immunogenicity needed to strongly prime innate effector functions or 
cytotoxic T lymphocytes (CTLs). However, in some conditions such as expression of an 
immunogenic transgene or delivery into inflamed tissues, the immune system can be 
sufficiently activated to destroy transduced cells. As with the humoral immune response, 
this activity varies by capsid serotype, gene promoter, and target cell type (91). 
1.13 Structural basis of the antibody response to AAV 
The structure of AAV1, 2, and 5 has been solved alone and in complex with 
several Fab fragments. By way of review, Fab fragments are obtained by digesting 
antibodies with papain to release the variable domains and one constant region of both 
the heavy and light chain. Thus, two Fab fragments and a single Fc portion are 
produced per IgG. The Fab fragments contain a single antigen-binding site, cannot 
crosslink virus capsids, and do not generally retain any of the constant region 
functionality. In addition, they are smaller than intact IgGs and thus have a smaller area 
of steric inhibition.  
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 In contrast to previous work showing a variety of structural conformational 
epitopes, the results of recent structural analyses show that most anti-AAV antibodies 
bind within a relatively limited footprint on raised areas around the threefold axis (168). 
Like other parvoviruses, in most serotypes the spikes at the three-fold axis of symmetry 
are the major feature projecting from the surface of the capsid. The receptor binding 
sites vary by serotype and specific cellular receptor, but where known tend to be located 
on these spikes (172). Interestingly, none of the antibodies tested against AAV or the 
autonomous parvoviruses bound to the other main raised feature of the viral capsid: the 
cylinder at the five-fold axis. Despite being accessible to the solvent, this loop may be a 
more flexible structure than the three-fold spike, and therefore less able to stimulate an 
effective antibody response (50). Alternatively, this structure may be partially covered by 
protein (the VP2 N terminus in the case of CPV) or the genome protruding from the pore 
at the five-fold axis. 
Of several recently produced anti-AAV1 monoclonal antibodies, one (AA4E4.G7) 
bound on the shoulder of the threefold spike, away from the receptor-binding site, 
whereas others were expected to overlap with this site (AA5H7.Dii, ADK1a)(B. Gurda, 
unpublished data). The antibodies analyzed in this study also bound with different 
stoichiometries; occupying from 33% (AA4E4.G7, 5H7.D11) to 100% (ADK1a) of the 
available epitopes.  This distribution of antigenic epitopes and the differences in 
structural interaction is reminiscent of other parvoviruses, where two overlapping 
regions of antibody binding have been described: one surrounding and one relatively 
distinct from the receptor-binding site. These differences in antibody interaction were 
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shown to be functionally relevant in previous studies of CPV infection, as antibodies 
were varyingly neutralizing as intact IgGs and as Fab fragments (53). 
1.14 Dissertation outline 
This thesis explores various aspects of parvovirus-host interactions. Chapters 2 
and 3 examine the interaction of the viruses with the host cell during viral entry. Chapter 
2 examines the early stages of entry of wild type viruses into host cells of different 
species, and underscores the complexity and rapid dynamics of viral endocytosis and 
intracellular trafficking. In Chapter 3, the role that the transferrin receptor cytoplasmic 
tail plays in directing the virus into the cell during infection is determined by the 
evaluation of receptor mutants where this domain is mutated or replaced with 
cytoplasmic tails from other type II membrane proteins.  
Chapter 4 discusses the interaction of the viruses with different hosts on the 
whole organism level, addressing aspects of Parvoviral evolution and the role of 
raccoons as an intermediate host. My role in this work was to examine the binding and 
uptake properties of recently described CPV-like viral strains isolated from raccoons as 
related to in vitro host range, and to characterize antigenic variation between these 
strains and other carnivore parvoviruses.  
Chapter 5 examines the interaction of the parvoviral capsid with the host immune 
system, specifically neutralizing antibodies. In this chapter, the mechanism of 
neutralization was evaluated for several anti-AAV1 and one anti-AAV5 monoclonal 
antibody.  
Finally, Chapter 6 summarizes the significance of the research contained herein and 
provides suggestions for future investigation. 
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CHAPTER 2: EARLY STEPS IN CELLULAR INFECTION BY PARVOVIRUSES: 
HOST-SPECIFIC DIFFERENCES IN RECEPTOR BINDING BUT SIMILAR 
ENDOSOMAL TRAFFICKING  
 
 
 
 
 
 
 
 
 
 
Modified from: Harbison C.E., Lyi S.M., Weichert W.S., Parrish CR. 2009. Early steps 
in cell infection by parvoviruses: host-specific differences in cell receptor binding but 
similar endosomal trafficking. J Virol. 83(20): 10504-14. With permission.
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2.1 Abstract 
Canine parvovirus type 2 (CPV) and feline panleukopenia virus (FPV) are closely 
related parvoviruses that differ in their host ranges for cats and dogs. Both viruses bind 
their host transferrin receptor (TfR), enter cells by clathrin-mediated endocytosis, and 
traffic with that receptor through endosomal pathways. Infection by these viruses 
appears to be inefficient and slow, with low numbers of virions initiating replication only 
several hours after cellular entry. Species-specific binding to the TfR controls viral host 
range, and in this study FPV and different antigenic variants of CPV differed in the level 
of cell attachment, uptake, and infection in canine and feline cells. During infection, CPV 
particles initially bound and trafficked passively on the filopodia of canine cells, while 
they bound to the cell body of feline cells. That binding was specifically associated with 
the TfR as it was disrupted by the addition of anti-TfR antibodies. Capsids were taken 
up from the cell surface with different kinetics in canine and feline cells, but unlike the 
cycle with the cellular TfR ligand, transferrin, most capsids did not recycle back to the 
cell surface. The intracellular trafficking of fluorescently-labeled virus was examined and 
capsids were found to enter Rab5-, 7-, or 11-positive endosomal compartments within 
minutes of uptake. Constitutively active (CA) or dominant negative (DN) Rab mutants 
changed the intracellular distribution of capsids and affected the infectivity of virus in 
cells. 
2.2 Introduction 
Cellular infection by animal viruses involves a specific sequence of steps that 
deliver the virus and its genome from the cell surface to the compartment where 
replication can occur. For non-enveloped viruses, infection initiates with binding to a 
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specific viral receptor and uptake into the cell by receptor-mediated endocytosis. 
Various factors can control the process of viral uptake, including the signaling and 
endocytic properties of the receptor(s) bound by the virus, the affinity of the virus for the 
receptor, and the structural features of the interaction in different environments (36, 61). 
Receptors may be located on the cell body and/or may be displayed on the extended 
lamellipodia or filopodia that markedly increase the surface area of the cell. Viruses 
binding to filopodia can be either passively delivered to the cell body for endocytosis by 
dynamic movement of the entire structure or may be actively trafficked along the actin 
filaments that support the filopodia by retrograde actin transport or the action of myosin-
2 motors (32, 57). Cross-linking and clustering of receptors by viral particles can 
influence the rate of endocytosis, and many viral receptors activate signaling pathways 
in this manner to alter the structure of the underlying cytoskeleton and enhance uptake 
(12, 30, 51). Once endocytosed, receptor-bound viruses are enclosed within vesicles 
and are trafficked within the endosomal pathways of the cell, where they may undergo 
structural alterations upon exposure to conditions such as low pH or proteases (36, 61). 
The specific receptor-mediated binding and entry pathways used by viruses often 
provide signals that trigger endosomal escape and allow the virus to establish infection.  
Markers for variety of endosomal compartment have been used in studies of viral 
entry. For example, Rab proteins are monomeric small GTPases that regulate 
endosomal membrane trafficking, and specific Rab proteins are associated with 
individual endosomal compartments. Among the many Rab proteins that have been 
described, Rab5 is primarily associated with the early endosome and regulates 
trafficking through that compartment, Rab7 is associated with the late endosome, and 
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Rab11 is associated with the recycling endosome (14, 58). Tracking viral particles as 
they move through the endosomal system has been used to define the steps in the 
entry and infection processes of a variety of different viruses, and has revealed many of 
the common features and variant processes that are used (7-9, 33, 71). 
Here we examine the uptake and infection of cells by parvovirus capsids, and 
compare some of the steps followed by capsids that differ in their receptor binding 
properties and host ranges. Feline panleukopenia virus (FPV) infects cats (50, 66), 
binds the transferrin receptor-1 (TfR) on feline cells, and uses that receptor for uptake 
and infection (27, 44). FPV does not bind the canine TfR, and does not infect dogs or 
cultured canine cells. Canine parvovirus type 2 (CPV) is a natural variant of FPV that 
emerged in 1978 after acquiring a small number of mutations that allow its capsid to 
bind the canine TfR (27). The original strain of CPV (CPV-2) spread worldwide in dogs 
during 1978, but some of the same mutations that gave it the canine host range 
rendered it unable to infect cats (66, 67). The original CPV-2 strains were replaced 
worldwide during 1979 and 1980 by a natural variant, CPV type-2a (CPV-2a), which 
contained an additional 4 to 5 changes in the VP2 coat protein (48, 49). Subsequently, 
the canine viruses have continued to evolve, and additional single mutations have been 
selected that further altered antigenic epitopes. In particular, strains altered at VP2 
residue 426 are designated CPV-2b (Asn426Asp) and CPV-2c (Asp426Glu)(13, 48). 
CPV-2a and its variants are able to infect both dogs and cats, but show reduced binding 
to the feline TfR on cells and in vitro (27, 42). In addition, the affinity of binding to the 
canine TfR is much lower than that seen for the feline TfR (42). 
The TfR is a type II membrane protein expressed in non-lipid raft regions of the 
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plasma membrane, and it facilitates iron uptake into cells by binding iron-loaded (holo) 
transferrin (Tf) at the neutral pH of the extracellular environment (2). TfR expression is 
tightly regulated and it is more highly expressed on dividing cells with high iron needs, 
which is advantageous for these viruses as they require cellular S phase for replication. 
The TfRs of mice and humans are also used as receptors for cell infection by other 
viruses, including the mouse mammary tumor virus and the New World hemorrhagic 
fever arenaviruses, respectively (52, 56). 
The TfR is assembled as a homodimer on the surface of the cell, and each 
monomer of the ectodomain is composed of protease-like, apical, and helical domains, 
as well as a 30Å membrane-proximal stalk (5, 20, 31). The transmembrane domain 
mediates membrane insertion and influences some aspects of trafficking within the cell, 
while the short cytoplasmic domain contains a tyrosine-threonine-arginine-
phenylalanine (YTRF) sequence that engages the clathrin-mediated endocytic 
machinery through adaptor protein-2 (AP-2) (53, 55). The TfR cytoplasmic sequence 
also includes one or two cysteines adjacent to the inner leaflet of the membrane that 
may be palmitoylated to influence the rate of receptor recycling, and contains 
sequences that control basolateral localization in polarized cells (41). In the normal 
pathway of TfR-mediated entry, the TfR-holoTf complex is transported into the 
endosomal system where low pH results in Tf conformational changes and iron release. 
A subset of the TfR-(iron free) apoTf complexes are rapidly recycled to the cell surface 
from the early endosome to release the apoTf, but a higher percentage passes through 
the perinuclear recycling endosome, remaining intracellular for a slightly longer period of 
time (21, 22, 24, 37, 38, 69, 70). The rate of uptake and the efficiency of TfR recycling 
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depend on the form of the ligand, and more than 97% of monomeric Tf recycles to the 
cell surface within 10-30 minutes regardless of the intracellular pathway taken. 
However, crosslinking TfRs with oligomeric Tf or antibodies causes the complexes to be 
retained within endosomes for longer periods and a higher proportion to be trafficked to 
late endosomes and lysosomes for degradation (35).  
While holoTf binds the membrane proximal side of the feline and canine TfR 
ectodomain (11), mutational analysis of the receptor has identified the importance of the 
apical domain for binding FPV and CPV capsids (43). The feline and canine TfRs differ 
in ~10% of their sequences, but the major difference controlling the CPV specific 
binding is a unique glycosylation site in the apical domain of the canine TfR (43). 
Alteration of the glycosylated Asn to Lys (the feline TfR residue) on the canine TfR 
background allowed FPV to bind, and also greatly increased the affinity of binding by 
CPV-2 and CPV-2a-related capsids (42). 
CPV and FPV have small (25nm) non-enveloped icosahedral capsids that 
package a single stranded DNA genome of ~5,120 bases (68). The particles are made 
up of two overlapping proteins, VP1 and VP2, with 90% of the capsid protein being VP2. 
VP1 contains a 143 residue amino (N)-terminal sequence that encodes phospholipase 
A2 (PLA-2) enzymatic activity, as well as basic amino acid motifs that play a role in 
nuclear localization (72). The VP1 unique region becomes exposed during cell entry 
without capsid disintegration, and the PLA-2 activity likely plays a role in endosomal 
escape by modifying the endosomal membrane (19, 76). 
Previous studies of cell entry by CPV, minute virus of mice (MVM), and various 
adeno-associated viruses (AAVs) show that viral uptake primarily occurs through 
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clathrin-mediated endocytosis. However, when the AP-2 interacting sequences in the 
cytoplasmic tail of the feline TfR are mutated or deleted, the variant receptor still allows 
CPV infection at similar efficiency to wild type TfR (26). The intracellular pathways of 
viral entry and trafficking have been examined in cells fixed at various times after uptake 
followed by antibody staining for virus and cellular markers. Time courses examined 
were between one and six hours, and sequential steps of trafficking were suggested 
whereby the virus passed from the early endosomes to the recycling endosome, with 
localization in late endosomes and lysosomes only at later time-points (65). By specific 
anti-VP1 fluorescent antibody staining, VP1 N terminus release was only observed 
several hours after uptake, possibly in a low pH degradative compartment (64, 72). In 
addition, CPV capsids appeared to remain associated with the receptor for up to four 
hours after virus uptake, as antibodies against the TfR cytoplasmic tail microinjected 
into feline CRFK cells blocked infection in this time period (73). Neutralizing the low pH 
of the endosomal system with ammonium chloride or Bafilomycin A1 also blocked 
infection, although it is not clear whether this was due to direct effects on the capsid or 
to indirect, global alterations on the cellular endosomal system. Evidence has also been 
found to suggest that the capsid undergoes only minor structural rearrangement as it 
passes through the intracellular environment. When the X-ray crystal structures of 
capsids of CPV and FPV were determined at low pH, in the presence of EDTA, or 
following digestion by a panel of proteases, only small changes in the orientation of 
surface loops on the viral capsid were observed (40, 60). 
Here we used microscopy to examine the dynamic steps of binding, uptake, and 
early trafficking by parvovirus capsids in live canine and feline cells. Labeled capsids 
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were seen to undergo rapid dissemination into multiple endosomal compartments within 
minutes of cellular attachment. Initial binding of CPV to canine cells involved filopodia, 
while in feline cells the virus bound primarily to receptors located on the cell body. In 
cells expressing green fluorescent protein (GFP)-conjugated Rab proteins to label 
different endosomal compartments, co-localization of viral particles with Rab5, 7, and 
11-positive endosomes was readily observed, and virions gradually accumulated near 
the microtubule organizing center (MTOC) over 20-45 minutes. The distribution of 
intracellular viruses in feline cells was altered by expression of either constitutively 
active (CA) or dominant negative (DN) mutants of the Rab proteins. DN Rab5 and Rab7 
and CA Rab5 inhibited infection, providing evidence for the importance of these 
compartments in the infectious pathway of parvoviruses.  
2.3 Materials and methods 
2.3a Cells and viruses 
Feline Crandall-Rees feline kidney (CRFK) and Norden laboratory feline kidney 
(NLFK) cells, and canine A72 and Cf2Th cells, were grown in a 1:1 mixture of McCoy’s 
5A and Liebovitz L15 (MCC/L15) media containing 5% fetal bovine serum. Chinese 
hamster ovary (CHO)-derived cells lacking the hamster TfR (TRVb cells) (39) were 
grown in Ham’s F12 medium containing 5% fetal bovine serum. 
Viruses were derived from infectious plasmid clones of FPV (FPV-b), CPV-2 
(CPV-d), and CPV-2b (CPV-39) strains (27, 47). Plasmids were transfected into NLFK 
cells and the viruses recovered titrated using TCID50 assays (46). Virus capsids were 
concentrated by polyethylene glycol precipitation followed by sucrose gradient 
centrifugation, then dialyzed against either PBS or 20 mM Tris-HCl (pH 7.5) and stored 
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at 4ºC (1, 40). 
2.3b Fluorescent markers and ligands, fluorescence microscopy, and intracellular 
localization 
Rab5, Rab11, and Rab7 genes with green fluorescent protein (GFP) fused to the 
N-termini were obtained from Craig Roy, Yale University, or in some cases prepared by 
site-directed mutagenesis. Constitutively active mutants included Rab5-Q79L, Rab7-
Q67L, Rab11-Q70V, and dominant negative mutants were Rab5-S34N, Rab7-T22N, 
and Rab11-S25N. Cells were transfected with plasmid DNA using Lipofectamine 
(Invitrogen, San Diego, CA), and 2 days later were seeded in culture dishes with 
coverslip inserts for imaging (MatTek, Ashland, MA).  
Canine Tf (Sigma, St. Louis, MO) was iron loaded as previously described (4). 
Purified CPV capsids, FPV capsids, or canine Tf were labeled with Alexa-488, Alexa-
594, or Alexa-647 dyes (Invitrogen) at 20% of the recommended concentrations for 30 
minutes at 20°C (27). The labeled capsids or Tf were dialyzed against 0.2M phosphate 
buffered saline at pH 8.2, passed through a P10 gel filtration column (Millipore, Billerica, 
MA), and stored at 4°C. Capsids were examined by fluorescence microscopy to ensure 
single particle labeling, and images collected were analyzed with ImageJ software (US 
National Institutes of Health, Bethesda, MD).  
2.3c Virus or Tf cell binding, uptake, and recycling  
Cells were incubated at 37°C for five minutes with either labeled capsids or Tf, 
then the media was replaced with phenol-red free Dulbecco’s Modified Eagle Medium 
(DMEM) and the cells were observed at various time points as indicated using a 37°C 
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100x-oil lens and time-lapse imaging. Images were collected with a Hamamatsu 
OrcaER CCD camera, with different labels collected sequentially as separate channels. 
Images were analyzed using SimplePCI software (Hamamatsu, Sewickley, PA). Co-
localization of virions with endosomal markers was determined with ImageJ software, 
and particle tracking was performed using the ImageJ manual tracker plugin (Institut 
Curie, Orsay, Fr). Confocal images were obtained using a Zeiss LSM510 microscope, 
and images were prepared and analyzed using the Zeiss ZEN 2008 software.  
As indicated, Alexa-488-labeled actin from rabbit muscle (Molecular Probes, 
Eugene, OR) was injected into cells at a concentration of 1 mg/ml using an Eppendorf 
injector and micromanipulator. Cells were incubated at 37°C for 60 minutes to allow 
actin diffusion and incorporation into cellular structures, then Alexa-594 labeled CPV-2 
capsids were added and visualized as described above. 
To determine the specific role of the TfR in virus or Tf binding to the cells, 
antibodies against the cytoplasmic tail or the ectodomain of the receptor were used. 
Antibody H68.4 (Zymed, South San Francisco, CA), recognizing the cytoplasmic tail of 
the TfR, was injected into cells using an Eppendorf microinjector and micromanipulator 
30 minutes prior to incubating the cells with virus or Tf. Rabbit antibodies prepared 
against the extracellular domain of the receptor were prepared from peptide 559 to 571 
of human TfR conjugated to Keyhole limpet hemocyanin as previously described, and 
were used for receptor visualization in this experiment (42). 
The amount of cell-associated Alexa-488-labeled virus or Alexa-647-labeled Tf 
was quantified with a FACScalibur flow cytometer and Cell Quest software (Becton-
Dickinson, San Jose, CA). Cells cultured in 10 cm2 dishes overnight were incubated with 
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10 µg/ml labeled ligand for one hour at 37°C. After two washes in Hank’s buffered saline 
solution without Mg2+ or Ca2+ (HBSS), cells were detached using 1mM 
Ethylenediaminetetraacetic acid (EDTA) in HBSS on ice, then fixed with 4% 
paraformaldehyde (PFA) in phosphate buffered saline (PBS) prior to analysis. One and 
two tailed Student’s t tests were performed to assess the differences between the 
geometric mean fluorescence intensity levels (MFI) after background subtraction. 
To examine the recycling of capsids or Tf, Alexa-488-labeled virus or Alexa-647-
Tf was bound to CRFK or Cf2Th cells on ice for 30 minutes. The cells were washed and 
warmed to 37°C in fresh media and the relative amounts of cell-associated capsids or Tf 
determined at various times of incubation using flow cytometry as above.  
2.3d Cell infection assays and relative infectivity  
Fifty percent tissue culture infectious dose (TCID50) titers were determined for 
freshly prepared stocks of the FPV, CPV-2, and CPV-2b strains of virus in CRFK and 
Cf2Th cells as previously described (46). The viral single stranded DNA in each 
inoculum was determined by quantitative polymerase chain reaction (qPCR) using a 
SYBRGreen-labeled probe (Applied Biosystems, Foster City, CA), and was 
standardized using known samples of the cloned CPV-2 genome. Student’s t tests and 
paired t tests were used where indicated to examine the differences between the 
logTCID50/genome for the different viruses. 
2.3e Time course of infection 
The rate of virus uptake was determined by measuring the infectivity in cells 
treated with neutralizing rabbit anti-CPV antiserum added at various times after 
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inoculation (45). Cells seeded at 2x 104 cells/cm2 were incubated with virus inocula 
diluted in DMEM with 0.1% BSA for 30 minutes on ice. The cells were cultured at 37°C 
in growth media, and at the times indicated medium containing 1:1000 dilution of rabbit 
anti-CPV serum was added. Cells were fixed after 24 hours with 4% PFA and stained 
with an anti-NS1 antibody (CE10) (75) and an Alexa-488-labeled goat anti-mouse IgG 
secondary antibody (Sigma). 
2.4 Results 
2.4a Cell binding levels 
Purified full CPV-2, FPV, and CPV-2b capsids were labeled with Alexa dyes at a ratio of 
five to 12 dye molecules per capsid. Microscopy analysis showed an even distribution of 
apparently single particles with similar levels of labeling (Figures 2.1A and B), and the 
capsids banded on sucrose gradients at the positions expected for full particles (results 
not shown). In general the labeled capsids showed similar overall patterns of cell 
binding and entry to those reported for unlabeled capsids examined after fixing and 
antibody staining, but allowed superior spatial resolution of individual capsids (65).  
Furthermore, the labeled capsids had similar levels of infectivity (data not shown).  The 
amount of labeled viruses binding to canine or feline cells depended on the specific 
combination of virus strain and host cell used (Figure 2.1). All viruses bound and 
entered feline cells (Figure 2.1C), though to different levels, and the level of cellular 
association was similar to that seen for unlabeled viruses detected by antibody staining 
(27). Although CPV-2 and CPV-2b both bound to canine cells, the level of cell-
associated CPV-2b observed was close to background levels, likely due to the low 
affinity of this interaction (Figures 2.1D and H) (42). Feline cells bound and endocytosed 
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CPV-2 and CPV-2b capsids to 3.5- and 5 -fold higher levels, respectively, than canine 
cells (Figures 2.1G and H). Comparisons between different viral strains showed that 
CPV-2 capsids bound to ~10-fold higher levels than did CPV-2b in all cell lines tested 
(Figures 2.1C, D, and I). In feline cells, FPV had an intermediate level of binding and 
uptake compared to the two CPV strains (Figure 2.1C). These differences were not 
related to the levels of TfR expression, as both the CRFK and Cf2Th cells bound 
equivalent amounts of canine Tf, while the TfR-negative TRVb cells bound neither virus 
nor Tf (Figures 2.1E and J).    
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Figure 2.1. Analysis of Alexa594-labeled CPV-2 full capsids by fluorescent 
microscopy. A and B) Diluted virus was sandwiched between 2 coverslips and imaged 
with a 100x oil lens. Panel B shows the fluorescence intensity associated with the 
particles shown in (A). C to E) Quantitative association of labeled capsids with canine or 
feline cells was determined by flow cytometry. The amount of FPV, CPV-2, or CPV-2b 
that was bound and taken up into (C) feline CRFK cells or (D) canine Cf2Th cells after 1 
hour at 37°C. E) Canine Tf was incubated with canine and feline cells under the same 
conditions as in (C and D). Untransfected TRVb cells not expressing TfR were used as 
a negative control for all assays. F to H) The same data are represented to allow 
comparison between binding and uptake of (F) FPV, (G) CPV-2, and (H) CPV-2b 
capsids in feline or canine cells. I and J) The mean and standard deviation from three 
independent experiments of the background-subtracted median fluorescence 
intensities, showing binding and uptake levels of the three viruses or canine Tf. (*=p< 
0.05); significant differences between groups. 
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 2.4b Infectivity of viruses in canine and feline cells 
The relative infectivity of FPV, CPV-2 and CPV-2b, determined as log 
TCID50/genome, varied depending on the species of cell line tested (Figure 2.2). Two 
canine (Cf2Th and A72) and two feline (NLFK and CRFK) cell lines were tested with two 
separately prepared inoculums of each virus, and similar patterns were seen for each 
host type. Data from one inoculum in one cell line per species is shown in Figure 2.2. 
CPV-2 had equal infectivity in canine and feline cells, while FPV and CPV-2b were 
significantly more infectious in feline than canine cells. About 1 × 105 virions per cell 
were needed to infect CRFK cells, with no significant differences in infectivity between 
the three viral strains.  CPV-2 was up to 100-fold more infectious than CPV-2b on a per-
genome basis in Cf2th canine cells, while FPV showed only background levels of 
infection in those cells. 
 
 
Figure 2.2. Relative infectivity of FPV, CPV-2, or CPV-2b in feline CRFK and 
canine Cf2Th cells. The mean log TCID50/genome +/- 1 standard deviation from three 
independent experiments is shown (*=p< 0.05). 
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2.4c Uptake from the cell surface  
In order to determine the rate of uptake from the surface of feline and canine 
cells, neutralizing antibodies were added to the extracellular medium at various times 
after virus addition, and the residual percentage of infection was compared to a control 
well with no antibody added. The infecting viruses were rapidly endocytosed into feline 
cells, and thus quickly acquired resistance to neutralization, with CPV-2 infection levels 
reaching 50% of control when the antibodies were added 10 minutes or more after virus 
addition.  The uptake into canine cells was slower, taking 45 minutes to reach 50% 
protection of the virus (Figure 2.3). 
 
 
Figure 2.3. Kinetics of uptake and infection of CPV-2 in feline and canine cells. 
The percentage of infecting virus that resisted antibody neutralization at various times 
after virus binding to feline CRFK or canine Cf2th cells was compared to control 
infections where no antibody was added. (* = p< 0.05; significant differences between 
feline and canine cells). 
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Fluorescence microscopy was used to follow the capsids into cells, and a clear 
difference was seen in the surface distribution of labeled capsids on canine versus 
feline cells. When incubated with feline CRFK cells, CPV-2 (Figure 2.4A) and CPV-2b 
(data not shown) capsids bound and were taken up uniformly over the cell surface. In 
contrast, lower levels of CPV-2 or CPV-2b particles bound to canine cells, and during 
time points between five and 15 minutes at 37ºC many capsids could be observed 
associating with filopodia rather than the main cell body (Figure 2.4B (CPV-2b data not 
shown)). Under the same conditions, Alexa-594-Tf bound evenly over both the feline 
and canine cells (Figures 2.4C and D), indicating that this pattern was not the result of 
altered receptor distribution.  
 
Figure 2.4. Association of CPV-2 with filopodia on canine cells. Alexa-594-labeled 
capsids were incubated with (A) feline or (B) canine cells for five minutes at 37°C then 
immediately observed. Alexa-594-Tf was also incubated with (C) feline and (D) canine 
cells under the same conditions. The white arrows highlight filopodia without virus or Tf 
bound, while the black arrow in (B) shows virus concentrating on the filopodia of canine 
cells. (E) Selected time-lapse frames 18 seconds apart showing CPV-2 particles (red) 
bound to filopodia of Cf2Th cells containing microinjected Alexa488-conjugated actin 
(green). The tracks show particle movement on the filopodia; the yellow arrow indicates 
one particle moving towards the cell at the same rate as filopodial retraction.  
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Alexa-488-labeled actin was microinjected into canine cells to highlight the 
cytoskeletal features of the filopodia. The CPV-2 particles bound to the filopodia of 
injected cells showed mostly random and bidirectional movement (Figure 2.4E), and did 
not move at the 1.8 to 3.2 µm/minute rate reported in other systems that engage the 
retrograde actin transport processes (32, 57). Nonetheless, capsids subsequently 
accumulated at the cell body, perhaps in association with filopodial retraction as this 
was directly observed in some cases (Figure 2.4E). Within about 10-20 minutes most 
virus was lost from the filopodia and became localized in intracellular vesicles.  
The attachment of virus capsids to filopodia on canine cells was specifically 
controlled by the surface expression of the canine TfR.  Either microinjection of an 
antibody recognizing the cytoplasmic sequence of the TfR (data not shown) or addition 
of an antibody against the ectodomain of the TfR to the medium (Figure 2.5), greatly 
reduced or eliminated the attachment of the virus (Figure 2.5B) to the filopodia and 
capsid accumulation in the cell cytoplasm compared to the untreated cells (Figure 
2.5A).  The same treatments reduced but did not eliminate the binding of labeled Tf to 
the cells (Figures 2.5D) compared to untreated cells (Figure 2.5C), and this result was 
inferred to be attributable to the greater affinity of Tf for the remaining accessible 
receptors on the cells.  
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Figure 2.5. Specificity of virus binding to TfR on canine cell filopodia. CPV-2 
capsids (A and B) or canine Tf (C and D) are bound and taken up into Cf2Th cells 
expressing actin-GFP. Addition of rabbit antibody against the TfR ectodomain to the 
extracellular medium reduces the binding and uptake of CPV-2 capsids (B) or canine Tf 
(D) to Cf2Th cells. Binding and uptake was performed under the same conditions for the 
antibody treated (B and D) and untreated cells (A and C). The arrowheads in (A) show 
individual viral particles binding to the filopodia.  
 
2.4d Endosomal trafficking of Tf and viral capsids 
To ensure that expression of the Rab-GFP constructs did not disrupt global 
endosomal trafficking patterns, we examined uptake and trafficking of Alexa-594-Tf and 
showed that it followed the endosomal pathways previously reported for the Tf-TfR 
complexe (63). Tf co-localized with vesicles positive for Rab5-GFP, a marker of the 
early endosome, within 10 minutes of uptake (Figure 2.6A) and with Rab11-GFP, a 
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marker of the recycling endosome, by 10 to 15 minutes (Figure 2.6B). Little Tf co-
localized with Rab7-GFP, a marker of the late endosome (Figure 2.6C). Recycling in 
feline and canine cells also had similar dynamics to those described for Tf in human 
cells, with loss of cell-associated Tf within 20-30 minutes attributable to completion of 
recycling and release at the cell surface (Figures 2.6D and E) (10, 54). In contrast, the 
level of labeled virus associated with the cells decreased only slightly over 60 minutes 
of incubation, indicating either that capsids were retained within the recycling endosome 
compartment or were diverted into other intracellular pathway(s) (Figures 2.6D and E). 
Soon after CPV-2 binding and uptake, particles were found within each of the 
three Rab-labeled endosomal compartments examined. Capsids co-localized and also 
showed co-movement with Rab5-GFP-labeled vesicles at the earliest time points 
imaged (5 minutes after uptake) (Figure 2.7A). At later times, the association with Rab5 
decreased, although limited co-localization was still seen after one hour or more, 
particularly in cells showing high levels of Rab5-GFP overexpression (Figure 2.7B). 
Expressing the CA Rab5-GFP mutant resulted in the formation of large, ring-shaped, 
Rab5-positive vesicles within the cells. Virus particles accumulated in those vesicles, 
and were retained for prolonged periods (up to hours) after uptake. In some cases, 
particles were associated with the inner wall of the vesicles, while in others they 
appeared to be released into the lumen (Figure 2.7C). Trafficking patterns of the 
particles in canine Cf2Th cells expressing Rab5-GFP were similar to those seen in 
feline cells (Figures 2.7D and E).   
 
 81 
 
Figure 2.6. Intracellular trafficking of labeled Tf (red) in CRFK cells containing 
GFP-Rab proteins (green) labeling different endosomal compartments. Co-
localization is shown with (A) Rab5 at 20 minutes and (B) Rab11 at 10 minutes after 
uptake but not with (C) Rab7 (27 minutes after inoculation shown). The large arrow 
highlights the perinuclear area, smaller vesicles showing co-localization are marked with 
small white arrows, and the cell body (white line) and nucleus (orange line) are outlined. 
Retention and/or recycling of capsids or Tf to the cell surface was measured in (D) 
CRFK or (E) Cf2Th cells by the decrease in the level of fluorescently labeled ligand over 
time. (*=p<0.05); significant differences in the relative level of cell-associated Tf vs. 
CPV-2.  
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Figure 2.7. The association of CPV-2 capsids with Rab5-GFP after endocytosis. 
Time-lapse frames show the co-localization and co-movement of Alexa594-labeled 
capsids with wild type Rab5-GFP in CRFK cells beginning at (A) 15 minutes and (B) 80 
minutes after uptake, over the indicated intervals. C) CRFK cells expressing CA Rab5-
GFP contain large vesicles that accumulate CPV-2 capsids; an example time-lapse 
series beginning 57 minutes after uptake is shown. (D and E) Rab5-GFP expressed in 
(D) Cf2Th or (E) CRFK cells, 15 minutes after virus uptake. Tracks of co-localized 
particles and vesicles are shown in A to C, while white arrows highlight co-localization in 
D and E. 
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Within 15 to 20 minutes of uptake, virus particles both co-localized and co-moved 
with Rab11- and Rab7-GFP positive vesicles (Figures 2.8A and B). Movement rates of 
the virus-containing vesicles varied from stationary to very rapid, and in some cases 
could not be accurately tracked even at frame rate intervals of 0.2 seconds.  
Bidirectional movement, most likely on microtubules, was seen for virus-containing 
vesicles labeled with each of the Rab proteins examined. Within 30 to 45 minutes, the 
virus-containing vesicles accumulated in a perinuclear location near the microtubule 
organizing center.  The perinuclear area has high concentrations of both Rab11 
(Figures 2.8C and D) and Rab7 (Figures 2.8E and F) positive vesicles. In feline cells in 
particular, co-localization of capsids with particular markers in this section of the cell 
was difficult even by confocal microscopy (results not shown).  
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Figure 2.8. Association of CPV-2 particles with Rab11-GFP or Rab7-GFP-positive 
vesicles in cells after uptake. A and B) Time-lapse frames over indicated intervals of 
CPV-2 binding to feline CRFK cells expressing (A) Rab11-GFP beginning at 11 minutes 
and (B) Rab7-GFP beginning 17 minutes after uptake. Co-localization and co-
movement of some particles with labeled vesicles are highlighted as individual tracks. C 
and D) Co-localization of virus with Rab11-GFP after uptake into (C) CRFK cells for 55 
minutes or (D) Cf2th cells for 46 minutes after uptake. The white arrows highlight polar 
accumulations of Rab11-positive vesicles. The yellow arrowhead in C indicates the tight 
perinuclear accumulation of virus in feline cells, while the white bracket in D shows that 
this area is relatively more disperse in canine cells. E and F) Co-localization of virus 
with Rab7-GFP is observable after uptake into both (E) CRFK cells shown at 96 
minutes, or (F) Cf2th cells shown at 61 minutes after uptake.  
 
Although viruses rapidly dispersed to multiple compartments after uptake in both 
feline and canine cells, some differences were seen in the intracellular distribution of 
virions. First, the patterns of accumulation at the perinuclear area differed. CRFK cells 
showed a tight accumulation of perinuclear viral particles in vesicles (Figures 2.8C and 
E, arrowheads), while in Cf2Th cells they clustered more loosely and many endosomes 
appeared to contain several particles (Figures 2.8D and F, bracketed area). 
Furthermore, in canine cells co-localization of these particle groups with Rab7-positive 
vesicles could be more clearly identified than in feline cells. 
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The pattern of virus association with Rab11 also differed between the two cell 
types. Clusters of Rab11-positive vesicles were seen near the cell periphery of both cell 
types (white arrows in Figures 2.8C and D). However, localization of virus within those 
peripheral or polar vesicles was only seen in feline cells. These results suggest subtle 
differences in the endosomal trafficking of virions entering different cell types.  
Expression of constitutively active (CA) Rab11 (Figure 2.8A) or Rab7 (Figure 
2.9B) showed virus co-localization patterns similar to those seen for the wild type Rab 
proteins. However, as shown in Figure 2.7C, the CA Rab5 disrupted the accumulation 
of virus at the perinuclear area, and particles were retained within large ring-shaped 
vesicles. The DN Rab5 had variable effects on intracellular trafficking. Some cells 
appeared to have similar trafficking patterns as seen with wild-type Rab5, but most cells 
showed moderate disruption of the perinuclear virus concentration (Figure 2.9C). The 
DN Rab7 largely prevented perinuclear capsid accumulation, and the virus was 
displaced to large vesicles dispersed throughout the cell (Figure 2.9D). Finally, 
expression of DN Rab11 did not appreciably disrupt accumulation of the virus at the 
perinuclear area (Figure 2.9E), suggesting that virus becomes localized within the late 
endosome at this location. For CPV-2 capsids, these patterns were similar in both 
canine and feline cells (data for canine cells not shown). Capsid release into the 
cytoplasm or nucleus was not readily observed in these studies, and these steps likely 
represent further bottlenecks in the entry process of parvoviruses (17).  
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Figure 2.9. Distribution of CPV-2 particles in CRFK cells expressing CA or DN 
Rab-GFP mutants. The individual Rab-GFP (green) and CPV-2 (red) channels are 
shown as well as the merged image. A) CPV-2 capsids in cells expressing CA Rab11-
GFP 35 minutes or (B) CA Rab7-GFP 39 minutes after uptake, showing similar behavior 
to wild-type CRFK cells with accumulation of virus capsids at the perinuclear area. C) 
DN Rab5-GFP at 43 minutes after uptake showing moderate disruption of the 
perinuclear virus concentration. D) DN Rab7-GFP (shown at 50 minutes after uptake) 
causes a substantial redistribution of virus-containing vesicles. E) Virus in cells 
expressing DN Rab11-GFP 59 minutes after uptake, showing that the virus maintains 
the ability to accumulate at the perinuclear area. Orange arrows highlight the 
perinuclear area in all cells. 
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Infection of cells expressing Rab-GFP proteins showed that the presence of wild-
type, GFP tagged proteins had little effect on infection rates, except for Rab7 which 
moderately increased infection (Figure 2.10). Expression of CA and DN Rab11 or DN 
Rab7 did not significantly affect infection rates, whereas expressing DN or CA Rab5, or 
DN Rab7, mutants reduced infection by about 50% in the expressing cells.  
 
 
Figure 2.10. The effect of wild type (wt) and CA or DN mutant Rab5-, Rab11- and 
Rab7-GFP expression on FPV cell infection. Percentage of cells expressing mutant 
Rab-GFP proteins that became infected by FPV compared to infection rates of non-
transfected cells are shown. (*=p<0.05). 
 
2.5 Discussion 
Here we examine the TfR-dependent binding, uptake, trafficking, and infection of 
cells by parvoviruses and show natural differences in the steps involved in feline and 
canine cells. Parvovirus infection is a complex process; the various parvoviruses that 
have been examined bind many different receptors and have been reported to follow a 
variety of different entry pathways with different dynamics (reviewed in 15 and 25). The 
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live-cell studies contained herein revealed the processes of CPV binding and entry 
when two distinct versions of the TfR were used. By using live cells and starting to 
image around five minutes after virus addition, our results illuminated a much more 
rapid and less linear process of endosomal trafficking than had been previously 
suggested. Virus particles taken up by the TfR were clearly identified in both recycling 
and late endosomes as early as 10 to 15 minutes after uptake. Although overexpression 
of the wild-type Rab proteins through transfection of GFP-conjugated constructs likely 
perturbed aspects of the endosomal system, the intracellular capsid distribution seen 
was generally similar to that of cells fixed and stained for endosomal markers, and 
infection rates in cells expressing those proteins was not reduced. Furthermore, the 
behavior of Tf in cells expressing wild-type Rab-GFP proteins has been examined in 
several studies and shows trafficking comparable to that seen in untransfected cells (29, 
63). Even when the CA Rab5 is expressed, normal global endocytic trafficking patterns 
continue with some efficiency despite the generation of abnormal, large, Rab5-positive 
vesicles (10).  
2.5a Binding and endocytosis  
Although the levels of TfR expression in feline and canine cells were similar as 
detected by Tf or antibody binding, CPV capsids bound to canine cells at much lower 
levels due to their much lower affinity of binding. Furthermore, the infection efficiencies 
for canine cells differed between the naturally variant CPV strains. The CPV-2a/b 
variants first emerged in 1979, and these quickly replaced the original CPV-2 in dogs 
worldwide (48). These antigenically variant viruses differ in their ability to infect and 
replicate in cats (66), and in their binding properties to feline and canine cells or purified 
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TfRs in vitro (42). Despite these differences, these viruses were seen here to have 
similar surface and intracellular trafficking patterns.  
CPV capsid endocytosis from the surface of canine cells was delayed compared 
to uptake into feline cells, and this is likely attributable to both the lower affinity of canine 
TfR binding and the time spent interacting with filopodia before endocytosis. Filopodia 
are dynamic structures that contain actin bundles covered in membrane and are 
prominent at the leading edges of mobile cells (28). In tissue culture cells, they present 
a large surface area and would therefore be of particular benefit for low-affinity binding 
interactions. The filopodial association observed was not a result of differences in 
receptor distribution, as labeled canine Tf bound evenly over these cells. Binding and 
cellular uptake of CPV was confirmed to be specifically associated with the TfR as it 
was inhibited by the addition of anti-TfR antibodies against either the cytoplasmic tail or 
the ectodomain (Figure 2.4). These antibodies cross-link the receptor and prevent 
normal patterns of trafficking and recycling such that they greatly reduce TfR expression 
on the cell surface (44, 73). Preferential binding of capsids to filopodia has been 
reported for other viruses, including retroviruses, papillomaviruses, and adeno-
associated viruses, and these are actively trafficked to the cell body by retrograde actin 
flow and/or myosin II acting on actin filaments (3, 32, 57). No consistent directional 
movement was seen for CPV particles on the filopodia of canine cells, but the bound 
virions accumulated at the base of these structures and entered the cells, at least in part 
due to the normal dynamic movement of the filopodia. We saw no evidence that CPV 
capsids induced the formation of filopodia or modified their behavior (62).  
 91 
Binding and entry via the cell surface or filopodia allowed similar efficiencies of 
CPV-2 infection of both feline and canine cells, while lower CPV-2b infection rates were 
seen in the canine cells. Nonetheless, the efficient endocytosis of viral capsids by the 
TfR allowed productive entry even for these low-affinity interactions. In previous studies, 
TfR binding has been shown to provide a structural interaction necessary for infection as 
replacement of the TfR ectodomain with binding domains of antiviral antibodies allowed 
attachment and uptake of virus but not infection (26).  
2.5b Endosomal trafficking 
At the earliest time-points imaged, labeled capsids co-localized with Rab5-
positive vesicles. Early endosomes are important in the initial sorting of many cargo 
molecules into their correct endosomal pathways, and this process depends on both the 
properties of the ligand and receptor (29, 59). The CA form of Rab5 induces large, ring-
like vesicles in cells (10, 16), and a high proportion of the CPV particles in this study 
were observed to enter these expanded vesicles and remain there for extended periods 
of one hour or more (Figure 2.7C). Many of these particles remained attached to the 
wall of the vesicle, most likely due to continued association with the TfR. This 
observation is in accordance with models showing prolonged receptor interactions and 
slow intracellular trafficking, and was also supported by experiments where infection 
was blocked by microinjection of antibodies against the cytoplasmic tail of the TfR up to 
four hours after inoculation (44). The DN Rab5 also disrupted normal trafficking of the 
virus to the perinuclear region in many cells, again suggesting that the early endosome 
is required for correct endosomal trafficking. Reduced infectivity was seen in cells 
expressing either mutant Rab5 protein.  
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Virus capsids were localized with both Rab11- and Rab7-positive vesicles by 15 
minutes of uptake, displaying a more rapid and complex virus trafficking pattern than 
had been previously suggested (64, 65). This trafficking was also different from that 
reported for monomeric Tf. The multivalent icosahedral virus interacting with the dimeric 
TfR could potentially result in cross-linked TfR-capsid complexes, which would be at 
least partly diverted into the degradative pathway based on the results of previous 
studies (35). Even with limited cross-linking, the large size of the virus capsid alone may 
alter trafficking within the tubular-vesicular endosomal sorting structures (6, 59).  
Parvoviruses have been suggested to escape from the endosome along the 
degradative pathway (18, 34), and this was supported by the finding that expression of 
DN Rab7-GFP significantly decreased infection. Because the viruses require cell 
division for genome replication, expression of DN Rab proteins may have globally 
disrupted the intracellular environment to indirectly inhibit replication. However, the 
mutants that disrupted the accumulation of virus at the perinuclear area (DN Rab5 and 
Rab7, but not DN Rab11) showed the largest decreases in infection rates, suggesting a 
role for this specific trafficking pathway in infection.  
The entry of viruses into cells by receptor-mediated endocytosis can involve a 
variety of pathways, and even within the parvovirus family receptors of many types are 
used for functional entry. These studies show that these viruses can efficiently use 
canine and feline TfRs with very different affinities of binding, and can initially follow 
different routes of uptake from the surface into feline and canine cells that then 
converge on the same vesicular compartments. This shows that the infection process 
can accommodate significant flexibility. In the case of CPV-2, binding to the canine TfR 
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resulted in the host range shift from cats to dogs, and subsequent evolution further 
modified host range and TfR binding properties. By examining the details of the initial 
cellular uptake and trafficking events, we further elucidate the essential properties of the 
capsid-receptor interaction and the entry pathways required for cell infection. 
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CHAPTER 3: ENDOCYTOSIS OF CANINE AND FELINE PARVOVIRUSES: 
ALTERING RECEPTOR TRANSMEMBRANE AND CYTOPLASMIC SEQUENCES TO 
SHOW REQUIREMENTS FOR INFECTION. 
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3.1 Abstract 
Canine and feline parvovirus (CPV and FPV) capsids bind the transferrin 
receptor type 1 (TfR) on the surface of host cells, are taken up by clathrin-mediated 
endocytosis, and are trafficked within the endosomal pathways of the cell leading to 
infection. The specific endocytic requirements for parvoviral infection were examined 
using variant receptors prepared from the feline TfR ectodomain joined to 
transmembrane and cytoplasmic sequences from other type II transmembrane proteins.  
Despite being expressed at the cell surface and able to bind transferrin (Tf), the 
chimeras with cytoplasmic and transmembrane domains from influenza neuraminidase 
(FluNA), Newcastle disease virus hemagglutinin neuraminidase (NDVHN), and 
parainfluenza 4a HN (PI4aHN) allowed little infection when compared to the wild type 
TfR. Chimeras with the cellular proteins asialoglycoprotein receptor 1 (Asialo) and Fcε 
receptor 2 (CD23) allowed approximately 50% of wild type infection levels. The mutant 
TfRs were associated with alterations in expression and uptake from the cell surface, 
and there was no specific requirement for the cytoplasmic tail to contain sequences for 
interaction with the clathrin endocytic machinery.  
 
3.2 Introduction 
The viral receptor plays many roles in the infection process of non-enveloped 
viruses. Binding to a specific protein or carbohydrate moiety tethers the virus to the cell 
surface and may initiate one or more events including receptor clustering, binding to 
additional receptors, structural changes in the virus capsid, activation of cell signaling 
pathways, and endocytosis (10, 29, 41, 57). Hijacking cellular endocytic pathways 
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allows the virus to rapidly gain entry into the cell, and viruses may use one or more 
cellular mechanisms for uptake from the cell surface. Many viruses, such as Ebola 
virus, influenza virus, and parvoviruses, interact with the clathrin endocytic machinery 
through their receptors (8, 11, 13, 38). The viruses can either recruit clathrin machinery 
to the binding site via the clustering of receptors, or may migrate on the surface of the 
cell and engage forming or pre-formed clathrin pits. Other viruses utilize caveolae for 
entry, such as the polyomavirus simian virus 40 (SV40), or may bind to a variety of cell 
surface molecules for entry via less well-characterized pathways (2). Uptake by 
macropinocytosis (Vaccinia virus), cholesterol-dependent entry (Polyomavirus), and 
non-clathrin, non-caveolar uptake processes (Murine Norovirus-1), as well as non-
specific membrane recycling have all been described for different viruses (16, 36, 37, 
50, 51).  
After uptake, viral particles may be routed through pathways that provide signals 
for infection, such as exposure to low pH or proteases. While there is some overlap 
between these pathways, cytoplasmic sorting signals can direct ligands to specific 
destinations within the cell (26, 45). Trafficking time within the vesicular system can vary 
from minutes to hours before the infecting particles leave the endosomes to enter the 
cytoplasm, with most DNA viruses further trafficking to the nucleus. Viruses utilizing 
clathrin-mediated endocytosis may be trafficked to low pH compartments such as the 
early and late endosomes where the pH signal alone or in concert with the action of 
cellular factors provides triggers for endosomal escape (12, 59). Intracellular trafficking 
following caveolar uptake delivers ligands to the endoplasmic reticulum and/or Golgi 
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complex, and viruses have evolved various mechanisms of escape from these 
compartments (42, 60). 
 We are studying the cellular infection process of two closely related parvoviruses 
with distinct receptor binding and host range properties. The canine and feline 
parvoviruses are small non-enveloped particles with T=1 icosahedral symmetry and a 
single stranded DNA genome of about five kb (27). Canine parvovirus (CPV) emerged 
in 1978 as a host range variant of feline panleukopenia virus (FPV) through the 
acquisition of a small number of mutations that allowed it to bind the canine cellular 
receptor, the transferrin receptor type 1 (TfR) (25). The original CPV, designated CPV 
type-2 (CPV-2), was rapidly replaced in the wild by antigenic and host range variants 
designated CPV type-2a, 2b, and 2c (e.g. CPV-2a) (49).  All of these strains share 
above 95% identity in capsid sequence, but differ in host range, antigenicity, and other 
properties. Capsids are assembled from a combination of 90% VP2 and 10% VP1 viral 
proteins, which share the same C-terminal sequence. The N-terminal VP1 unique 
sequence becomes exposed during viral entry, is required for infection, and contains 
sequences with phospholipase A2 (PLA-2) and nuclear targeting activity (19, 63). The 
PLA-2 may modify endosomal membranes to facilitate release into the cytoplasm, and 
the nuclear localization sequences may mediate capsid passage past the nuclear 
envelope. However, the mechanism underlying both of these entry steps is still poorly 
understood (62).   
The TfR is a type II membrane protein that is expressed as a homodimer on the 
cell surface (14). The ectodomain is comprised of protease-like, apical, and helical 
domains, while the cytoplasmic domain contains a Tyr-Thr-Arg-Phe (YTRF) sequence 
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that mediates endocytosis through clathrin-coated pits (6, 9, 30). The length and 
specific sequence of the transmembrane domain mediates its insertion in non-lipid raft 
areas of the plasma membrane. The normal intracellular TfR trafficking pathway routes 
97% of internalized receptors through the early endosome to the recycling endosome 
and back to the surface within 15 to 20 minutes (55, 58, 61). In studies with 
experimentally oligomerized Tf, the receptor is retained for much longer periods within 
endosomes and a higher percentage is trafficked to the late endosomes and lysosomes 
where it is degraded (32). 
The roles, routes, and kinetics of specific receptor-mediated endocytic pathways 
in cell infection have only been partially defined for CPV. The CPV capsid interacts with 
the TfR apical domain at a raised region on the capsid surrounding the threefold axis of 
icosahedral symmetry, designated the threefold spike (44). Residue changes in this 
domain influence viral binding such that only CPV can interact with the canine TfR to 
infect canine cells, though different strains vary in their binding affinity (20, 23, 25). Virus 
binding does not compete with transferrin uptake, which interacts with the membrane-
proximal portion of TfR (17). The TfR provides specific structural interactions with the 
capsid that allow cell infection, as viral binding to sialic acids or artificial receptors 
prepared from antibody binding domains fused to the TfR transmembrane and 
cytoplasmic sequences allows viral endocytosis but not completion of the replication 
cycle (24).  
CPV capsids, like Tf, are rapidly taken up by clathrin-mediated endocytosis (22, 
46). However, infection kinetics in feline cells are very slow, as cytoplasmic 
microinjection of antibodies against either the cytoplasmic tail of the TfR or the capsid 
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can block infection when added four or eight hours after uptake, respectively (63). By 
immunofluorescence microscopy, capsids can be found co-localized with several 
endosomal compartments within minutes, rapidly associating with markers of the early, 
recycling, and late endosomes (22). The markers utilized in these studies include a 
variety of Rab adaptor proteins, which function to regulate endosomal trafficking within 
the cell (43, 64). Specific Rab proteins mark generally distinct cellular compartments 
including Rab5 in the early endosome, Rab7 in the late endosome, and Rab11 in the 
perinuclear recycling endosome (34, 39). Structural changes in the capsid, such as the 
release of the VP1 unique sequence, occur within one or more of these compartments 
during the trafficking process and are required for infection. However, the controlling 
factors that determine the rate and direction of viral capsid trafficking within the 
endosome and how those factors affect the success of the infection are still not well 
understood. 
 We previously examined infection in cells expressing mutant feline TfRs 
expected to have reduced interaction with the clathrin-mediated endocytic machinery 
and a chimeric TfR with the transmembrane and cytoplasmic sequences replaced with 
those from the influenza virus neuraminidase protein (FluNA-TfR) (24).  In this study the 
clathrin-interaction sequence mutants still allowed efficient virus infection, although the 
FluNA-TfR chimera did not. This suggested that while clathrin-mediated endocytosis is 
dispensable, the properties of the plasma membrane or the subsequent trafficking 
pathways of the capsids are important for cellular infection by these parvoviruses. 
 Here we further examine the functional steps leading to infection by comparing 
the functionality of the feline TfR ectodomain fused to transmembrane and cytoplasmic 
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tails from several other viral and cellular-origin proteins with differences in reported 
membrane association and trafficking properties. This approach to evaluating the 
specific requirements for endocytic uptake has been validated in other studies (18). For 
example, in cells expressing wild-type nectin 1 as a cellular receptor, herpes simplex 
virus (HSV) fuses with the plasma membrane soon after receptor binding and does not 
require exposure to intracellular signals to trigger this event. Chimeric receptors fusing 
the extracellular domain of the cellular receptor Nectin 1 to the epidermal growth factor 
receptor or to a glycosylphosphatidylinositol (GPI) anchor were successful in retargeting 
the virus to be either taken up into the endosomal system through clathrin-mediated 
endocytosis or via lipid raft domains of the plasma membrane, respectively. HSV entry, 
membrane fusion, and infection did not require any specific transmembrane or 
cytoplasmic sequences to be present in the cellular receptor, as long as the structural 
interaction of the virus with the extracellular domain remained intact (18). 
In the present study, chimeric TfRs with the transmembrane and cytoplasmic 
domains replaced with those from other type II membrane proteins were tested by 
expression on hamster cells lacking the endogenous TfR (TRVb cells). Most receptors 
were expressed as functional proteins on the cell surface, but the chimeras containing 
sequences from viral glycoproteins were inefficient at infection. The localization of the 
virus with intracellular markers showed that endocytosed capsids could be found in 
multiple endosomal locations, and that there was not a single defined pathway of entry.   
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Table 3.1. The cytoplasmic and transmembrane sequences of the mutant or 
chimeric feline TfRs tested in this study.  The source of each sequence is given 
along with the amino acid sequence in single letter code.  The predicted 
transmembrane sequences are underlined, and sequences with predicted functionality 
are indicated in bold. The first few amino acids of the shared ectodomain from the feline 
TfR are indicated in italics.    
FelTfR Wild-type feline TfR,  
Genbank AF276984.1  
SwissProt Q9MYZ3 
MMDQARSAFSTLFGGEPLSYTRFSLA
RQVDGDNSHVEMKLAADEEENVDNN
MRDNGASVTKPKRFNGFICYGTIAIILF
FLIGFMIGYLGYCKRVEAK 
FelTfR-
Δ3-32 
Feline TfR, cytoplasmic residues 
3-32 deleted 
MMHVEMKLAADEEENVDNNMRDNG
ASVTKPKRFNGFICYGTIAIILFFLIGFM
IGYLGYCKRVEAK 
FelTfR-
ATAA 
Feline TfR, YTRF residues 20-24 
mutated to ATAA 
MMDQARSAFSTLFGGEPLSATAASL
ARQVDGDNSHVEMKLAADEEENVDN
NMRDNGASVTKPKRFNGFICYGTIAII
LFFLIGFMIGYLGYCKRVEAK 
Asialo-
FelTfR 
Asialoglycoprotein receptor I 
Genbank BAB83508.1 
SwissProt P07306 
MTKEYQDLQHLDNEESDHHQLRKGP
PPPQPLLQRLCSGPRLLLLSLGLSLLL
LVVVCVIGSQNSQRVEAK 
CD23-
FelTfR 
FC Epsilon receptor 2 
Genbank M15059 
SwissProt P06734 
MEEGQYSEIEELPRRRCCRRGTQIVL
LGLVTAALWAGLLTLLLLWHWDTTQR
VEAK 
Ii-FelTfR Invariant chain  
Genbank CAA25192.1 
SwissProt P04233 
MHRRRSRSCREDQKPVMDDQRDLIS
NNEQLPMLGRRPGAPESKCSRGALY
TGFSILVTLLLAGQATTAYFLYQQRVE
AK 
PI4aHN-
FelTfR 
Parainfluenza 4a hemagglutinin 
neuraminidase 
EMBL AAA46799.1 
SwissProt P21526 
MQDSHGNTQILNQANSMVKRTWRLL
FRIATLILLVSIFVLSLIIVLQSTPGRVEA
K 
FluNA-
FelTfR 
Influenza neuraminidase  
Genbank AAA91326.1 
SwissProt P03470 
MNPNQKIITIGSICMVVGIISLILQIGNIIS
IWISRVEAK 
NDVHN-
FelTfR 
Newcastle disease virus 
hemagglutinin neuraminidase 
Genbank AAA46670.1 
SwissProt P12554 
MNRAVCQVALENDEREAKNTWRLVF
RIAILLLTVMTLAISAAALAYSIRVEAK 
SV5HN-
FelTfR 
Simian virus 5 hemagglutinin 
neuraminidase  
Genbank AAB21114.1 
SwissProt P04850 
MVAEDAPVRATCRVLFRTTTLIFLCTL
LALSISILYESLITQKQIMSQDVIEAK 
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3.3 Materials and methods 
3.3a Cells and viruses 
Chinese hamster ovary (CHO)-derived cells lacking the hamster TfR (TRVb cells) 
(35) were grown in Ham’s F12 medium containing 5% fetal bovine serum.  Norden 
Laboratory feline kidney (NLFK) cells were grown in a 1:1 mixture of McCoy’s 5A and 
Liebovitz L15 media with 5% fetal bovine serum.   
 Parvoviruses were derived from infectious plasmid clones of FPV (FPV-b), CPV-
2 (CPV-d), and CPV-2b (CPV-39) strains (25, 48).  Plasmids were transfected into 
NLFK cells, and the viruses were titered using tissue culture infectious dose (TCID50) 
assays (47). Virus capsids were concentrated by polyethylene glycol precipitation 
followed by sucrose gradient centrifugation, then dialyzed against either PBS or 20 mM 
Tris-HCl (pH 7.5) and stored at 4ºC (1).   
3.3b TfR clones and mutants 
 TfR clones prepared from the feline TfR (Genbank AF276984) are listed in 
Table 3.1.  New chimeric receptors constructed in this study used the transmembrane 
and cytoplasmic sequences from the cellular proteins asialoglycoprotein receptor-1 
(Asialo-TfR) (Genbank BAB83508.1), the Fc-epsilon receptor-2 (CD23-TfR)(Genbank 
M15059), and the MHC class II invariant chain (Ii-TfR) (Genbank CAA25192.1). Viral-
derived chimeras utilized the cytoplasmic and transmembrane sequences of the HN 
protein from simian virus 5 (SV5HN-TfR) (Genbank AAB21114.1), Newcastle disease 
virus (NDVHN-TfR) (Genbank AAA46670.1), and parainfluenza virus 4a (PI4aHN-TfR) 
(EMBL AAA46799.1). The alternative cytoplasmic and TM sequences were synthesized 
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and cloned in place of the equivalent feline TfR sequence in the mammalian cell 
expression vector pcDNA3.1(-) (Invitrogen, Carlsbad, CA). Other previously described 
mutant TfRs contained influenza neuraminidase sequences (NA-TfR), or were based 
upon the FelTfR with the sequence between residues two and 32 deleted (FelTfRΔ3-32) 
or with the cytoplasmic YTRF sequence mutated to ATAA (FelTfR-ATAA) (24). 
Following conformation of correct sequence replacement, the plasmids were transfected 
into TRVb cells using Lipofectamine according to manufacturer’s instructions 
(Invitrogen).  
3.3c Fluorescent labeling of virus or Tf 
As previously described, canine Tf (Sigma Aldrich, St. Louis, MO) was iron 
loaded, and purified CPV capsids, FPV capsids, or canine Tf were labeled with 
Alexa488 (Invitrogen) (4, 5, 22, 25).  Dyes were used to label viruses at 20% of the 
recommended concentrations, and after labeling the capsids were separated from free 
dye by a PD10 desalting column (GE Healthcare, Waukesha, WA) and dialysis against 
0.2M phosphate buffered saline (PBS) at pH 8.2.   
3.3d Determining TfR expression levels and Tf uptake 
To detect receptor expression, TRVb cells transiently transfected with the variant 
TfR constructs were seeded onto coverslips, fixed with 4% paraformaldehyde (PFA) for 
20 minutes, then incubated with an anti-TfR ectodomain monoclonal antibody (T4F3) 
diluted in permeabilization buffer (PBS containing 1% BSA and 0.1% Triton X-100). 
Bound IgG was detected with a goat anti-mouse IgG-Alexa 488-labeled secondary 
antibody (Sigma). Receptor expression was quantified using a FACScalibur flow 
cytometer (Becton-Dickinson, San Jose, Calif.).  
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To examine virus and Tf uptake, transfected cells were incubated in solution at 
37°C with either 10 µg/ml of purified Alexa488-labeled CPV-2 virus capsids or 
Alexa488-labeled Tf diluted in Dulbecco’s Modified Eagle medium (DMEM) containing 
0.1% bovine serum albumin (BSA) for times ranging from 15 seconds to 60 minutes. 
Cells were washed three times in ice-cold medium prior to quantification of cell-
associated virus or Tf using flow cytometry as above. 
3.3e Cell infection assays 
To measure viral infection rates, cells transfected with the variant TfRs were 
incubated with FPV, CPV-2, or CPV-2b inocula at a MOI of 5 for one hour, then washed 
and incubated at 37°C for a further 48 hours.  Prior to fixation with 4% PFA, the cells 
were incubated with Alexa 488-labeled Tf for 30 minutes to score for receptor 
expression. After fixation and washing in PBS, cells were permeabilized with 0.1% 
Triton X-100 and further stained for receptor expression using the T4F3 antibody as 
above. Infected cells were identified by immunostaining with an Alexa 594-conjugated 
monoclonal antibody (CE-10) against nonstructural protein-1 (66).  The proportion of 
infected cells was determined as the percentage of the TfR-expressing cells that 
became infected and expressed the NS1 protein. Student t tests were used to 
determine the significance of differences in infection rates.   
3.3f Membrane localization 
The membrane association of the receptors was tested by resistance to cold 
detergent extraction similar to the method previously described (24). The extracted and 
detergent resistant fractions were tested for the presence of the TfR or caveolin-1 by 
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Western blot, using an anti-TfR antibody (U1D4) or anti-caveolin antibody (Sigma) and 
a horseradish peroxidase-conjugated secondary antibody.  
3.3g Fluorescence microscopy  
Markers tested in these studies included the previously described GFP-labeled 
Rab5, Rab11, and Rab7 as markers of the early, recycling, and late endosomal 
compartments, respectively (22). To determine viral uptake using the variant TfRs, 
TRVb cells cotransfected with the different receptor constructs and one of these 
markers were incubated with labeled virus or Tf for 5 min at 37°C. After washing with 
warm phenol-red free DMEM, time lapse images were obtained at the times indicated 
with a 37°C 100× oil lens.  Separate channels were collected sequentially using a 
Hamamatsu OrcaER CCD camera. Image analysis was performed using SimplePCI 
(Hamamatsu, Sewickley, PA) and ImageJ software (US National Institutes of Health, 
Bethesda, MD), including the ImageJ manual tracker plugin for detecting virus-vesicle 
co-movement (Institut Curie, Orsay, Fr). 
 
3.4 Results 
3.4a Construction of receptor chimeras 
We prepared a series of chimeric TfRs containing the cytoplasmic and 
transmembrane sequences from a variety of type II membrane proteins fused to the 
stalk and ectodomain of the feline TfR (Table 3.1), with the junction site within a few 
residues of the transmembrane-ectodomain boundary. Chimeras included sequences 
from cellular proteins including the asialoglycoprotein receptor (Asialo-TfR), the low 
affinity Fc fragment of IgE receptor II (CD23-TfR), and the invariant chain (Ii-TfR). Other 
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chimeras were prepared with cytoplasmic and transmembrane sequences of type II 
hemagglutinin neuraminidase (HN) proteins from paramyxoviruses including simian 
virus 5 (SV5HN-TfR), Newcastle disease virus (NDVHN-TfR), and parainfluenza virus 
4a (PI4aHN-TfR). One chimera with the transmembrane and cytoplasmic domain 
replaced with that from the influenza NA protein (FluNA-TfR) has been previously 
described (24). Two clones used as controls in these studies have also been previously 
described, and include mutants of the feline TfR whose altered cytoplasmic sequences 
were expected to disrupt the association with adaptor protein 2 (AP-2) and clathrin-
mediated endocytosis (FelTfR-∆3-32, FelTfR-ATAA) (24, 44). Several of these chimeras 
contain sequences which, at least in the context of native protein, lead to interaction 
with the clathrin endocytic machinery (Figure 3.1). These motifs include tyrosine-
containing motifs such as YXXΦ, where X is any amino acid and Φ is any bulky, 
hydrophobic amino acid, and were present in the wild-type FelTfR and CD23-TfR 
chimeras. Alternate clathrin-interacting motifs include a dileucine (LL) patch in Asialo-
TfR and PI4aHN-TfR and an unusual extracellular glutamic acid motif proposed to be 
functional in the SV5HN-TfR. Other sequences with functionality in their native proteins 
include a “LI…ML” motif for lysosomal targeting in Ii-TfR, and a transmembrane “VGIIS” 
sequence for targeting to lipid raft domains within the plasma membrane in FluNA-TfR. 
The NDVHN-TfR cytoplasmic and transmembrane domains contained no known motifs. 
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Figure 3.1. Diagrammatic representation of the variant TfR clones highlighting 
features with predicted functionality. The receptors are grouped by sequence origin, 
with feline TfR mutants in neutral colors, chimeras with cytoplasmic tails from cellular 
proteins in reds and purples, and chimeras with tails from viral proteins in blues and 
greens. Highlighted in boxes are sequences involved in clathrin-mediated endocytosis 
(tyrosine-containing motifs, dileucine sequence, and an extracellular glutamic acid), 
lysosomal targeting (LI…ML), and segregation into lipid raft domains (VGIIS). The 
length of the cytoplasmic and transmembrane domains is drawn approximately to scale.  
 
3.4b Expression of cloned receptors 
Cells transiently transfected with the variant receptor constructs were stained 
with a monoclonal antibody against the TfR ectodomain (an area conserved between 
the mutants) to determine whether the clones could be expressed as intact proteins 
within the cell. The Ii-TfR and SV5HN-TfR chimeras showed less than five percent of 
cells expressing only low levels of receptor and were excluded from further analysis 
(data not shown). Of the remaining receptors, most mutant and chimeric receptors 
expressed equivalent levels of TfR to wild-type FelTfR in TRVb cells (Figure 3.2). Only 
the FluNA-TfR had significantly lower expression than the wild-type receptor (~22%). 
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However, the expression level of FluNA-TfR was comparable to that seen in wild-type 
feline NLFK cells (Figure 3.2B), indicating that most receptor constructs are actually 
significantly overexpressed. By microscopy, the distribution of the transfected wild type 
FelTfR receptor throughout the cell (Figure 3.2C) was comparable to that of NLFK cells 
(Figure 3.2D), and the receptors had a patchy distribution consistent with their 
localization on endosomal membranes and the cell surface.  
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Figure 3.2. Cellular expression of the different TfR mutants after transfection into 
TRVb cells. A) Expression of the wild-type and mutant receptors in permeabilized 
TRVb cells was quantified using an anti-TfR ectodomain antibody and an Alexa-488 
conjugated secondary antibody. Expression level as determined by flow cytometry in 
three independent experiments is shown as raw mean fluorescence intensity (MFI) of 
the transfected population or of the whole population for untransfected TRVb cells; 
receptors with significantly lower expression than wild-type FelTfR in TRVb cells are 
indicated (p<0.05). B) Expression level of the TfR in wild-type NLFK feline cells, as 
described in (A). Fluorescence microscopy showing the expression pattern of the TfR in 
permeabilized (C) TRVb cells expressing wild type FelTfR or (D) NLFK cells as 
indicated, detected using a monoclonal antibody raised against the TfR ectodomain.  
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3.4c Infection by parvoviruses in cells expressing variant TfRs 
The receptor mutants were tested for their ability to mediate parvovirus infection 
in transiently transfected cells. The data for FPV infection are shown in Figure 3.3, as it 
has the highest levels of infection and is the easiest to interpret differences, though the 
infectivity patterns were similar for CPV-2 and CPV-2b inocula (data not shown). The 
wild-type FelTfR and the two clathrin motif mutants (FelTfR-ATAA, FelTfR-∆3-32) 
(Figure 3.3A) mediated infection levels similar to that of untransfected, wild-type NLFK 
feline cells (Figure 3.3B), with approximately 25-30% of transfected cells becoming 
infected. The chimeric receptors with cytoplasmic tails from cellular receptors (Asialo-
TfR, CD23-TfR) mediated significantly lower levels than wild-type but retained 
approximately 15% infection rates of transfected cells. Finally, consistently very low 
levels of infection were obtained using the viral protein-TfR chimeras (FluNA-TfR, 
PI4aHN-TfR, and NDVHN-TfR), which showed 0-5% infection of transfected cells 
(Figure 3.3A).   
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Figure 3.3.  FPV infection of TRVb cells expressing the wild type or mutant feline 
TfRs or wild-type feline cells.  A) Cells were transfected with plasmids expressing the 
variant TfRs, incubated for two days, and then were re-seeded for 24 hours and 
inoculated with five TCID50 units of FPV. After 48 hours, receptor expression was 
detected with Alexa-488 labeled canine Tf and staining with an anti-TfR extracellular 
domain monoclonal antibody. The percentage of infected cells was determined by 
staining with an Alexa-594 conjugated anti-NS1 viral protein antibody. Results of at 
least three independent experiments are shown as the infected percentage of 
transfected cells, or the total percentage of TRVb cells that expressed viral antigen, and 
significantly different groups are indicated by the symbols above each column (p<0.05). 
B) Infection of wild-type NLFK feline cells, performed as described in (A). C) Example 
images of infection in TRVb cells transfected with (C) wild-type FelTfR or (D) NDVHN-
TfR. Cells expressing the TfRs are shown in green, and infected cells have red nuclei 
due to the presence of viral NS1 antigen (white arrow in (C)). Red arrows in (C) and (D) 
depict transfected but uninfected cells, and the yellow boxes indicate nuclei of 
untransfected cells stained with DAPI (blue).  
 
  118 
 
 
 
 
  119 
3.4d Determining the functionality of variant receptors for binding Tf and CPV 
Binding and uptake of fluorescently labeled canine Tf or CPV capsids were used 
to assess functionality of the receptors for binding and endocytosis of these ligands 
(Figure 3.4). The mutant receptors showed variable levels of Tf uptake that in most 
cases was 50-60% of wild-type (Figure 3.4A). Only Asialo-TfR retained equivalent levels 
of Tf uptake to the wild-type FelTfR, while NDVHN-TfR and FluNA-TfR had the lowest 
levels of transferrin uptake, both less than 40% of wild-type. All the variant receptors 
allowed CPV binding and uptake at levels comparable to wild-type, except for NDVHN-
TfR that bound ~50% and FluNA-TfR that bound ~20% of wild-type level (Figure 3.4B).  
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Figure 3.4. Functionality of mutant receptors for binding and uptake of Tf or CPV-
2. Transiently transfected TRVb cells expressing the various receptors were incubated 
for one hour at 37°C with 10 mg/mL Alexa-488 labeled (A) canine Tf or (B) CPV-2, then 
washed extensively. Cell-associated fluorescence was detected using flow cytometry. 
The mean fluorescence intensity (MFI) of ligand binding to the transfected population or 
the complete population of untransfected TRVb cells, measured in at least 3 
independent experiments, is shown. Receptors binding significantly less ligand than the 
wild-type receptor are indicated (p<0.05). C) Example flow cytometry plots showing the 
binding levels of TRVb cells transfected two of the variant TfRs, as well as 
untransfected NLFK (positive control) and TRVb (negative control) cells. Cells were 
incubated with Alexa488-CPV-2 or Cy5-Tf alone (green and red data, respectively) or 
together (blue data). Control cells with no ligand added are shown in orange.  
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To further examine the endocytic defects in cells expressing the variant 
receptors, the kinetics of Tf uptake were examined by binding for short periods of time 
ranging from 15 seconds to 20 minutes (Figure 3.5). Most of the receptors showed 
slower uptake kinetics than wild-type, except for Asialo-TfR. The viral chimeras that 
allowed the lowest levels of infection (FluNA-TfR, NDVHN-TfR, PI4aHN-TfR) also had 
the slowest rates of accumulation as determined by the slope of the curve in different 
segments. Furthermore, after binding for 10 and 20 minutes, these three chimeras had 
attained only 20% of wild type association levels.  
 
 
Figure 3.5. Kinetics of canine Tf uptake into cells expressing the variant feline 
TfRs. Cells were incubated with Alexa-488-labeled canine Tf at 37°C for the indicated 
times, then were rapidly diluted in ice-cold media to stop further endocytosis. Cells were 
washed, and cell-associated Tf was quantified using flow cytometry. Graphs indicate the 
mean fluorescence intensity of the transfected population at each time point normalized 
to maximum binding to wild-type FelTfR.  
 
3.4e Differences in membrane localization of variant TfRs 
Cold detergent extraction was used to determine the localization of a subset of 
receptors to lipid raft areas of the plasma membrane (Figure 3.6). The wild-type FelTfR, 
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Asialo-TfR, and PI4aHN-TfR primarily segregated to the non-lipid raft associated, 
detergent extracted fraction, while only FluNA-TfR stayed associated with the lipid raft 
membrane subdomains in the detergent resistant fraction as has been previously shown 
(24). Western blotting for caveolin-1 was used as a positive control for a protein 
expected to associate to lipid rafts, and as expected showed ~50% association with 
detergent resistant membranes (data not shown).  
 
 
Figure 3.6.  Association of a subset of the chimeric TfRs with detergent insoluble 
membranes. The results show Western blots of the cold detergent resistant and 
extracted fractions from cells expressing the wild-type or mutant TfRs.  The blots were 
probed with an anti-TfR monoclonal antibody and a horseradish peroxidase-conjugated 
secondary antibody. Not shown are blots stained with an anti-caveolin antibody showing 
~50% of this protein localizing to the detergent resistant fraction.   
 
3.4f Differences in intracellular trafficking of CPV in association with variant TfRs 
Alexa488-labeled CPV-2 uptake into cells expressing a subset of the receptor 
chimeras was examined by fixed and live-cell microscopy, and the receptors showed 
distinct patterns of uptake in some cases.  The wild-type FelTfR allowed apparent rapid 
uptake from the cell surface and localization to a perinuclear region within the first 30 to 
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45 minutes of incubation, comparable to results previously obtained in feline cells 
(Figure 3.7A) (22).  In contrast, the chimeric TfRs with cytoplasmic and TM sequences 
from viral proteins (PI4aHN-TfR and FluNA-TfR) bound virus at the cell surface, but 
similar showed little apparent endocytosis within 10 minutes with the majority of virus 
localized at the cellular periphery (Figure 3.7B and C).   
 
 
Figure 3.7. Altered endocytosis associated with mutant TfRs. Uptake of Alexa-594-
fluorescently labeled virus into cells expressing mutant TfRs and Rab7-GFP, a marker 
of the late endosome, was examined by live-cell microscopy. Virus was incubated with 
cells for five minutes, then washed and imaged at 10-15 minutes total time. Shown are 
representative images of the different uptake patterns observed, including (A) wild type 
FelTfR demonstrating rapid uptake, and (B) PI4AHN-TfR or (C) FluNA-TfR showing the 
delay in uptake by the viral chimeras. In each image, viral particles are red, and the late 
endosomal compartment is depicted in green. 
 
After a 45 minute incubation, the majority of capsids had concentrated in the 
perinuclear region in cells expressing the wild-type FelTfR and could be readily 
observed to co-localize with Rab7, a marker of the late endosome (Figure 3.8A). In cells 
expressing FluNA-TfR, virions were still located in the cell periphery at later time points 
(examined up to 2 hours) (Figure 3.8B), though by this later time point capsids had 
begun to localize to the perinuclear area in the PI4aHN-TFR expressing cells (data not 
shown).        
  124 
 
Figure 3.8. Intracellular trafficking patterns of virus associated with variant TfRs. 
Endocytosis of Alexa 594-fluorescently labeled virus into cells co-expressing mutant 
TfRs and Rab7-GFP was examined by live-cell microscopy for up to two hours after 
binding. A) After 20 to 45 minutes, virus bound to the wild-type FelTfR reached the 
perinuclear area and could be seen to co-localize and co-traffic (arrows) with the Rab7 
marker of the late endosome. B) In cells expressing FluNA-TfR the virus remained 
localized at the cell periphery with little movement for extended periods of time. A series 
of six time-lapse images from a portion of each cell is shown at left, with frames set five 
seconds apart. The complete image of the representative cell is shown at right, 
highlighting the area shown in the time-lapse images (white box).  
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3.5 Discussion 
The specific receptor binding interaction and the endocytic pathways followed by 
incoming virus capsids are important for the success of infection. While some of the 
requirements for cellular entry have been defined for parvoviruses, little is known about 
the requirements or flexibility for using specific uptake and intracellular trafficking 
pathways. Here we used a variety of approaches to assess the uptake and trafficking of 
the virus-receptor complex early in infection. The receptors were expressed in cells that 
do not otherwise bind the virus as they lack the endogenous TfR. This allows analysis of 
mutant TfR properties without the background of other receptors. The hamster-origin 
TRVb cells expressing wild-type FelTfR became susceptible to infection at levels similar 
to those of feline cells, suggesting that although the receptor was significantly 
overexpressed in many cells in this context, other aspects of the infection process are 
comparable between cells from the different species (cats and hamsters). In this study, 
the receptor uptake and trafficking properties were altered using mutant and chimeric 
TfRs with alternative cytoplasmic and transmembrane domains. The extracellular 
domain is identical between the mutants except for the first few residues of the stalk 
domain, which is not involved in ligand binding, so that the structural interaction 
between the virus and receptor is expected to be preserved. Thus the differences in 
virus uptake and infection are most likely explained by one or more alterations in cell 
surface receptor density and distribution, mechanism and efficiency of endocytosis, and 
intracellular trafficking. 
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3.5a Expression of variant receptors 
Although expressed from the same promoter, the receptors varied in their levels 
of cellular expression as measured by antibody staining. The invariant chain chimera (Ii-
TfR) showed only very low levels of cellular expression, likely due to the presence of a 
lysosomal targeting sequence in its cytoplasmic domain. The SV5 chimeric receptor 
(SV5HN-TfR) also expressed poorly, possibly due to misfolding or some other defect in 
expression or trafficking. The other receptors, except for FluNA-TfR, were expressed at 
levels approximately three times higher than in native feline cells, and bound antibody to 
levels within two-fold of wild-type FelTfR expressed in TRVb cells. This level of 
expression should be considered when analyzing the uptake patterns of these 
receptors, as the degree of cross-linking, mechanism of uptake, and/or other factors 
may be affected by receptor expression level and surface density.  
3.5b Endocytosis of the variant TfRs 
The sequences used to construct the receptor chimeras were derived from type II 
cellular or viral glycoproteins that traffic to the cell surface, a property clearly essential 
for a protein to act as a primary receptor for mediating infection by extracellular viruses. 
Binding of Tf for very short periods (15 to 30 seconds) can be taken as a rough 
measure of the amount of receptor present on the cell surface at any one time. The 
results show that all receptors were functionally expressed on the cell surface, although 
as with overall cellular expression, the surface levels were variable between the 
mutants. The mutant receptors also varied in their ability to bind and take up Tf over 
longer periods of time, and the timeframe used in Figure 3.4 (60 minutes at 37°C) was 
chosen to mimic the conditions used in infection. When this long incubation was used, 
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the patterns of binding for Tf and CPV-2 generally paralleled the whole-cell expression 
level as measured by antibody staining, although Tf was a more sensitive ligand for 
detecting deficiencies in uptake between the cellular mutants. Why most of the mutants 
bind comparatively less Tf than wild-type FelTfR after a one-hour incubation but do not 
show significant differences in CPV binding over this time frame is unclear. The large 
size of virus capsids and the ability to cross-link at least some receptors may result in 
reduced efficiency of endocytosis and receptor recycling that would limit the rate at 
which cumulative increase in viral association (and thus differences) could be detected. 
Differences in the kinetics of Tf uptake over periods of seconds to minutes were 
also found between the mutant receptors. During cellular infection, CPV capsids attach 
to the cell surface and are endocytosed into clathrin-coated pits within approximately 
two minutes (D. Cureton, personal communication). In studies using Tf as a ligand, TfR 
uptake occurs rapidly with ~10% of the surface population endocytosed per minute (32). 
Thus the measured time points are appropriate given the expected uptake kinetics of 
the wild-type receptor. TfR uptake kinetics have been previously studied in vitro by 
binding Tf for varying amounts of time and then removing the residual surface 
proportion of Tf by an acid wash followed by a neutral pH wash. This treatment mimics 
the conditions seen in a normal round of endocytosis, and allows examination of how 
quickly bound Tf is endocytosed under different conditions. Acid washing did not 
remove the Alexa-488-labeled Tf from the surface of the cell (data not shown), so the 
results in Figure 3.5 show the kinetics of cumulative Tf association with the cell. While 
less transferrin is bound overall in those mutants where expression is less than wild-
type FelTfR as measured by antibody staining, these data also indicate that the rate of 
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uptake varies between the receptors. While this experiment cannot specifically 
distinguish the contribution of endocytosis versus receptor recycling rates, it does begin 
to address the overall dynamics of the different mutant receptors. Further studies would 
be required to separate out the specific differences between the receptors during 
individual steps of the receptor trafficking cycle.  
3.5c Association of the TfRs with membrane subdomains 
The final aspect of receptor surface expression examined in this study involved 
determining association of the variant TfRs with lipid raft domains. The association of 
viral receptors with plasma membrane micro-domains rich in cholesterol and 
sphingolipids (lipid rafts) or non-raft-associated membrane domains can affect pathways 
available for uptake as well as intracellular destination. Often defined by their relative 
resistance to extraction with cold Triton X-100, raft association can give a crude 
indication of receptor properties related to membrane sub-localization (52). Although the 
composition and properties of these micro-domains are still unresolved, they appear to 
represent regions of different lipid composition that are small (five to 10 nm) and 
dynamic in size and composition (65). Clustering of protein and lipid components can 
increase the size and stability of these domains and can trigger endocytosis through 
raft-associated pathways. Raft association is also involved in the budding process of 
some viruses during viral egress, and specific transmembrane sequences can target 
individual viral proteins, such as the influenza virus neuraminidase, to these structures 
(7). Protein targeting to lipid rafts can also be achieved through association with 
additional proteins, as is the case with the HN protein of some paramyxoviruses (53). 
The NDV HN protein, for example, segregates to detergent resistant membranes only 
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through association with the viral fusion (F) protein and not based of any intrinsic 
feature of the HN protein itself (28). In the context of the chimeric receptors, the FluNA-
TfR chimera has been previously shown to segregate to lipids rafts (24). 
A subset of receptors were tested for lipid raft association in this study, but the 
sensitivity of Western blotting for the transfected receptors precluded visualization of the 
NDVHN-FelTfR and CD23-TfR chimeras. Without the presence of the viral F protein for 
targeting, the NDVHN-TfR would likely behave similarly to the PI4aHN-TfR construct 
and would not segregate to rafts; however, this remains to be confirmed experimentally. 
CD23-TfR was also unable to be visualized, but given its expected interaction with the 
clathrin machinery it is likely to behave like Asialo-GPR and wild-type FelTfR and  
segregate to non-lipid raft domains of the plasma membrane.  
3.5d Pathways to parvoviral infection 
Although CPV and FPV bind the wild-type feline TfR and are rapidly 
endocytosed, the subsequent fate of the virus and the requirements for specific 
pathways to infection are not well understood. Under normal cellular conditions, the Tf-
TfR complex follows a well defined pathway of rapid clathrin-mediated uptake into the 
early endosome, with >99% of the complexes rapidly recycling to the plasma membrane 
through the pericentriolar recycling endosome (54). Cross-linking of the TfR alone is 
enough to retain the receptor in the endosomal system for longer periods of time, and 
may divert a higher percentage into the degradative compartment, regardless of the 
specific transmembrane and cytoplasmic sequences (32). This may be the case for the 
multivalent viral ligand, despite structural studies that have suggested that only one or a 
few receptors become associated with each viral capsid because, as with bivalent 
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antibodies, binding of only two receptors would be enough to facilitate cross-linking (21). 
The importance of the degradative compartment for infection was previously suggested 
by experiments where infection was inhibited in cells expressing a dominant negative 
form of the Rab7 protein normally associated with the late endosome, but not in cells 
expressing a dominant negative form of the Rab11 protein associated with the recycling 
endosome (22). The invariant chain chimera (Ii-TfR) was constructed as an attempt to 
determine the effects of diverting a higher percentage of receptor into the degradative 
compartment, but this receptor was not measurably expressed on the cell surface and 
was unable to be tested. 
Previous results also showed that the virus rapidly disseminates to multiple 
intracellular compartments during a timeframe in which it is expected to remain 
associated with the receptor (22, 63). This result was also seen with the mutant TfRs in 
this study, though quantifying the proportion of virus-receptor complexes entering 
individual compartments during perinuclear accumulation was difficult due to poor 
resolution and high background GFP signal. However, the particle to infectivity ratio of 
CPV and FPV is very high, and simply characterizing the location where the majority of 
viral particles go may not reflect what compartments are actually important for infection. 
Additional studies will be required to clarify these requirements, specifically in the 
context of the signals that the virus requires in order to initiate infection, for example low 
pH and exposure to intracellular factors such as proteases.  
 In this study, mutant and chimeric transferrin receptors were examined to 
determine the importance of the transmembrane and cytoplasmic domains for cellular 
uptake and infection by parvoviruses. Chimeric and mutant receptors mutants were 
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identified that allowed entry and infection within two fold of the wild-type receptor, 
indicating that there are no specific sequence requirements contained in the wild-type 
version of these domains. The infection-permissive receptors had tails with sequences 
from proteins expected to use clathrin-mediated endocytosis (asialoglycoprotein 
receptor I, Fc epsilon receptor II), as well as receptor mutants that lacked the YTRF 
internalization sequence (FelTfR-ATAA, FelTfR-Δ3-32) and thus had no known clathrin 
interacting motifs. These results show that there is no absolute requirement for 
sequences that interact with components of the clathrin-mediated mechanism of 
endocytosis. Finally, while the receptors prepared from viral type II glycoproteins allow 
some level of receptor expression and can bind capsids and mediate endocytosis, those 
led to only very low levels of infection. Cellular infection by viruses requires a certain 
threshold level of viral uptake, but beyond that these results indicate that the 
transmembrane and cytoplasmic receptor domains do play a role in the infection 
process by determining how the receptor is trafficked to and from the cell surface. 
Further studies should seek to clarify the role for specific endocytic pathways and 
intracellular trafficking destinations that are required by parvoviruses to trigger 
uncoating in an environment that leads to productive infection.  
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CHAPTER FOUR: THE ROLE OF INTERMEDIATE HOSTS IN  
CROSS-SPECIES VIRUS TRANSMISSION DURING ADAPTATION OF  
CANINE PARVOVIRUS TO DOGS 
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4.1 Abstract 
  Understanding the factors that lead to the successful cross-species transmission 
of viruses is critical to anticipating and potentially controlling disease emergence. Here 
we show that the emergence of parvoviruses in raccoons resulted from multiple cross-
species transmissions of feline panleukopenia virus (FPV) and canine parvovirus (CPV).  
CPV is a host range variant of FPV that caused a global pandemic in dogs when it 
emerged in 1978. By 1980, the original CPV type-2 (CPV-2) had been replaced in the 
wild by an antigenic variant designated CPV type-2a (CPV-2a), and additional CPV-2b 
and CPV-2c variants have arisen more recently as single point mutations of CPV-2a.  
Most raccoon isolates examined here fell between CPV-2 and CPV-2a in phylogenetic 
trees, identifying this species as an intermediate host that facilitated the evolution of 
later CPV strains. These strains had a spatial distribution covering much of the eastern 
United States and molecular clock estimates place their origin in the 1980s, suggesting 
that they have been circulating unrecognized for over 20 years. All CPV-like raccoon 
viruses had an aspartic acid at VP2 residue 300 that evolved in parallel multiple times 
across the parvovirus phylogeny. In the raccoon viruses derived from CPV, this 300Asp 
mutation, in combination with additional changes at other capsid surface residues, 
resulted in the inability to infect canine cells. These mutations were also associated with 
unique transferrin receptor (TfR) binding patterns and reactivity with monoclonal 
antibodies. The sequence of the raccoon TfR was intermediate between the feline and 
canine TfR, further supporting a role for raccoons in CPV evolution and adaptation. 
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4.2 Introduction 
The transfer of viruses into new hosts is a cause of novel disease epidemics that 
pose a significant threat to human and animal health. However, the genetic and 
evolutionary mechanisms underlying cross-species virus transmission are still only 
partially understood. Well-documented historical examples of host-jumping events are 
rare, but provide opportunities to define the processes that underpin viral emergence.  
Here we examined a series of parvoviruses that have transferred from different hosts 
into raccoons (Procyon lotor) in North America, providing multiple examples of cross-
species virus transmission and host adaptation.   
Feline panleukopenia virus (FPV) and FPV-like viruses infect and cause disease 
in many animals within the order Carnivora, including large and small cats, mink, 
raccoons, and foxes. Previous studies have shown that these viruses are not readily 
distinguishable genetically or antigenically (36, 41). Canine parvovirus type-2 (CPV-2) 
emerged as a new virus of dogs in the late 1970s, and its capsid protein differs by only 
a few amino acids from FPV (14, 26, 33). The original 1978 CPV-2 strain was replaced 
worldwide between 1979 and 1980 by a genetic and antigenic variant, designated CPV 
type-2a (CPV-2a). All extant canine viruses are descendents of CPV-2a, including the 
mutants termed CPV-2b and CPV-2c that are defined by substitutions of residue 426 in 
the capsid protein VP2 (31).  
The host ranges associated with FPV and CPV-2 are largely determined by 
mutations in the viral capsid proteins that control the ability to bind the transferrin 
receptor type 1 (TfR) on their host cells (13, 24). FPV does not infect dogs or canine 
cells in vitro due to the presence of a glycosylation specific for the canine TfR that 
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prevents FPV attachment (23). CPV-2 acquired the ability to bind the canine TfR and 
thus gained the canine host range by substitutions at VP2 residues 93 (Lys to Asn) and 
323 (Asp to Asn) (5), but had lost the feline host range due to concurrent changes at 
residues 80, 564, and 568. The CPV-2a variant contained additional VP2 changes at 
residues 87 (Met to Tyr), 101 (Ile to Thr), 300 (Ala to Gly), and 305 (Asp to Tyr). These 
changes expanded the viral host range by allowing the virus to once again infect cats 
while simultaneously decreasing its binding affinity for the feline TfR (23, 42).   
In addition to controlling viral host range, the genetic differences between 
parvovirus strains affect antigenicity. The capsid’s two major antigenic sites are found 
near the top of the three-fold spike (“A site”) and near the center of the asymmetric unit 
of the capsid, partially overlapping with the TfR binding site (“B site”) (10, 37). Different 
reactivity with monoclonal antibodies (MAbs) can readily distinguish FPV, CPV-2, and 
the newer CPV variants (34, 37). 
 Raccoons are found throughout their native North American range, as well as in 
parts of Europe and Asia following introductions to those continents in the twentieth 
century (22, 44). They have long been recognized as a host for a virus antigenically 
indistinguishable from FPV that has been named raccoon parvovirus (RPV) (18, 43).  
Historically, raccoons were reported to be resistant to CPV-2 infection (2, 4). However, 
since 2007, parvovirus isolates have been recovered from raccoons in North America 
that appeared to be derived from CPV-2 (16). Here we show that multiple independent 
introductions of FPV- and CPV-like viruses into raccoons have occurred, and that these 
viruses harbor key changes in capsid residues associated with host adaptation, TfR 
binding, and viral antigenicity. 
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4.3 Materials and methods 
4.3a Cells and cell culture 
CHO-derived TRVb cells that lack an endogenous TfR (19) were grown in Ham’s 
F12 media containing 10% fetal bovine serum. Crandell Reese feline kidney (CRFK) 
cells, Norden Laboratory feline kidney (NFLK) cells, and canine CF2Th and A72 cells 
were grown in 1:1 mixture of McCoy’s 5A and Liebovitz L15 media with 5% fetal bovine 
serum. 
4.3b Viruses and their preparation 
The viruses examined here are listed in Table 4.1. For virus isolation, 
homogenized tissue or fecal samples were filtered and used to infect CRFK or NLFK 
cells. Viral DNA was amplified using polymerase chain reaction (PCR) directly from 
tissue extracts or after passage in cell culture. For formalin-fixed paraffin-embedded 
(FFPE) blocks, viral DNA was extracted using a commercial QuickExtract FFPE DNA 
Extraction Kit (Epicentre Biotechnologies, Madison, WI). Amplification was performed 
using Phusion Hot Start High Fidelity DNA polymerase (Finnzymes, Espoo, Finland). 
Amplicons covering the complete VP2 protein sequence, or the entire nonstructural and 
structural coding regions in some cases, were sequenced directly or after cloning using 
a PCR Cloning Kit (Qiagen, Valencia, CA). Products amplified from FFPE tissues were 
truncated (186 bp) and focused on the critical region that included VP2 residues 297, 
300, 305, and 323. Control viruses were derived from infectious plasmid clones of FPV 
(FPV-b), CPV-2 (CPV-d), and CPV-2b (CPV-39) (13, 27) and purified as previously 
described (1). Viral inocula were prepared by passage in NLFK cells, homogenizing the 
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supernatant and cell fractions using freeze-thaw cycles, and clarifying the inoculum 
through a Steriflip filter (Millipore, Billerica, MA).  
 
Table 1. Parvovirus isolates. The prototype strains of FPV, CPV-2, and CPV-2b 
examined here and new isolates obtained in this study, grouped where appropriate 
when obtained from the same outbreak. Clinical features of the outbreak are included 
where available from the sample submission forms received with the diagnostic sample. 
 
Isolate Origin 
county, 
state, date 
Number affected in 
outbreak, age, mortality 
CPV/Rac/VA/118-A/07 Virginia 
Sept, 2007 
8, 4-5 months old, 4 died. 
CPV/Rac/GA/287/08 
CPV/Rac/GA/289/08 
CPV/Rac/GA/349/08 
Georgia 
Oct-Nov, 
2008 
Several infections,  
2-7 months, 3 died.  
CPV/Rac/TN/351/09 Tennessee 
May, 2009 
2 litters affected, <1.5 
months old, multiple deaths 
CPV/Rac/FL/381/09 Florida 
July, 2009 
Several infected,  ~1 month 
old, 1 death.  
CPV/Rac/VA/278/09 Virginia 
Aug, 2009 
Unknown number affected, 
<6months old, 4 deaths 
CPV/Rac/KY/358/09 
CPV/Rac/KY/9552/09 
CPV/Rac/KY/3817/09 
Kentucky 
Nov, 09 
23 affected, unknown age, 
unknown mortality. 
CPV/Rac/NY/92742/10 New York 
Aug, 2010 
Several affected, <6 months 
old, 6 deaths. 
CPV/Rac/NJ/76836/10 New Jersey 
Aug, 2010 
8 affected, 14-16 weeks old, 
7 deaths.  
CPV/Rac/WI/37/10 Wisconsin 
2010 
Unknown 
CPV/Bobcat/KS/44/10 Kansas 
2010 
Unknown 
FPV/Rac/CA/208/10 California 
2010 
Unknown 
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4.3c Evolutionary analysis 
The VP2 sequences of different carnivore parvovirus were compiled from 
GenBank (n = 498), one of which (GenBank accession M24005) was sampled from a 
raccoon in 1979. These sequences were combined with the 18 raccoon sequences 
determined here, resulting in a final data set of 516 sequences of length 1755 bp. All 
sequences included in this analysis covered at least 2/3 of the VP2 gene. Similar 
analyses were also conducted using full-length sequences of NS1 and VP2 where 
available (61 and 125 sequences, respectively). Sequence alignments were obtained 
using MUSCLE 3.7 (8). The phylogenetic relationships among these sequences were 
inferred using the maximum likelihood (ML) method implemented in PAUP* 4.0 (39), 
incorporating the general time-reversible substitution model with invariant sites and a 
gamma distribution of among-site rate variation (GTR+I+Γ4), and were partitioned by 
codon positions as this was the best-fit nucleotide substitution model determined by 
Modeltest 3.7 (35). Tree-bisection-reconnection (TBR) branch swapping was also 
employed. To assess the robustness of the phylogenetic groupings observed, a 
bootstrap resampling analysis was performed using 1000 replicate neighbor-joining 
trees estimated under the ML substitution model described above, again utilizing PAUP* 
4.0. 
The time to the most recent common ancestor (TMRCA) of the raccoon 
sequences was estimated using the Bayesian Markov Chain Monte Carlo (MCMC) 
method available in the BEAST package (7). This analysis incorporated the nucleotide 
substitution model described above, as well as a relaxed (uncorrelated lognormal) 
molecular clock and the conservative Bayesian skyline model as a coalescent prior.  
 145 
Statistical support was depicted as 95% Highest Probability Density (HPD) values, and 
the MCMC analysis was run until convergence was achieved in all parameters. The 
BEAST analysis also allowed us to infer the Maximum Clade Credibility (MCC) tree for 
these data, such that TMRCA values could be estimated for specific nodes. The MCC 
tree was topologically very similar to that produced in the ML analysis. 
4.3d The raccoon transferrin receptor (rTfR)  
Messenger RNA (mRNA) from raccoon Pl 1Ut (NBL-9) cells (ATCC, Manassas, 
VA) or from raccoon tissues was extracted using the Oligotex Direct mRNA Mini kit 
(Qiagen), amplified using reverse transcriptase PCR (RT-PCR), and was cloned into the 
pcDNA3.1(+) plasmid and sequenced as previously described (24).  
4.3e Antigenic analysis 
28 mouse or rat monoclonal antibodies (MAbs) against CPV-2, FPV, or CPV-2b 
have been previously described (28, 30, 34). For hemagglutination inhibition (HI) 
assays, antibodies were tested using standard methods, and titers were compared to 
the virus against which the MAb was raised (37). Briefly, MAb hybridoma supernatant 
was serially diluted and incubated with 8 hemagglutinating (HA) units of virus for one 
hour at 20°C. Feline erythrocytes (0.5% v/v) in 20 mM Bis±Tris (pH 6.2) and 150 mM 
NaCl were added and the plates incubated at 4°C for 2 hours (3, 40). HI titer was 
scored as the first MAb dilution containing greater than 50% agglutinated cells, and was 
compared relative to the prototype virus against which the MAb was raised. 
4.3f Cell infection and binding assays 
Infection in NLFK, A72, or Cf2Th cells was assessed using standard methods for 
TCID50 assays (42). Cell binding was analyzed using purified virus capsids as indicated 
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diluted to 10 µg/mL in DMEM 0.1% BSA and incubated in solution for 60 minutes at 
37°C with NLFK or Cf2Th cells, or TRVb cells transfected with plasmids expressing the 
feline, canine, or raccoon TfR (9). Cells were fixed with 4% paraformaldehyde (PFA), 
and cell-associated virus capsids were detected with MAb 2 and goat anti-mouse-Alexa 
488 (Sigma). Binding level was quantified using a Guava EasyCyte Plus flow cytometer 
(Guava Technologies).  
 
4.4 Results  
4.4a Parvoviruses in raccoons  
We analyzed parvoviruses isolated between 2007 and 2010 from juvenile raccoons 
in several states in the USA, as well as raccoon viruses in our collections that were 
originally sampled between 1978 and 1990 (Table 4.1). All examined animals from 
2007-2010 exhibited diarrhea associated with severe enteritis and had parvovirus 
antigen expression in the intestines, mesenteric lymph nodes, and/or less frequently in 
the cerebellum (data not shown). 
 The 19 VP2 sequences of viruses from raccoons were aligned with 497 FPV- 
and CPV partial VP2 sequences and subjected to phylogenetic analysis. Sequences of 
CPV-like viruses isolated from leopard cats (Prionailurus bengalensis) in Vietnam and 
Taiwan also fell within the major CPV-2a group, but were clearly distinct from the 
raccoon viruses. Notably, the lineages of raccoon isolates fell into several unrelated 
clusters across the carnivore virus phylogeny. These results indicate multiple cross-
species transmission events into raccoons from both cats and dogs (Figure 4.1). While 
one raccoon isolate was most closely related to CPV-2b-like viruses and several 
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grouped among the FPV, most (n = 13) sequences of viruses from raccoons fell 
between the CPV-2 and CPV-2a sequences (Figure 4.1). These latter raccoon isolates 
were collected between 1982 and 2010 and were obtained from states along the 
eastern seaboard of the US from Florida to New York State, as well as from Wisconsin, 
Texas, and California (Table 4.1). This position on the phylogeny identifies these strains 
as evolutionarily intermediates between CPV-2 and CPV-2a. Equivalent analyses of 
NS1 gene sequences (61 samples) and the complete VP2 gene (125 samples) 
confirmed these evolutionary relationships (data not shown).  
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Figure 4.1. Maximum likelihood (ML) phylogeny of carnivore parvoviruses based 
on 516 sequences of the VP2 gene. The sequences used represent feline 
panleukopenia viruses (green), viruses isolated from raccoons (blue), and the different 
strains of CPV (CPV-2, black; CPV-2a, red; CPV-2b, yellow; and CPV-2c, pink) are 
organized by their evolutionary relationship. As the mink enteritis viruses (MEV) 
clustered closely with those from cats they were also colored green. Sequences of 
viruses from leopard cats are indicated with stars. The tree is rooted using the oldest 
sequence included in the analysis (FPV/Cat/UK/62). Bootstrap values >0.90 are marked 
by asterisks. Branch lengths are drawn to scale of nucleotide substitutions per site. 
Insert: expansion of the phylogenetic tree section containing the main group of raccoon 
sequences, highlighting the amino acid substitutions that occurred on each branch. 
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 The emergence date of the raccoon viruses was inferred using a relaxed 
molecular clock analysis of the VP2 data set. Accordingly, the main group of raccoon 
isolates was estimated to have diverged from CPV between 20 to 30 years ago (95% 
HPD values), such that it has been undetected for at least 20 years. Raccoon isolates 
that fell outside of the main cluster, either within FPV or CPV-2b, had more recent 
origins (95% HPD values = 4-19 years ago). Comparable values were obtained using 
the full-length NS1 and VP2 data sets.   
 Many variant residues in the raccoon viruses were located within capsid protein 
structures that influence host range, TfR binding, and antibody binding (Figure 4.2). A 
key change occurred at VP2 residue 300, which is polymorphic among the carnivore 
parvoviruses (Figure 4.2). This residue was an Ala in the original RPV, FPV and CPV-2, 
and a Gly in CPV-2a-derived viruses in dogs. Most notably, residue 300 was Asp in all 
CPV-derived isolates from raccoons irrespective of their position on the phylogeny and 
hence whether they were derived from FPV or CPV (Figure 4.2). The CPV-derived 
raccoon viruses also contained polymorphisms at the following VP2 residues: 224 (Gly 
or Arg), 232 (Ile or Thr), 297 (Ser or Ala), and 305 (Asp or His) (Figures 4.1 and 4.2).   
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Figure 4.2. Parvovirus VP2 capsid protein sequences. Shown are phylogenetically 
important positions associated with the viruses recovered from raccoons in different 
parts of the USA between 1979 and 2010, as well as viruses recovered from leopard 
cats in Vietnam in 1997, and a bobcat in Kansas USA in 2010. We also include the 
sequences at each position for the prototype FPV, CPV-2 and CPV-2a-related viruses. 
 
4.4b Antigenic analysis 
Many of the mutations in the raccoon virus capsids occurred within known 
antigenic sites, most notably at VP2 residue 224 (“A site”) and VP2 residues 300 and 
305 (“B site”) (10, 37). Representative strains containing the most common combination 
of mutations (300Asp with 305His (e.g. CPV/Raccoon/GA/287/08) or 300Asp with 
224Arg (e.g. CPV/Raccoon/VA/118-A/07)) were tested for reactivity with MAbs prepared 
against FPV, CPV-2, or CPV-2b and showed significant differences in their antigenic 
binding patterns (Figure 4.3). All CPV-derived raccoon strains tested showed decreased 
reactivity with “B site” antibodies, primarily due to the 300Asp mutation, and the 
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CPV/Raccoon/VA/118-A/07 virus (containing the additional mutation at “A site” residue 
224Arg) showed decreased reactivity with 26 out of 28 MAbs tested, presumably due to 
loss of reactivity with antibodies at both sites.  
4.4c In vitro host range and transferrin receptor binding 
We tested the infectivity of representative raccoon virus isolates and the 
prototype FPV, CPV-2 and CPV-2b strains in feline and canine cells. All virus inocula 
infected feline cells to similarly high titers (105 to 107 TCID50/mL). FPV, and the FPV- 
and CPV-derived viruses from raccoons showed 500- to >10,000-fold lower titers in 
canine cells (Figure 4.4). The CPV-2 isolate with the 300D mutant alone showed a one 
to two log reduction of infectivity for canine cells compared to feline cells, as was 
previously shown (17, 25). 
To examine the specific binding of the raccoon viruses to different host receptors, 
we cloned the raccoon TfR complementary DNA (cDNA) from mRNA extracted from a 
raccoon cell line. This was found to be 88-89% identical at the amino acid level to dog 
and cat TfRs. The TfR apical domain, which controls virus binding, was more similar to 
the cat TfR as it did not contain the canine-specific glycosylation site at amino acid 
residue 384 (Asn in dog TfR, Lys in cat and raccoon TfR). The CPV-2 and CPV-2b 
capsids bound to cells expressing feline or raccoon TfR and, to a lower level, the canine 
TfR (Figure 4.5A, C, and E). FPV, an FPV-like raccoon isolate (RPV-79-4176/TX), and 
two representative CPV-derived raccoon isolates showed binding to the raccoon and 
feline TfRs, but did not bind the canine TfR above background levels (Figure 4.5B, D, 
and E).   
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Figure 4.3. Antigenic analysis of viral variants. The hemagglutination inhibition 
assay and MAbs prepared against capsids of FPV (names in red), CPV-2 (names in 
blue), or CPV-2b (names in black) capsids were used to antigenically distinguish 
different raccoon isolates.  Titers are compared to those of the capsid type used for 
immunization. Four different viruses from raccoons were tested, along with prototype 
FPV (FPV/Cat/NY/FPV-b/68), CPV-2 (CPV-2/Dog/IL/CPV-d/79), and CPV-2b (CPV-
2b/Dog/TX/CPV-39/84), and the experimentally derived 300Asp mutant of CPV-2. Black 
squares indicate binding +/- 2-fold of the original titer, shaded squares indicate a 4- to 
16-fold reduction in titer, and open squares indicate a >16-fold reduction in titer. 
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Figure 4.4.  Relative infectivity of the raccoon isolates in canine and feline cells. 
Infection assays were performed in NLFK feline cells (black bars), or A72 (gray bars) or 
Cf2Th (white bars) canine cells. Three different raccoon isolates (designations 
containing Rac, see also Table 4.1) were tested, along with prototype strains of FPV 
(FPV/Cat/NY/FPV-b/68), CPV-2 (CPV-2/Dog/IL/CPV-d/79), and CPV-2b (CPV-
2b/Dog/TX/CPV-39/84), as well as the 300Asp mutant of CPV-2. Virus titers were 
determined by TCID50 assay in each cell line.  Error bars indicate +SD based on three 
independent experiments. 
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Figure 4.5. Binding of capsids and canine transferrin to the feline, raccoon, and 
canine TfRs. Receptors were expressed on TRVb cells that lack endogenous TfR, and 
binding levels were assayed by flow cytometry.  Cells were incubated with Cy-5 
conjugated-transferrin to detect TfR-expressing cells, and with virus capsids detected 
with MAb 2. (A) Tf and CPV-2 and (B) CPV/Rac/VA/118-A/07 bind to feline and raccoon 
TfRs.  (C) Tf and CPV-2 (CPV-2/Dog/IL/CPV-d/79) bind to canine TfR.  (D) The raccoon 
isolates (CPV/Rac/VA/118-A/07 shown) do not bind the canine TfR.  E) Graphs of cell-
associated Tf and virus are plotted as mean fluorescence intensity units (MFI); error 
bars +SD from the mean for 3 independent experiments (= significant binding over 
background, p<0.05). 
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4.5 Discussion 
Our studies of raccoon parvoviruses illustrate several key aspects of cross-species 
transmission and emergence of novel viruses. The most striking and surprising 
observation was that the major group of raccoon parvoviruses examined in this study 
fell between CPV-2 and CPV-2a on phylogenetic trees, such that they represent 
evolutionary intermediates between these antigenic variants and have been apparently 
circulating undetected for at least 20 years. In addition, these raccoon viruses contain 
key amino acid substitutions in the four VP2 codons that became fixed in CPV-2a after 
its global spread in dogs. Of these substitutions, those at residues 87 (Leu) and 101 
(Thr) were the same in both CPV-derived raccoon viruses and CPV-2a compared with 
the more ancestral CPV-2 (Met and Ile, respectively). The two remaining strain-specific 
codons (300 and 305) exhibited different amino acid residues in CPV-2, CPV-derived 
raccoon viruses, and CPV-2a.  Residue 300 was Asp in the raccoon isolates, rather 
than Ala (CPV-2) or Gly (CPV-2a), while residue 305 was either His (unique to raccoon 
isolates) or Tyr (also in CPV-2a), but not Asp (CPV-2). The Asp at residue 300 has 
been previously detected in some CPV-derived viruses from leopard cats in Vietnam 
and cats in Taiwan, and was also selected experimentally in a CPV-2 virus passaged in 
feline cells (15, 17, 20, 29). For the ancestral raccoon virus to give rise to CPV-2a, only 
a single change in codon 300 was required (Asp to Gly), which represents a single 
transitional mutation that could have occurred either before or after the transfer back to 
dogs. A previously studied experimental change of the neighboring VP2 residue 299 
from Gly to Glu similarly blocked binding to the canine TfR and also prevents canine cell 
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infection, providing further support for the importance of this region in determining host 
range (13, 25). 
4.5a A signature amino acid mutation was selected multiple times 
Residue 300 in the viral capsid clearly plays a key role in the control of host 
range of carnivore parvoviruses. In particular, the 300Asp mutation appeared multiple 
times in the VP2 phylogeny and always associated with changes in host range, strongly 
suggesting that it is selectively favored and facilitates adaptation to raccoons and cats.  
The 300Asp mutation creates a novel hydrogen bond between surface loops of the 
capsid that likely stabilize the surface architecture. This interaction may play a role in 
inhibiting infection of canine cells by reducing the ability of the capsid to bind the canine 
TfR (17). The raccoon viruses also contained additional substitutions that further 
inhibited infection in canine cells; for example, VP2 224Arg or 305His were associated 
with the presence of residue 300Asp and had >100 fold reduced infection in canine cells 
compared to CPV-2 with the 300Asp mutation alone.  
 We observed other changes common to the raccoon viruses derived from 
different hosts, indicative of parallel changes in these viruses. The presence of residue 
323Asn among the FPV-like viruses from raccoons was particularly interesting as this 
mutation was also associated with the species jump from cats (FPV) to dogs (CPV) (5).  
VP2 residue 297 was another notable example, as the change from Ser to Ala in CPV-
2a in dogs was only seen after about 1990 (6, 12, 21), and this mutation was also 
largely fixed in the raccoon viruses derived from CPV.  
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4.5b Functional effects of changes on receptor and antibody binding 
Many of the amino acid changes studied here fell within known binding sites for 
the TfR and antibodies and had effects on capsid functionality related to binding various 
carnivore TfRs and MAb reactivity (10, 11). Positive selection of virus variants that have 
specific structural interactions with the TfRs from cats, raccoons, and dogs would be 
expected, given the importance of this interaction for cell infection (13, 23). A role for 
antigenic selection is less easy to define, as the specific effects would depend on the 
immune status of the different hosts. In many cases immunity against parvoviruses, and 
immune selection in unvaccinated juveniles, depends on the nature of viruses infecting 
the mothers who contribute maternal antibodies that protect against infection. Some 
raccoon viruses reacted with only a small number of the 28 antibodies tested here, 
suggesting that immune escape is likely to be a source of selection pressure on some of 
these virus variants. 
4.5c Virus evolution and emergence 
Our study provides two more general insights into the process of cross-species 
virus transmission and emergence. First, natural selection of one or two necessary 
changes in the capsid amino acid sequence – such as the 300Asp in raccoons and 
300Gly in dogs – is apparently readily accomplished as it has occurred on multiple 
occasions. Similar observations have been seen in the adaptation of influenza viruses 
among mammalian species (32, 33), indicating that, in many cases, successful 
emergence is not limited by mutational availability. This is particularly likely when the 
donor and recipient species are relatively closely related, such that the adaptive valley 
separating them is shallow (38). Second, as the major cluster of raccoon parvovirus 
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sequences fell between CPV and CPV-2a, we suggest that the potential role of 
intermediate hosts such as raccoons should be investigated in cases where major 
changes in viral phenotype occur even within in the same host species. Similarly, 
intermediate hosts may provide a bridge between two widely separated hosts, as has 
previously been reported or inferred for a number of other viruses (32). Furthermore, 
future studies of virus biodiversity will likely demonstrate the existence of intermediate 
hosts in other cases of cross-species transmission. However, the mutational pathways 
involved may be complex, some of the specific mutations found in viruses from the 
intermediate host will likely not be found, or will have been altered, in the final host. In 
the case studied here, the signature change of VP2 residue 300 from Ala to Asp in 
raccoons was followed by a change to Gly in CPV-2a. As such, these studies 
underscore the need for considering a variety of related hosts in order to fully 
understand the mechanisms of viral evolution allowing cross-species transmission.  
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CHAPTER 5: NEUTRALIZING PROPERTIES OF 
 ANTIBODIES AGAINST AAV1 AND AAV5 CAPSIDS 
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5.1 Abstract 
Monoclonal antibodies (MAbs) were prepared against AAV type 1 (AAV1) and 5 
(AAV5) capsids and were purified as intact antibodies and, in some cases, Fab 
fragments. Four IgG and 3 IgM antibodies were prepared against AAV1. One IgG and 6 
IgM antibodies were prepared against AAV5 from mice pre-immunized with AAV1 
capsids and boostered with AAV5 four days before hybridoma preparation. The anti-
AAV1 MAbs showed cross-reactivity only with AAV6, while the AAV5 antibodies were 
slightly cross-reactive with AAV1 but not other serotypes. All antibodies were specific for 
assembled capsids and were able to neutralize the homologous virus, though with 
different efficiencies. Fab fragments of the MAbs were generally poorly neutralizing. 
Different antibodies appeared to have various mechanisms of neutralization that 
primarily included inhibition of receptor binding but also post-attachment neutralization 
in one case. 
5.2 Introduction 
 Adeno-associated viruses (AAVs) are non-pathogenic, non-enveloped viruses 
with a single stranded DNA genome packaged into an ~25 nm diameter icosahedral 
capsid. They are classified within the Parvoviridae family, genus Dependovirus. The 4.7 
kb genome lacks a viral DNA polymerase gene, and these viruses are dependent on 
cellular polymerases as well as on their helper viruses, usually adenovirus, to provide 
functions essential for replication. Many AAV strains are currently under investigation as 
vectors for therapeutic gene delivery due to a variety of features that make them 
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attractive vector candidates (1, 7, 32). These include the a) stability of the capsid that 
facilitates handling of the vectors during production and transport, b) inability of the virus 
to replicate without helper gene products, c) lack of disease associated with infection, d) 
ability to induce long term expression of packaged genes in some cases lasting up to 
months or years, and e) ability to transduce a variety of dividing and non-dividing cells 
(47). Since their initial discovery in the 1960s as contaminants of Adenovirus 
preparations, more than 12 AAV serotypes have been identified in a variety of host 
species that possess varying natural tissue tropisms and receptor binding properties 
(14, 52). Genetic modification of viral capsids has further expanded this repertoire for 
targeting to cell types of specific gene therapy interest (5, 34).  
 The capsid is assembled from a total of 60 copies of three overlapping capsid 
proteins, VP1, VP2, and VP3, in an approximately 1:1:10 ratio. The core of the capsid is 
formed by an eight-stranded β-barrel, with the intervening loops between the β strands 
responsible for the specific features of the capsid surface. The different serotypes of 
AAV have capsid proteins that are ~60-80% identical in amino acid sequence (10, 11), 
and the differences in antigenicity and tissue tropism between the serotypes stem 
primarily from mutations within the surface loops.  
AAV2 was initially isolated from a human genital lesion. It was the first serotype 
to be studied in detail and is the capsid type with the largest number of ongoing clinical 
gene therapy trials for delivery of genes to treat disease states such as cystic fibrosis 
and hemophilia (13, 41). The primary cellular receptor for AAV2 is heparin sulfate 
proteoglycan (HSPG), though the virus can use a variety of co-receptors including αVβ5 
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integrins and human fibroblast growth factor receptor 1 (FGF1) (16, 35, 42).  
Despite a relatively low immunogenicity compared to other viral vector systems, 
humoral immunity leading to virus neutralization has been a major barrier to clinical 
trials involving AAV2 in humans (46). Anti-AAV2 neutralizing antibodies can be detected 
in up to 30%-80% of human subjects in different studies, and these antibodies may be 
capable of neutralizing the virus and preventing transgene expression even during the 
first administration (2, 3, 27, 56). Furthermore, in immunologically naive individuals, 
even one therapeutic application of AAV2 vectors can elicit the generation of memory B 
cell responses that can preclude the effectiveness of repeat dosing where that is 
necessary for sustained gene expression (39). These responses are affected by the 
route, dose, and serotype of the administered virus, as well as the identity, expression 
level, and promoter of the transgene product (21, 44). 
More recently, additional serotypes have been evaluated as alternate gene 
therapy vectors. AAV1 originates from non-human primates, and is of interest because 
of its superior ability to transduce muscle and hematopoitic stem cells compared to 
other AAV serotypes. Another serotype, AAV5, has higher levels of muscle, airway 
epithelia, and brain tissue transduction compared to AAV2 (18, 55, 57). Both of these 
serotypes utilize sialic acids as the primary cellular receptor, and AAV5 also binds to the 
platelet derived growth factor receptor (PDGF) as a co-receptor (23, 48). Serotypes 5, 
7, and 8, and other genetically modified variants are of specific interest because they 
are the most divergent from AAV2 and in some studies appear to have lower levels of 
pre-existing immunity in humans (4, 12, 15).  
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Repeated administration of transgenes packaged by sequentially different AAV 
capsid serotypes has been attempted to circumvent the problems encountered with the 
development of anti-vector antibodies. The capsids of different serotypes can vary up to 
20% in amino acid sequence, so that antibodies tend not to significantly cross-react, 
and thus this strategy has met with some success in reducing vector neutralization (19, 
54). Another approach is to concurrently administer immunosuppressants (such as 
cyclosporin) with the AAV vector to temporarily reduce immune responses to the virus 
capsid and/or transgene, and that has also been successful in some clinical trials (30). 
Despite the importance of antibodies in the anti-viral response to AAV, little is 
known about the major antigenic epitopes on the capsid surface or the mechanism(s) of 
antibody neutralization. Antibodies can neutralize viruses by a variety of mechanisms 
(36). The “single hit model” describes neutralization by as few as one antibody binding 
to one key site on the viral capsid. Inactivation is achieved by rendering the capsid non-
infectious, for example, by the antibody mimicking the structural interaction of the virus 
with the cellular receptor to induce conformational changes associated with genome 
release or another aspect of entry (8). This model of neutralization has been suggested 
to act in the anti-viral response against picornaviruses, but appears not to be involved in 
viral neutralization in most cases (24). The “multi-hit model” explains neutralization as 
the result of antibodies coating the surface of the capsid by occupying a certain 
threshold percentage of available epitopes to directly or sterically prevent interactions 
with target cells. A variety of factors affect the number of antibodies per viral capsid 
needed to prevent cellular infection in vivo, including epitope accessibility and 
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organization as well as overall capsid size (25). For icosahedral viruses, capsid surface 
area is generally proportional to the number of antibodies needed for neutralization. 
However, in some cases not all of the accessible epitopes need to be coated in order to 
neutralize the virus, and the threshold stoichiometry varies by antibody and virus (40). 
Furthermore, these antibodies may neutralize by varying mechanisms, including 
aggregating viral particles, directly or indirectly preventing receptor binding, inhibiting 
viral uncoating and genome release, and by Fc region interaction with other 
components of the immune system (26, 31, 49). 
Some information has been gathered for antibody neutralization mechanisms of 
parvoviruses, primarily for AAV2 and for the autonomous parvoviruses canine 
parvovirus (CPV) and minute virus of mice (MVM). Studies of CPV and MVM antigenic 
epitopes examined naturally antigenically variant CPV strains with changes at residues 
that also affect viral host range as well as experimentally derived escape mutants from 
neutralizing MAbs (29, 37, 43). The structures of eight different anti-CPV Fab antibody 
fragments bound to the virus capsid were determined using cryo-electron microscopy, 
and those showed that ~62% of the capsid surface was involved in antibody binding. 
The only regions not covered by those antibodies in that study were two depressed 
regions, and the cylinder surrounding the fivefold axis of symmetry. (17).  Interestingly, 
the major epitopes that varied between antigenically distinct naturally occurring CPV 
strains fell into two small regions of the capsid surface. This suggests that although 
most antibodies bind on or near the protrusions at or surrounding the icosahedral 
threefold axis, a complex interaction exists between the capsid surface and the host 
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antibody response. Thus the sites involved in antibody binding may be constrained by 
other required functions of the capsid surface. 
 Studies of AAV2 examining a small number of MAbs or polyclonal anti-capsid 
antibodies show that antibody binding is affected by changes in only a small number of 
sites on the capsid, and that reactivity can be reduced by mutations of residues within 
those sites (22, 33). Some of the mutations also change the receptor binding properties 
of the capsid, particularly those that affect binding to HSPG. Nonetheless, many of 
those mutants retained similar infectivity to wild-type capsids (28). For AAV2, binding of 
antibodies to different epitopes as described by mutational analysis show neutralization 
of infectivity by either inhibition of receptor binding or at post-attachment steps (50). A 
panel of mutant AAV2 capsids with surface residue mutations to Ala or other amino 
acids was examined for binding to HSPG and reactivity with an anti-AAV2 MAb (A20), 
polyclonal antibodies in three human sera, or to a pool of human IgGs (28). Some 
mutations prevented A20 antibody binding and neutralization, and others reduced virus 
sensitivity to neutralization by the individual sera by up to 42-fold, or by a pool of sera 
up to four-fold. There was not always a direct relationship between the change in IgG 
binding and neutralization, indicating that not all IgGs were equally efficient.   
 Here we describe a number of MAbs (both IgGs and IgMs) produced against the 
capsids of AAV1 and AAV5. The structural analysis of the specific antibody-capsid 
interaction for a subset of these antibodies has been described elsewhere (Figure 5.1, 
B. Gurda, manuscript in preparation). The results of these studies showed that most 
antibodies recognize a small region on the virus capsid, close to known receptor-binding 
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sites on the three-fold axis. The stoichiometry of binding by these antibodies varied, with 
most antibodies binding only once per three-fold spike (e.g. anti AAV1 antibodies 5H7 
and 4E4, Figure 5.1A and B). The consequence of this low occupancy is that even at 
saturation, 40 out of 60 VP monomers remain potentially open for receptor interaction 
depending on the area of steric inhibition provided by the antibody. In contrast, the Anti-
AAV5 antibody 3C5 (Figure 5.1C) bound to all three monomers around the three-fold 
axis, such that the capsid was nearly completely covered by Fabs at saturation. The 
orientation of Fab binding also differed between the AAV1 antibodies, with 5H7 binding 
nearly perpendicular to the capsid surface (Figure 5.1A, top panel) and 4E4 binding at 
an angle (Figure 5.1B, top panel). Of the anti-AAV1 antibodies, 4E4 had a larger 
surface area of interaction extending down the shoulder of the three-fold axis, and 
possessed the only binding footprint that crossed the two-fold axis for potential 
interaction with neighbouring VP subunits (Figure 5.1A and B, bottom panels). By 
comparing the reactivities of these various mouse antibodies with their homologous 
capsids we seek to define the efficiency of antibody attachment to these viruses and the 
processes of neutralization that may negatively impact the delivery of AAV-mediated 
gene therapy products.  
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Figure 5.1. Structures of selected Fabs in complex with AAV capsids. Shown are 
the structures of AAV1 bound by the A) 5H7 or B) 4E4 Fab fragment (top panels) and 
the footprint of binding on the viral asymmetric unit (bottom panels). The viral capsid is 
depicted in purple, and the Fab density in light gray. The structure of the AAV1:9A8 
complex was not determined in this study and is not shown.  C) Structure and footprint 
of AAV5 bound by the 3C5 Fab fragment, similar to A and B above except that the 
capsid is depicted in dark gray.  (From B. Gurda, manuscript in preparation, with 
permission.)  
 
5.3 Materials and methods 
5.3a Capsid production and immunizations 
 Empty AAV1, AAV2 and AAV5 capsids comprised of VP1, 2 and 3 proteins were 
expressed from baculoviruses under the control of the late promoter, grown in HI5 
insect cells and purified using cesium chloride and sucrose gradients as previously 
described (20, 45). Mice were immunized with 0.1 µg AAV1 capsids initially by the 
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subcutaneous route, with Freund’s complete adjuvant in the first immunization and 
Freund’s incomplete adjuvant for the later immunizations. For the final booster, purified 
AAV1 or AAV5 capsids were administered intravenously in PBS. Three days later the 
spleen cells were recovered and the lymphocytes were fused to mouse myeloma Sp2/0 
cells according to standard methods using polyethylene glycol to create antibody-
secreting hybridomas (38). Hybrid cells were selected in the presence of hypoxanthine-
aminopterin-thymidine (HAT) and screened for anti-AAV antibody production by ELISA 
or immunohistochemistry. Positive cells were cloned three times.   
5.3b Viruses and cells  
GFP-pseudopackaged AAV1 and AAV5 capsids were prepared as previously 
described (6). Briefly, 293T cells were transfected with pAAV1RC or pAAV5cap and 
pAAV2 rep78, a plasmid containing the adenovirus helper genes, and a plasmid 
containing the GFP gene controlled by a mammalian promoter and flanked by the AAV2 
genome inverted terminal repeats. Virus capsids were harvested 48 hours after 
transfection and purified using a cesium chloride step gradient. The highest titer 
fractions were identified by qPCR and TCID50 analysis in Cos-1 or HeLa cells. 
 Empty AAV1 and AAV5 virus like particles were fluorescently labeled with Alexa-
488 dyes (Invitrogen, Carlsbad, CA), following the manufacturer’s instructions, with 
purification as previously described. The degree of labeling was determined to be 10-15 
days per capsid, and the capsids were identified to be primarily single particles using 
the method outlined in (20).  
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5.3c Production and purification of MAb and Fab fragments 
MAb-producing hybridomas were grown in 500 mL culture bags, and the IgGs 
were isolated from the supernatant using HiTrap Protein G columns (GE LIfesciences, 
Piscataway, NJ). To produce Fabs, the IgGs were digested using a Fab preparation kit 
(Thermo Scientific, Rockford, IL), and the monomeric Fab were further purified by 
chromatography using a Sephadex G100 column (Sigma, St. Louis, MO). IgG and 
ELISA and/or immunofluorescence confirmed Fab specificity and reactivity.  
5.3d ELISA and dot blot analysis of viral binding 
To examine the reactivity of the MAbs against different strains of AAV, both 
ELISA and dot blots of purified capsids were performed. Purified capsids (4 µg/ml in 
bicarbonate buffer (pH 9.6)) were adsorbed to Probind polystyrene ELISA plates 
(Corning, Lowell, MA).  Antibodies were added and incubated for one hour at 22°C, 
followed by addition of a secondary horseradish peroxidase (HRP)-conjugated goat 
anti-mouse antibody and AEC substrate. For membrane dot-blots, capsids of each AAV 
were spotted on nylon membranes, incubated with the antibody supernatant for one 
hour followed by a secondary anti-mouse HRP antibody (Sigma). The bound antibody-
conjugated HRP was detected with Supersignal luminescent substrate (Thermo 
Scientific) and exposed to X-ray film. 
5.3e Neutralization assays   
AAV1 and AAV5 capsids packaging GFP under the control of the CMV promoter 
were incubated with ten-fold dilutions of purified intact IgGs or Fab fragments as 
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indicated for 60 minutes at room temperature (22°C). This mixture was incubated with 
Cos-1 or HeLa cells at a fixed genome per cell ratio and incubated for one hour at 37°C. 
The cells were washed, and fresh growth media was added to the cells. The percentage 
of infected cells was measured by quantifying the number of cells expressing GFP at 48 
hours post infection using flow cytometry, and was compared to a control well with no 
antibody added. Post attachment neutralization was performed by mixing the same 
concentration of virus as above with cells for 30 minutes at 4°C prior to the addition of 
antibody at the same dilutions as above. After an additional hour at 4°C the cells were 
washed extensively, and warm growth media was added. Cells were assayed for GFP 
expression at 48 hours post infection as above. 
5.3f Assay for antibody-mediated inhibition of cellular binding 
Alexa-488-labeled empty AAV1 and AAV5 capsids were incubated in solution with 
serial 10-fold dilutions of purified intact IgGs or Fab fragments as indicated for 60 
minutes at room temperature. This mixture was incubated with Cos-1 or HeLa cells at a 
concentration of 25,000 genomes per cell and incubated for one hour at 4°C. The cells 
were washed extensively in cold growth media and assayed for viral binding compared 
to a control well with no antibody added, as measured by Alexa-488 mean fluorescence 
intensity (MFI) using flow cytometry.  
 
5.4 Results 
5.4a Antibody production 
 We prepared panels of MAbs against AAV1 and AAV5 capsids using two 
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different immunization strategies. The first involved repeated immunization of AAV1 
capsids two to three months prior to the fusion of spleen cells. This protocol resulted in 
the production of four IgG- and four IgM-secreting hybridomas against AAV1. Seeking 
to prepare cross-reactive antibodies by the sequential administration of alternate 
serotypes, we immunized mice twice with AAV1 capsids, then gave a final intravenous 
immunization of AAV5 capsids four days prior to the fusion. That protocol resulted in the 
isolation of nine IgM- and one IgG-secreting hybridomas against AAV5.  A subset of the 
antibodies selected for further analysis is shown in Table 5.1.  
 
Table 5.1. Mouse anti-AAV MAbs selected for further studies. The immunizing 
antigen and isotype are indicated. *=IgM antibodies were tested for cross-reactivity in 
dot blot analysis but were not further tested for neutralizing ability.  
Monoclonal antibody 
(MAb) 
Designation in 
text 
Parental AAV 
antigen 
Isotype 
AA4E4.G7 4E4 AAV1 IgG2a 
AA5H7.D11 5H7 AAV1 IgG2a 
AA9A8.B12 9A8 AAV1 IgG1 
BB3C5.F4 3C5 AAV5 IgG3 
BB9F7.F12 9F7 AAV5 IgM* 
BB8F1.E8 8F1 AAV5 IgM* 
 
5.4b Cross-reactivity among different AAV serotypes 
Cross-reactivity between the AAV1 and AAV5 MAb hybridoma supernatant and 
several AAV serotypes was tested by ELISA and Western dot blot analysis (ELISA data 
not shown) (Figure 5.2 and 5.3). The B1 antibody was used to confirm the presence of 
virus capsids in the dot blot assay; this antibody was raised against AAV2 and is 
directed at a linear peptide at the C-terminus of the VP3 common region present in all 
AAVs tested except AAV4 (50). A commercial antibody generated against AAV4 
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capsids, ADK4, was used as a positive control to verify the presence of this virus during 
the dot blot assays.  
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Native dot blot analysis of the anti-AAV1 and anti-AAV5 MAbs against 
AAV1, 2, and 4-9. No cross-reactivity of AAV1 or AAV5 MAbs for other serotypes is 
seen, except for anti-AAV1 antibody recognition of AAV6 capsids. The B1 antibody 
recognizes a linear epitope in denatured capsids near the two-fold axis and is used as a 
positive control to demonstrate the presence of non-parental AAV serotypes. The ADK4 
monoclonal antibody (AAV4 specific) is used as a positive control for AAV4 capsids 
since the B1 epitope is not present in this serotype. 
 
The MAbs were found to recognize conformational epitopes on assembled capsids 
as they did not react with any linear epitopes in denatured capsids (data not shown, J. 
Chiorini, personal communication). Dot blots of a subset of the antibody panel binding to 
intact capsids are shown in Figure 5.2. The eight anti AAV-1 antibodies were specific for 
the capsids used to immunize the mice, and showed cross-reactivity with serotype 6 but 
not with any other strain tested (AAV1, 2, 4, 5, 7-9). The anti-AAV5 MAbs displayed no 
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cross-reactivity in this initial analysis, but when tested at high concentrations had a 
weak reaction with AAV1 (Figure 5.3A). However, this reaction was abrogated at even 
slightly higher dilutions of hybridoma supernatant (Figure 5.3B).  
 
 
 
 
 
 
 
 
Figure 5.3 MAb characterization and cross-reactivity at high concentrations. A) 
Native blot using a MAb hybridoma supernatant dilution of 1:4. Recognition of native 
AAV1 by the anti-AAV5 monoclonals is evident at this dilution. B) Serial dilutions of the 
anti-AAV5 MAb hybridoma supernatant tested against native AAV1 and 5 capsids. A 
lack of recognition is already seen at a 1:25 dilution. 
 
5.4c Neutralization ability of the MAbs  
The selected anti-AAV1 and anti-AAV5 IgGs (Table 5.1) were tested for the ability 
to neutralize virus infection; the anti-AAV5 IgMs were not tested. Neutralization was 
defined as the dilution that gave a 50% or greater reduction of cellular transduction by 
AAV1 and AAV5 vectors packaging the GFP-gene, scored as the percentage of GFP-
expressing cells 48 hours after infection and compared to a control well with no antibody 
added. All of the antibodies neutralized as intact IgGs although with different efficiencies 
(Figure 5.4A). The 4E4 IgG was the most efficient and neutralized at 50- and 500- fold 
D
D	  
D
D	  
3C5       8F1    9F7       A) B) 
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lower concentrations than the 5H7 and 9A8 antibodies, respectively. The Fabs were 
each less neutralizing than their IgG counterparts, with the 5H7 antibody retaining the 
highest level of neutralizing ability as a Fab fragment. The 4E4 and 9A8 Fab fragments 
reached 50% neutralization only at the highest concentration tested (Figure 5.4B). A 
similar pattern was seen with the anti AAV5 antibody, 3C5 (Figure 5.4C). This antibody 
was neutralizing as an intact IgG at a level similar to the 9A8 anti-AAV1 antibody, but 
was non-neutralizing as a Fab fragment. Figure 5.4D shows the specificity of the 
antibody-virus interaction as neither IgGs nor Fabs raised against CPV (MAbs 15 and 
16) nor an anti-bovine serum albumin IgG were neutralizing even at the highest 
concentration.  
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Figure 5.4. Neutralization of AAV1 and AAV5 by MAb IgGs and Fabs. A and B) 
Serial dilutions of selected anti-AAV1 (A) IgGs or (B) Fabs were pre-incubated with 
AAV1 capsids packaging the GFP gene under the control of the CMV promoter, then 
inoculated on Cos-1 cells and scored for infection after 48 hours by flow cytometry. Data 
are normalized to a control where no antibody was added C) Serial dilutions of the 
single anti-AAV5 IgG and Fab were tested for the ability to neutralize AAV5 transduction 
of HeLa cells as in (A) and (B). D) Control IgGs and Fabs directed against canine 
parvovirus or bovine serum albumin are unable to neutralize when added under the 
same conditions as above (AAV1 data shown). 
 
5.4d Mechanism of antibody neutralization 
 The antibodies were tested for their ability to inhibit receptor binding (Figure 5.5). 
Each anti-AAV1 IgG was able to inhibit receptor binding to <20% of control levels, but 
they varied in efficiency (Figure 5.5A). Similar to the findings in the infection 
neutralization assay, the 4E4 antibody reduced viral association with cells at the lowest 
concentrations out of the three antibodies tested. The Fab fragments were less 
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inhibitory of receptor binding than their IgG counterparts, and only the 5H7 antibody 
reduced the level of cell-associated virus to <50% of control levels as a Fab (Figure 
5.5B). Neither the anti-AAV5 3C5 IgG nor Fab fragment reduced the level of cell-
associated virus to <80% of control levels (Figure 5.5C). Control antibodies did not 
inhibit the viruses’ ability to attach to cells (Figure 5.5D).   
 
 
 
Figure 5.5. Ability of the anti AAV1 and anti-AAV5 MAbs to inhibit receptor 
binding. A and B) Serial dilutions of selected anti-AAV1 (A) IgGs or (B) Fabs were pre-
incubated with Alexa-488 fluorescently labeled empty AAV1 capsids, and then were 
added to Cos-1 cells. Flow cytometry was used to determine the level of cell-associated 
fluorescent virus and was compared to a control where no antibody was added. C) 
Serial dilutions of the anti-AAV5 3C5 IgG and Fab were tested for the ability to inhibit 
Alexa-488 labeled AAV5 receptor binding to HeLa cells as in (A) and (B). D) Control 
IgGs and Fabs directed against canine parvovirus or bovine serum albumin are unable 
to inhibit receptor binding when added under the same conditions as above (AAV1 data 
shown). 
 
 
 
 
 
182 
 To identify potential neutralization mechanisms other than inhibition of receptor 
binding, the antibodies were tested for their ability to neutralize AAV infection after the 
virus had already attached to cells (Figure 5.6). Of the anti-AAV1 antibodies, only the 
4E4 IgG gave 50% neutralization at the highest two concentrations tested when added 
after virus attachment (Figure 5.6A), and none of the Fabs significantly neutralized the 
virus (Figure 5.6B). Neither the anti-AAV5 3C5 IgG nor Fab inhibited infection after the 
virus had bound to cells (Figure 5.6C).   
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Figure 5.6. Ability of the anti AAV1 and anti-AAV5 MAbs to neutralize at a post-
attachment step. A and B) AAV1 capsids packaging the GFP gene were inoculated 
onto Cos-1 cells at 4°C to allow virus attachment but not endocytosis. Serial dilutions of 
selected anti-AAV1 (A) IgGs or (B) Fabs were added after 30 minutes for one hour, then 
unbound antibodies and virus were removed by extensive washing. Cells were warmed 
to 37°C and scored for infection after 48 hours by flow cytometry. Data are normalized 
to a control where no antibody was added C) Serial dilutions of the anti-AAV5 3C5 IgG 
and Fab were tested for the ability to neutralize AAV5 capsids packaging the GFP gene 
after attachment to HeLa cells as in (A) and (B). 
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5.5 Discussion 
5.5a Anti-AAV monoclonal antibody production 
Antibodies are an essential component of the immune response to AAV. The 
antibody response develops shortly after infection and can protect against subsequent 
exposures to both the initial immunizing virus and antigenically related viruses in some 
cases. Here we developed IgG and IgM antibodies reactive against AAV1 and AAV5 
capsids to examine the antigenic structures of the capsids, as well as the cross-
reactivity and neutralization properties of the antibodies. The AAV capsid was a potent 
antigen for stimulating antibody production, and only four days after immunization with 
AAV5 (in mice previously immunized with AAV1) we were able to prepare a panel of 
several anti-capsid antibodies. Multivalent viral capsids are effective B cell antigens that 
may elicit some immediate T-cell independent responses, and this is likely the reason 
for the vigorous anti-AAV5 response seen here (9). T-helper cell epitopes may also be 
shared between the AAV1 used for pre-immunization and the AAV5 capsids given in the 
final boost, and may that affect the response against the second virus. Although the 
mice had been previously immunized with AAV1, most of the antibodies produced were 
IgMs directed against AAV5, with only one IgG. In similar studies of canine parvovirus 
capsids we prepared anti-capsid IgM hybridomas four days after primary immunization 
of naïve mice, suggesting that the pre-immunization with AAV1 was not necessary for 
the early response seen here (C Parrish, unpublished data). 
The structures of the antibody-capsid complexes were solved by cryo-electron 
microscopy for some of the antibodies examined here, and all were found to bind within 
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a relatively limited footprint on the capsid surface. The antibodies all bound to the 
prominent spike near the three-fold axis of the capsid, adjacent to the receptor-binding 
domain. Only the binding site of the anti-AAV1 4E4 antibody extended across the two-
fold axis with the potential to cross-link VP subunits. Although the area around the five-
fold axis protrudes from the capsid surface and might be expected to be an attractive 
feature for antibodies, structural analysis has previously identified flexibility in the 
surface loops at this location in CPV capsids (17). This property, if also present in the 
AAV capsid, could be expected to interfere with the tightly controlled structural 
interactions required for antibody binding and may account for the lack of antibodies 
found directed against this area.  
5.5b Cross-reactivity of the anti-AAV monoclonal antibodies 
The MAbs produced in this study react with AAV1 and AAV5 capsids and provide 
a variety of useful reagents for the study of AAV immunogenicity and cellular entry. The 
antibodies were generally not cross-reactive between serotypes, except for the anti-
AAV1 antibodies that also reacted with AAV6 capsids. These two serotypes share 
99.2% sequence identity, and the capsid proteins differ by only six amino acids. While 
these viruses do show some differences in receptor binding and transduction efficiency, 
they are the most closely related of any of the serotypes and thus it is not necessarily 
surprising to see some antibody cross-reactivity (51, 53). The anti-AAV5 antibodies 
showed only weak cross-reactivity with AAV1, despite that the mice were immunized 
twice with AAV1 and only once with AAV5 shortly before lymphocyte harvesting. The 
hybridomas obtained from these mice were screened and cloned based only on their 
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reactivity with AAV5, and strongly-reactive anti-AAV1 B cells produced during the initial 
two immunizations were not selected for by this screening method. The particular 
features of each capsid type that attract the antibody response therefore must differ 
between serotypes, supporting their separation as distinct serotypes and the practice of 
using sequential administration of different AAVs for repeat transgene delivery in clinical 
trials to reduce vector neutralization.  
5.5c Neutralizing ability of the anti-AAV antibodies  
All the anti-AAV specific antibodies neutralized the viruses as intact IgGs, but 
they had different neutralization abilities across the six-log concentration profile tested. 
Of the three anti-AAV1 IgGs tested, 4E4 was able to neutralize at the lowest 
concentration and had the largest coverage of any antibody where the structure was 
solved. As it binds at an angle to the capsid surface, it likely provides more steric 
hindrance to prevent interaction of the virus with the target cell. The structural 
interaction of 9A8 with AAV1 has not been solved and its epitope is unknown, but it was 
poorly neutralizing. Thus, it may have a different structural interaction, poor affinity, or 
may be less able to cross-link particles than the other two antibodies examined in this 
study.  
The anti-AAV5 3C5 IgG possessed a neutralization profile similar to that of the 
least efficient anti-AAV1 antibody, 9A8. This MAb binds to all 60 VP capsid protein 
monomers so that the entire capsid appears to be coated by antibodies at saturation 
(Figure 5.1C). However, this antibody was produced only after four days of 
immunization with AAV5 and may represent an immature antibody with a relatively low 
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affinity that is easily displaced to allow the virus to infect cells. Further studies would be 
needed to compare the reactivity of this antibody to those produced by a three-step 
immunization as was done for AAV1 in this study.  
Given that the location of the antibody footprints appeared at or near the 
receptor-binding sites, inhibition of receptor binding was hypothesized to be a logical 
mechanism of neutralization. The shapes of the infection neutralization curves were 
similar to the binding inhibition curves for the anti-AAV1 antibodies, suggesting that this 
was in fact a major mechanism used. The most highly neutralizing IgG (4E4) and Fab 
(5H7) were the most effective in interference with receptor binding. As a whole, the 
Fabs were poorly inhibitory of receptor binding compared to the intact IgGs, and were 
also poorly neutralizing. The could be a result of the smaller area of steric inhibition 
provided by the Fab fragments that lack the bulky Fc domain and second Fab arm, 
rendering them less able to prevent the access of sialic acids to the capsid surface. 
Alternatively, the inability of Fab fragments to cross link viral particles may also be a 
factor contributing to their low efficacy of neutralization.  
When tested for the ability to neutralize the virus after it had already attached to 
receptors, only the 4E4 IgG, and none of the Fabs, was able to significantly inhibit 
infection. The mechanism by which this post-attachment neutralization occurred was not 
determined, but the structure of the 4E4 antibody-virus complex provides some clues. 
The 4E4 antibody is the only MAb with a binding site that extends across the two-fold 
axis of symmetry and has the potential to cross link subunits, stabilize the capsid 
structure, and interfere with required conformational changes during entry. As the Fab 
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fragment did not neutralize the virus after attachment, the implication is either that the 
antibody is binding bivalently to stabilize the capsid structure or that another mechanism 
is at work. For example, the post-attachment neutralization may be due to an isotype 
specific constant region (Fc) mediated function within the cell, as the 4E4 antibody is of 
a different subclass than the other two anti-AV1 antibodies. A recent study has identified 
a TRIM-21 dependent, Fc mediated, intracellular neutralization mechanism, and this or 
a related functionality may be of some relevance here (31).  
The antigenic structures of viral capsids recognized by antibodies are key to the 
development of protective immune responses. The AAVs provide an important model 
system to examine the antigenic structure of simple capsids, as there are several 
genetically and antigenically distinct viruses that have been classified by DNA sequence 
analysis. The results of these studies provide insights into the particular features of the 
AAV capsids that draw the antibody response, and highlight that, while other 
mechanisms may be used in some cases, inhibition of receptor binding is a major 
mechanism by which antibodies neutralize AAVs. Future studies are ongoing to develop 
antibody escape mutants that retain the receptor-binding properties of the wild-type 
virus. These efforts seek to circumvent the interference of humoral immunity on the 
delivery of AAV-derived gene therapy vectors, and if successful would be relevant for 
the many ongoing clinical trials using AAV to deliver genes of interest for a variety of 
disease states.  
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
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6.1 Contextual framework 
Parvoviruses must cross a number of hurdles to reach the nuclei of host cells 
and complete their replication cycle. In nature they must first survive in the environment 
long enough to reach the host and gain access to target tissues with cells permissive for 
replication. Inside the host, they must also evade a variety of innate and adaptive 
immune mechanisms, such as neutralizing antibodies, specifically tailored to combat 
incoming pathogens. Even once they gain access to a target cell, to reach the nucleus 
the virus must still traverse the dense cellular landscape that includes obstacles at the 
plasma membrane, the network of interconnected endosomal compartments, the 
cytoplasm with its tightly compacted cytoskeletal networks, and finally the nuclear 
envelope and lamina. The studies contained herein advance our understanding of how 
parvoviruses navigate a pathway to infection despite the numerous roadblocks imparted 
by the host. 
Furthermore, the landscape of obstacles changes on both short and long time 
scales, as both the host and the virus continue to evolve in concert with each other in 
what has been termed the “host-pathogen arms race” (4). As a relatively recent virus 
that emerged about 35 years ago, CPV-2 and its relatives provide a model for viral 
emergence which is broadly applicable to a variety of contemporary emerging diseases. 
Given the ever-increasing contact between wildlife and domestic animal species and 
between animals and humans, the occurrence of these types of outbreaks is likely only 
to increase in the future. Though they are still relatively rare, we have witnessed several 
examples of rapid changes in viral host range or virulence in recent years, including 
Hendra virus, SARS corononavirus, avian and swine influenza that have emerged in 
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humans, the jump of A/H3N8 equine influenza virus into dogs, and the rapid emergence 
of a virulent systemic strain of feline calicivirus from a normally innocuous upper 
respiratory pathogen in cats (VS-FCV) (1, 5, 6). Understanding the effects that small 
differences among viral strains can have on host range, tissue tropism, antigenicity, and 
virulence is essential for being able to predict and manage outbreaks of new or newly 
recognized diseases, particularly those that arise from a host-jumping event. 
6.2 Parvovirus receptor recognition and cellular uptake  
The cellular receptor is the key to viral entry into host cells, and is important for 
determining host range and tissue tropism. The virus attaches to the receptor at the cell 
surface, and in the case of carnivore parvoviruses the TfR is used for receptor-mediated 
endocytosis and trafficking to specific intracellular locations. Chapter 2 further 
elucidated the details of this entry process in the context of the evolutionary variation of 
different viruses and hosts. The results showed that despite differing by only a few 
amino acids, the feline and canine viruses have somewhat different interactions with the 
receptor on the surface of canine and feline cells. Not only do they bind with an 
apparently different affinity (as evidenced by the level of cell-associated virus), but they 
also bind with a different surface distribution (on filopodia of canine cells), and are taken 
up with different kinetics in canine and feline cells. These features likely affect the 
efficiency of cellular infection, given the importance of the specific interaction of the 
virus with the TfR and the requirements for certain (as yet poorly defined) intracellular 
signals that alert the virus it is in an environment permissive for genome release.  
The requirements for specific interactions between the TfR and cellular 
components were analyzed in Chapter 3 using variant feline TfRs with transmembrane 
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and cytoplasmic domains derived from alternate cellular and viral type II membrane 
proteins, or with mutations in the native cytoplasmic domain. A total of 10 different 
receptors, including wild-type, were analyzed for expression and functionality in allowing 
binding, endocytosis, and infection by CPV and FPV. Of these, eight out of the 10 were 
expressed at sufficient level to warrant further study. Although these receptors showed 
some variation in the ability to endocytose transferrin and virus capsids, these results 
confirm that some chimeric receptors can be expressed in a functionally intact way on 
the cell surface. However, of the eight receptors tested, only the two feline TfRs with 
mutated cytoplasmic domains allowed infection at wild type levels. The chimeric 
receptors fell into two groups based on sequence of origin; chimeras with cellular 
proteins allowed intermediate levels of infection while viral protein chimeras allowed 
only low levels.  Future studies will further elucidate the mechanisms behind these 
differences in infection efficiency. The results presented in Chapter 3 begin to address 
these questions by showing that viruses bound to the least permissive receptors had 
slower uptake kinetics and different intracellular distributions following endocytosis, 
suggesting that alternate pathways of uptake may be directing most of these viruses to 
non-productive compartments.  
6.3 Intracellular trafficking of parvoviruses 
Despite variations in behavior between wild-type feline and canine parvoviruses 
at the cell surface, differences in the intracellular trafficking patterns between the viral 
strains analyzed were not easily distinguishable and only subtle differences of unknown 
importance were identified. The results presented here show that after uptake by wild-
type receptors on healthy cells, virus capsids became rapidly dispersed throughout 
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several endosomal compartments and could be found in early, late, and recycling 
compartments within the first 10 minutes after uptake. However, the particle-to-
infectivity ratio for parvoviruses is very high and simply observing where the majority of 
the particles go may not necessarily identify the infectious pathway. For this, 
confirmation by a variety of additional approaches is required.  
The importance of the degradative pathway in infection was supported in Chapter 
2 by the finding that disrupting membrane trafficking within the early and late 
endosomes using dominant negative forms of Rab5 or Rab7 inhibited infection, while 
disrupting the recycling endosome with a dominant negative Rab11 protein did not. 
Furthermore, in Chapter 3, capsids bound to chimeric receptors with cytoplasmic tails 
from viral proteins that did not efficiently traffic to the perinuclear area were also the 
most deficient in infection. However, the proportion of viruses entering specific different 
endosomal compartments at this location was not determined in these studies due to 
the limited resolution of our imaging technology. Furthermore, in neither of these studies 
was virus directly observed escaping the late endosomal or lysosomal compartments, 
and the mechanisms by which membrane penetration, cytoplasmic trafficking, and 
nuclear entry occur have remained elusive. Further experiments will seek to examine 
these issues, as the later steps of entry between endosomal trafficking and nuclear 
import appear to be major bottlenecks in the parvovirus infection process. Specific 
areas of interest include the potential role of intra-endosomal cellular factors in 
modifying the viral capsid or facilitating conformational changes involved with exposure 
of the VP1 N terminus or genome, and the specific roles for the phospholipase A2 
domain and nuclear localization signals contained within the VP1 N terminus.  
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Finally, these studies demonstrated the utility of fluorescently-labeled capsids in 
the study of the early steps of virus interactions with cells. They appear to behave very 
similarly to unlabeled capsids, allow for easy quantitative detection of the level of cell-
associated virus, and allow us to follow virus entry into live cells in real time. As such, 
this technology was utilized in each study contained within this dissertation, and is also 
being applied to studies by others in the laboratory.  
6.4 The role of antibodies in parvoviral infection and evolution 
 Antibodies play a central role in the control of parvoviral infections, and no doubt 
exert a selective pressure on the viral capsid as it passes from host to host. However, 
the ability of the host immune response to select for viral mutations that escape from 
this pressure is constrained by structural limitations imposed by the need to preserve 
vital functions such as receptor binding and the flexibility to package and release the 
genome in the proper environment. In the case of FPV and CPV, the appearance of 
antigenically variant strains has occurred simultaneously with alterations in host range, 
suggesting a multi-factorial driving force for viral evolution. Presumably, this is also the 
case in the evolution of CPV-2 as it passed through raccoons, which were identified in 
Chapter 4 as a newly-recognized intermediate host in the adaptation of CPV to dogs. 
The CPV-2-like strains isolated from raccoons were found to have alterations in both 
reactivity with antibodies and in the ability to bind the canine TfR and use it to infect 
canine cells. 
The major antigenic sites on the CPV capsid have been defined, and those 
overlap with structures important for receptor binding. In general, these sites are 
thought to be easy targets for the immune response as they tend to be located on 
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prominent features of the viral capsid, maximizing presentation to the host cell and as a 
byproduct, to the immune response. For CPV and FPV, receptor binding is a key 
determinant in host range and is dependent on specific features of both the host TfR 
and the virus capsid. On the receptor side, the TfR contains species-specific mutations 
throughout different carnivore families and genera, and ongoing studies in the lab are 
teasing out the significance of these differences in the evolution and host-switching of 
carnivore parvoviruses (J. Kaelber, personal communication).  
On the capsid side, of particular relevance to the mutations seen in the CPV-2 
derived isolates from raccoons as detailed in Chapter 3, VP2 residue 300 is located in 
the “B” antigenic site and has mutated more than once since the virus first emerged in 
the 1970s. Other key changes in raccoon strains also fell within antigenic sites, 
including VP2 residue 224 in the “A site” and VP2 residue 305, also in the “B site” (3). 
Combinations of changes at those two sites led to loss of reactivity with all but a small 
number of mouse and rat monoclonal anti-FPV or anti-CPV antibodies. The raccoon 
strain with changes of residues 300 and 224 together evaded detection by nearly all of 
the 30 anti-FPV and -CPV antibodies tested, which may be taken as an approximation 
of the polyclonal antibody response. It remains to be seen whether the emergence of 
strains similar to these will cause a problem for our domestic animals; however, despite 
that changes at these sites are apparently relatively readily selected, these viruses have 
been circulating undetected in raccoons for 20 years and they have failed to cause a 
detectable disease epidemic among companion animals, possibly due to the varying 
fitness landscapes traversed during passage between different hosts. 
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Serological studies would be beneficial in determining the prevalence of 
seropositivity in raccoons from different geographic locations. Other carnivores such as 
foxes and mustelids should also be examined more closely for seropositivity and 
incidence of parvoviral disease, and the viral sequences determined in cases when 
active infections are found. This effort would be useful for tracking the ongoing 
incidence and evolution of virus strains in different hosts and may be helpful in detecting 
and managing novel and potentially dangerous viruses in the future. In addition, 
analysis of specific antibodies produced by raccoons and other natural hosts would be 
interesting to determine whether the epitopes recognized fall into these same antigenic 
sites as defined by the mouse and rat antibody response, or are unique. 
Future studies addressing the antibody response of the dog should also be 
undertaken, as the epitopes recognized by the canine B cell repertoire have not been 
specifically defined. Though they likely share similarities with the sites identified by 
rodent antibodies, a specific study in dogs may be useful for designing future generation 
vaccines, especially in light of (so far mostly unfounded) concerns about escape of the 
virus from vaccine immunity. Beginning in 2000, the appearance of the CPV-2c 
antigenic variant containing a single point mutation at VP2 residue 426 sparked a 
controversy and near-panic about this issue. While current evidence is that 
contemporary vaccines protect effectively against this strain, the potential for 
emergence of a virus variant that is not protected against does exist. In each case of 
viral evolution of CPV, only a small number of changes (though always more than one) 
were necessary to achieve the major jumps in host range. In fact, within the last few 
years, there has been mounting anecdotal evidence for increased incidence of 
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parvoviral enteritis in dogs older than the normal six to16 weeks, including fully 
vaccinated adult dogs. A limited amount of VP2 sequencing has been undertaken from 
diagnostic samples submitted to the diagnostic lab at Cornell University, and while 
some recurring mutations have been seen, no conclusive patterns of accumulated 
mutations have been found (unpublished data, and E. Dubovi, personal 
communication). Once again, only ongoing surveillance will be able to tease out the 
significance of any individual or combined mutations. 
6.5 Antibody limitations to parvoviruses as gene therapy vectors 
 The antibody response is also a key hurdle in the development of adeno-
associated viruses as gene therapy vectors. Humoral immunity can prevent the 
application of these vectors in a significant proportion of the human population, as 
studies have identified anti-capsid antibodies in up to 80% of the population in some 
cases (2). The study in Chapter 5 sought to define the functionality of antibodies 
produced in mice against AAV1 and AAV5. Previous structural studies showed that like 
the autonomous parvoviruses, these antibodies were directed against a limited footprint 
on the viral capsid that overlapped with the receptor-binding site (B. Gurda, personal 
communication). The results presented here showed that despite binding to a similar 
location, the antibodies were variably effective at neutralizing cellular transduction and 
that this neutralization was likely favored by the larger area of steric hindrance, the 
bivalency, or the Fc region of the intact IgG as most Fab fragments were poorly 
neutralizing. The mechanism of neutralization was primarily associated with inhibition of 
receptor binding in many cases, although for one antibody (3C5, anti-AAV5) the inferred 
affinity was too low to show this directly. Only one antibody (4E4, anti-AAV1) was able 
 204 
to neutralize after the virus had bound to cells, indicating that it may have an alternate 
mechanism of neutralization.  
 Future studies should seek to examine the neutralization properties of additional 
antibodies, preferably isolated from human lymphocytes, as only a small number of 
mouse antibodies were tested in the current study. Increasing the diversity of antibodies 
may allow for the identification of additional epitopes and mechanisms of neutralization, 
or may simply strengthen the hypothesis that inhibition of receptor binding is truly the 
most important target for the antibody response. In addition, AAV escape mutants that 
reduce or eliminate binding by the various antibodies should be experimentally selected 
or designed in silico. This work is currently ongoing (M. Agbanje-McKenna, personal 
communication). Despite the limited footprint of interaction with MAbs, a full AAV1 
escape mutant would likely involve changes at more than one residue, based on the 
slightly different binding sites antibodies 5H7 and 4E4. In addition, given that escape 
mutations would be very near the site for receptor interaction, these mutants must be 
rigorously tested to ensure that they maintain the correct receptor binding properties 
and tissue tropism(s) before being developed as gene-delivery vectors. If successful, 
these strains could have tremendous clinical impact as they would circumvent the 
current major hurdle preventing therapeutic gene delivery by parvoviruses.  
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